masran的个人主页 - 老虎社区

masran

masran

暂无个人介绍

IP属地：未知

275关注

16粉丝

0主题

0勋章

2021-12-24

pls like

Japan health panel approves Merck's oral COVID-19 treatment

2021-09-25

hope to success

Cathie Wood Knows Something About Zoom That You Don’t

2021-12-21

thx

抱歉，原内容已删除

2021-11-05

like pls

S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares

2021-10-13

like pls

Why you won’t know it when a bear market starts

2021-12-18

like pls

3 Warren Buffett Stocks I Like Heading Into 2022

2021-11-30

good

Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates

2021-09-27

like pls

Tesla and General Motors picked by Goldman Sachs as auto winners in tough environment

2021-12-24

thx

What are MKM Partners 'Black Swan' Internet predictions for 2022?

2021-11-16

pls like

Lucid Stock Gains as Q3 Shows No Major Surprises for 'Car of the Year' Recipient

2021-09-25

like pls

5 Top Consumer Stocks To Watch Ahead Of October 2021

2021-12-10

like pls

Grab and Lucid stocks plunged more than 10%

2021-09-25

best

Dow Jones, S&P 500 end with gains up after bumpy week, but Nike drags

2021-12-16

need booster

Rebound Anticipated For Singapore Stock Market

2021-11-09

good

Earnings Scheduled For November 9, 2021

2021-12-23

like pls

U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use

2021-12-02

coming up soon

Xpeng Motors shares changed from up to down by 4%

2021-09-29

seriously?? hmm

5 Ultra-Popular Stocks With 120% to 190% Upside, According to Wall Street

2021-09-27

hmm

抱歉，原内容已删除

2021-12-10

wow

Crypto stocks dipped in morning trading

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3582888796077977,"uuid":"3582888796077977","gmtCreate":1619796055209,"gmtModify":1630548061864,"name":"masran","pinyin":"masran","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":16,"headSize":275,"tweetSize":98,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":698851498,"gmtCreate":1640347839561,"gmtModify":1640347839791,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698851498","repostId":"1156159690","repostType":4,"repost":{"id":"1156159690","pubTimestamp":1640335867,"share":"https://www.laohu8.com/m/news/1156159690?lang=&edition=full","pubTime":"2021-12-24 16:51","market":"us","language":"en","title":"What are MKM Partners 'Black Swan' Internet predictions for 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1156159690","media":"seekingalpha","summary":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Bla","content":"<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.</p>\n<p>So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.</p>\n<p>The \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.</p>\n<p>Kulkarni said Facebook's(NASDAQ:FB)<a href=\"https://laohu8.com/S/CASH\">Meta</a> could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.</p>\n<p>\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.</p>\n<ul>\n <li>Kulkarni's other Black Swan predictions are:</li>\n <li>SPAC IPOs will outperform traditional IPOs and direct stock listings.</li>\n <li><a href=\"https://laohu8.com/S/UBER\">Uber</a>(NYSE:UBER)launches its own robotaxi service in several U.S. cities.</li>\n <li><a href=\"https://laohu8.com/S/TWTR\">Twitter</a>(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.</li>\n <li>DoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.</li>\n <li><a href=\"https://laohu8.com/S/AAPL\">Apple</a>(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.</li>\n <li>Google's(NASDAQ:GOOG)YouTube get in position to go public.</li>\n <li>Snap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.</li>\n <li>As a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and&nbsp;falling demand for Peloton (PTON) products next year.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What are MKM Partners 'Black Swan' Internet predictions for 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat are MKM Partners 'Black Swan' Internet predictions for 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 16:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as...</p>\n\n<a href=\"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","TWTR":"Twitter","GOOG":"谷歌","DASH":"DoorDash, Inc.","PINS":"Pinterest, Inc.","AAPL":"苹果","PTON":"Peloton Interactive, Inc."},"source_url":"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1156159690","content_text":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.\nThe \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.\nKulkarni said Facebook's(NASDAQ:FB)Meta could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.\n\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.\n\nKulkarni's other Black Swan predictions are:\nSPAC IPOs will outperform traditional IPOs and direct stock listings.\nUber(NYSE:UBER)launches its own robotaxi service in several U.S. cities.\nTwitter(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.\nDoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.\nApple(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.\nGoogle's(NASDAQ:GOOG)YouTube get in position to go public.\nSnap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.\nAs a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and falling demand for Peloton (PTON) products next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":992,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698851243,"gmtCreate":1640347676382,"gmtModify":1640347676614,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698851243","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":869,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698965862,"gmtCreate":1640278323261,"gmtModify":1640278323493,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"good to hear","listText":"good to hear","text":"good to hear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698965862","repostId":"1192606453","repostType":2,"repost":{"id":"1192606453","pubTimestamp":1640241432,"share":"https://www.laohu8.com/m/news/1192606453?lang=&edition=full","pubTime":"2021-12-23 14:37","market":"us","language":"en","title":"AMC Theatres reaches lease deals, will open Los Angeles and Chicago theatres","url":"https://stock-news.laohu8.com/highlight/detail?id=1192606453","media":"seekingalpha","summary":"AMC Theatres(NYSE:AMC)has reached lease agreements and plan to reopen theatres in the Los Angeles an","content":"<p>AMC Theatres(NYSE:AMC)has reached lease agreements and plan to reopen theatres in the Los Angeles and Chicago markets.</p>\n<p>The company is expected to begin operations at AMC Northridge Fashion Center 10, formally a Pacific theatre and at AMC Chicago 14, formally an Arclight location in NEWCITY located in the Lincoln Park neighborhood, under a new name in spring of 2022.</p>\n<p>With these two new locations plus AMC American at Brand 18 and AMC&nbsp;The Grove&nbsp;14, AMC has now acquired four former Pacific &amp; Arclight locations in 2021</p>\n<p>AMC remains in active discussions with other property owners regarding additional currently closed locations.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Theatres reaches lease deals, will open Los Angeles and Chicago theatres</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Theatres reaches lease deals, will open Los Angeles and Chicago theatres\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 14:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3782877-amc-theatres-reaches-lease-deals-will-open-los-angeles-and-chicago-theatres><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC Theatres(NYSE:AMC)has reached lease agreements and plan to reopen theatres in the Los Angeles and Chicago markets.\nThe company is expected to begin operations at AMC Northridge Fashion Center 10, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3782877-amc-theatres-reaches-lease-deals-will-open-los-angeles-and-chicago-theatres\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://seekingalpha.com/news/3782877-amc-theatres-reaches-lease-deals-will-open-los-angeles-and-chicago-theatres","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1192606453","content_text":"AMC Theatres(NYSE:AMC)has reached lease agreements and plan to reopen theatres in the Los Angeles and Chicago markets.\nThe company is expected to begin operations at AMC Northridge Fashion Center 10, formally a Pacific theatre and at AMC Chicago 14, formally an Arclight location in NEWCITY located in the Lincoln Park neighborhood, under a new name in spring of 2022.\nWith these two new locations plus AMC American at Brand 18 and AMC The Grove 14, AMC has now acquired four former Pacific & Arclight locations in 2021\nAMC remains in active discussions with other property owners regarding additional currently closed locations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691250012,"gmtCreate":1640213796164,"gmtModify":1640213796381,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691250012","repostId":"1131862374","repostType":4,"isVote":1,"tweetType":1,"viewCount":725,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693712913,"gmtCreate":1640078865625,"gmtModify":1640078865830,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693712913","repostId":"1149530831","repostType":4,"repost":{"id":"1149530831","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640078220,"share":"https://www.laohu8.com/m/news/1149530831?lang=&edition=full","pubTime":"2021-12-21 17:17","market":"us","language":"en","title":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.","url":"https://stock-news.laohu8.com/highlight/detail?id=1149530831","media":"Tiger Newspress","summary":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Ma","content":"<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p>\n<p>\"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p>\n<p>The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p>\n<p>This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p>\n<p>\"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p>\n<p>\"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p>\n<p>The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p>\n<p>This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p>\n<p>\"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149530831","content_text":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.\n\"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"\nThe EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.\nThis expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).\n\"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693692245,"gmtCreate":1640011205087,"gmtModify":1640011205299,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"NIO very impressive","listText":"NIO very impressive","text":"NIO very impressive","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693692245","repostId":"1164238522","repostType":2,"repost":{"id":"1164238522","pubTimestamp":1640004157,"share":"https://www.laohu8.com/m/news/1164238522?lang=&edition=full","pubTime":"2021-12-20 20:42","market":"us","language":"en","title":"Nio impresses Bank of America with ET7 reveals, expansion plans","url":"https://stock-news.laohu8.com/highlight/detail?id=1164238522","media":"seekingalpha","summary":"Bank of America reiterates a Buy rating on Nioafter taking in the electric vehicle maker's product event over the weekend.Nio  will kick off order confirmation of the flagship ET7 on January 20 and plans to start making deliveries on March 28, 2022. During the event, Nio  is noted to have highlighted 20 new features and specs that have been added or enhanced, including the 0-100 km/h acceleration improved to 3.8 seconds from 3.9 seconds.\"On the power network front, NIO has 733 power stations to ","content":"<p>Bank of America reiterates a Buy rating on Nio(NYSE:NIO)after taking in the electric vehicle maker's product event over the weekend.</p>\n<p>Nio (NIO) will kick off order confirmation of the flagship ET7 on January 20 and plans to start making deliveries on March 28, 2022. During the event, Nio (NIO) is noted to have highlighted 20 new features and specs that have been added or enhanced, including the 0-100 km/h acceleration improved to 3.8 seconds from 3.9 seconds.</p>\n<p>\"On the power network front, NIO has 733 power stations to date, while NIO targets to have 1,300 battery swap stations, 6,000 super chargers and 10,000 destination chargers across China by end-2022,\" notes analyst Ming Hsun Lee.</p>\n<p>On the global expansion front, Nio (NIO) plans to enter Germany, Netherlands, Sweden and Denmark in 2022.</p>\n<p>Shares of Nio (NIO) are&nbsp;down 2.30%&nbsp;premarket to $29.36 on a down day overall for Chinese stocks.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio impresses Bank of America with ET7 reveals, expansion plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio impresses Bank of America with ET7 reveals, expansion plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781543-nio-impresses-bank-of-america-with-et7-reveals-expansion-plans><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bank of America reiterates a Buy rating on Nio(NYSE:NIO)after taking in the electric vehicle maker's product event over the weekend.\nNio (NIO) will kick off order confirmation of the flagship ET7 on ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781543-nio-impresses-bank-of-america-with-et7-reveals-expansion-plans\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/news/3781543-nio-impresses-bank-of-america-with-et7-reveals-expansion-plans","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1164238522","content_text":"Bank of America reiterates a Buy rating on Nio(NYSE:NIO)after taking in the electric vehicle maker's product event over the weekend.\nNio (NIO) will kick off order confirmation of the flagship ET7 on January 20 and plans to start making deliveries on March 28, 2022. During the event, Nio (NIO) is noted to have highlighted 20 new features and specs that have been added or enhanced, including the 0-100 km/h acceleration improved to 3.8 seconds from 3.9 seconds.\n\"On the power network front, NIO has 733 power stations to date, while NIO targets to have 1,300 battery swap stations, 6,000 super chargers and 10,000 destination chargers across China by end-2022,\" notes analyst Ming Hsun Lee.\nOn the global expansion front, Nio (NIO) plans to enter Germany, Netherlands, Sweden and Denmark in 2022.\nShares of Nio (NIO) are down 2.30% premarket to $29.36 on a down day overall for Chinese stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699829799,"gmtCreate":1639783265714,"gmtModify":1639783265921,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699829799","repostId":"2192497854","repostType":4,"repost":{"id":"2192497854","pubTimestamp":1639746681,"share":"https://www.laohu8.com/m/news/2192497854?lang=&edition=full","pubTime":"2021-12-17 21:11","market":"us","language":"en","title":"3 Warren Buffett Stocks I Like Heading Into 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2192497854","media":"Motley Fool","summary":"Three of Buffett's largest holdings look strong heading into 2022.","content":"<p>Warren Buffett and his company&nbsp;<b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) are well known for their stock-picking abilities that have been proven over many decades. For this prowess, along with Berkshire's success in the other businesses the conglomerate operates in, the stock has consistently been a winner.</p>\n<p>Between 1965 and 2020, Berkshire's stock has generated compounded annual gains of 20%, compared to the <b>S&amp;P 500</b>'s compounded annual gain of 10.2%, including dividends, over the same timeframe. It's for this very reason that investors watch Buffett and Berkshire's stock picks so closely. Here are three Buffett stocks I like heading into 2022.</p>\n<h2>1. Bank of America</h2>\n<p>America's second-largest bank by assets,&nbsp;<b>Bank of America</b> (NYSE:BAC), also happens to be the second-largest position in Buffett and Berkshire's equities portfolio. Buffett first got in on Bank of America coming out of the Great Recession and currently owns more than 1 billion shares worth nearly $45.8 billion. Early in the pandemic in the middle of 2020, Buffett took advantage of the beaten-down bank sector to plow another $2 billion into Bank of America and now owns nearly 12% of the financial institution's outstanding shares.</p>\n<p>Shares of Bank of America have climbed more than 47% this year and are up more than double from pandemic lows. While the valuation has gotten high, I like Bank of America because it is well-positioned to deal with higher inflation, higher interest rates, and more difficult market conditions that could be seen next year. Higher interest rates benefit Bank of America tremendously because the yields on many of the loans at the bank will increase along with the rate hikes. The consumer is currently in great shape. Since banking is linked to the overall economy and gross domestic product in the U.S. is expected to grow about 4% next year, I think the bank is going to have a good year.</p>\n<h2>2. American Express</h2>\n<p>Berkshire owns more than 151 million shares of the credit card company <b>American Express</b> (NYSE:AXP) for a total value of roughly $24.7 billion, making it the third-largest holding in Berkshire's portfolio. American Express has also had a nice year with the stock price up more than 38%.</p>\n<p>There are two main reasons I like American Express heading into 2022. For one, because the consumer has been so healthy, Americans have been paying off their credit card bills and haven't had as much need to take on debt. As money and benefits from previous stimulus bills run down, that won't always be the case. At the beginning of December, <i>The Wall Street Journal</i> reported that credit card applications had recently hit a pandemic high.</p>\n<p>American Express is also big in the travel, airlines, and lodging businesses, so the more the world continues to recover from the pandemic and COVID-19, the more its business will benefit. Some of those travel-related sectors still aren't fully back yet, especially when you think about international travel.</p>\n<h2>3. U.S. Bancorp</h2>\n<p>Buffett and Berkshire own more than 144 million shares valued at nearly $8.3 billion of the large regional bank <b>U.S. Bancorp </b>(NYSE:USB). The bank is a high-performing commercial bank. It also runs a unique payments business that includes retail credit, debit, prepaid cards, global merchant acquiring, and corporate payment solutions in sectors such as aviation, fleet, transportation, and travel.</p>\n<p>Because the payments business operates in these sectors, the segment could still recover further in 2022 as the world rebounds from COVID-19. Additionally, management is very focused on further integrating the payments and commercial banking businesses because 72% of the bank's business banking customers still don't have a payments product, and half of U.S. Bancorp's payments customers don't have a banking product.</p>\n<p>There's a lot of opportunity for cross-selling. U.S. Bancorp also recently announced its intention to acquire the U.S. banking division of <b>Mitsubishi UFJ Financial Group</b>. This deal will give U.S. Bancorp an additional 190,000 business banking customers and more scale in California, both things that are in line with U.S. Bancorp's current strategy.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Warren Buffett Stocks I Like Heading Into 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Warren Buffett Stocks I Like Heading Into 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/3-warren-buffett-stocks-i-like-heading-into-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett and his company Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) are well known for their stock-picking abilities that have been proven over many decades. For this prowess, along with ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/3-warren-buffett-stocks-i-like-heading-into-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4207":"综合性银行","BK4553":"喜马拉雅资本持仓","USB":"美国合众银行","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4176":"多领域控股","BRK.A":"伯克希尔","BK4166":"消费信贷","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4504":"桥水持仓","AXP":"美国运通","BRK.B":"伯克希尔B","BAC":"美国银行"},"source_url":"https://www.fool.com/investing/2021/12/17/3-warren-buffett-stocks-i-like-heading-into-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192497854","content_text":"Warren Buffett and his company Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) are well known for their stock-picking abilities that have been proven over many decades. For this prowess, along with Berkshire's success in the other businesses the conglomerate operates in, the stock has consistently been a winner.\nBetween 1965 and 2020, Berkshire's stock has generated compounded annual gains of 20%, compared to the S&P 500's compounded annual gain of 10.2%, including dividends, over the same timeframe. It's for this very reason that investors watch Buffett and Berkshire's stock picks so closely. Here are three Buffett stocks I like heading into 2022.\n1. Bank of America\nAmerica's second-largest bank by assets, Bank of America (NYSE:BAC), also happens to be the second-largest position in Buffett and Berkshire's equities portfolio. Buffett first got in on Bank of America coming out of the Great Recession and currently owns more than 1 billion shares worth nearly $45.8 billion. Early in the pandemic in the middle of 2020, Buffett took advantage of the beaten-down bank sector to plow another $2 billion into Bank of America and now owns nearly 12% of the financial institution's outstanding shares.\nShares of Bank of America have climbed more than 47% this year and are up more than double from pandemic lows. While the valuation has gotten high, I like Bank of America because it is well-positioned to deal with higher inflation, higher interest rates, and more difficult market conditions that could be seen next year. Higher interest rates benefit Bank of America tremendously because the yields on many of the loans at the bank will increase along with the rate hikes. The consumer is currently in great shape. Since banking is linked to the overall economy and gross domestic product in the U.S. is expected to grow about 4% next year, I think the bank is going to have a good year.\n2. American Express\nBerkshire owns more than 151 million shares of the credit card company American Express (NYSE:AXP) for a total value of roughly $24.7 billion, making it the third-largest holding in Berkshire's portfolio. American Express has also had a nice year with the stock price up more than 38%.\nThere are two main reasons I like American Express heading into 2022. For one, because the consumer has been so healthy, Americans have been paying off their credit card bills and haven't had as much need to take on debt. As money and benefits from previous stimulus bills run down, that won't always be the case. At the beginning of December, The Wall Street Journal reported that credit card applications had recently hit a pandemic high.\nAmerican Express is also big in the travel, airlines, and lodging businesses, so the more the world continues to recover from the pandemic and COVID-19, the more its business will benefit. Some of those travel-related sectors still aren't fully back yet, especially when you think about international travel.\n3. U.S. Bancorp\nBuffett and Berkshire own more than 144 million shares valued at nearly $8.3 billion of the large regional bank U.S. Bancorp (NYSE:USB). The bank is a high-performing commercial bank. It also runs a unique payments business that includes retail credit, debit, prepaid cards, global merchant acquiring, and corporate payment solutions in sectors such as aviation, fleet, transportation, and travel.\nBecause the payments business operates in these sectors, the segment could still recover further in 2022 as the world rebounds from COVID-19. Additionally, management is very focused on further integrating the payments and commercial banking businesses because 72% of the bank's business banking customers still don't have a payments product, and half of U.S. Bancorp's payments customers don't have a banking product.\nThere's a lot of opportunity for cross-selling. U.S. Bancorp also recently announced its intention to acquire the U.S. banking division of Mitsubishi UFJ Financial Group. This deal will give U.S. Bancorp an additional 190,000 business banking customers and more scale in California, both things that are in line with U.S. Bancorp's current strategy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690583165,"gmtCreate":1639691863789,"gmtModify":1639691863955,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"let see","listText":"let see","text":"let see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690583165","repostId":"2191674549","repostType":2,"repost":{"id":"2191674549","pubTimestamp":1639569287,"share":"https://www.laohu8.com/m/news/2191674549?lang=&edition=full","pubTime":"2021-12-15 19:54","market":"us","language":"en","title":"3 Ultra-Popular Stocks Expected to Increase Sales 981% to 5,569% in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2191674549","media":"Motley Fool","summary":"Jaw-dropping sales growth doesn't always tell investors the full story.","content":"<p>In a little over two weeks, the curtain will close on what should go down as another winning year for the stock market. Through this past weekend, the broad-based <b>S&amp;P 500</b> had gained 25%, which is more than double its average annual total return, including dividends, of 11% over the past four decades.</p>\n<p>But for some ultra-popular stocks, their growth period is just beginning. According to Wall Street's consensus estimate, three widely followed companies are expected to deliver sales growth in 2022 ranging from a low of 981% to as much as 5,569%</p>\n<h2>Sundial Growers: Consensus estimate of 981% sales growth in 2022</h2>\n<p>The first ultra-popular stock expected to deliver a more than tenfold increase in revenue for the upcoming year is Canadian marijuana stock <b>Sundial Growers</b> (NASDAQ:SNDL). Wall Street has Sundial pegged to bring in almost $540 million in sales in 2022, up from an estimated $50.5 million this year.</p>\n<p>Cannabis is a rapidly growing industry, and Canada was the first developed country to give adult-use weed the green light. Since the Oct. 17, 2018, legalization of recreational pot, legal weed sales have been on a fairly steady incline.</p>\n<p>Unfortunately, Canadian licensed producers (LPs) have fared poorly. National and provincial regulators have been slow to authorize growing and retail licenses, and the LPs themselves did a poor job of managing their assets, budgeting their cash, and assessing the actual demand for pot products.</p>\n<p>The reason Sundial is expected to deliver such a sizable jump in revenue next year has everything to do with acquisitions and virtually nothing to do with organic growth. In July, Sundial closed a cash-and-stock deal to acquire retailer <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a>. It's also in the midst of purchasing liquor store chain <b>Alcanna</b> (OTC:LQSIF) in an all-stock deal that was initially valued at $346 million.&nbsp; The Alcanna buyout, should it close, will represent the bulk of Sundial's sales boost in 2022.</p>\n<p>While I understand that some investors are fascinated by penny stocks and believe they offer more upside potential than established companies with higher share prices, this rarely turns out to be the case. Sundial, whose shares could be purchased for less than $0.59 as of this past weekend, has been burying its investors under the weight of new share issuances for 14 months and counting. The company has issued approximately 1.6 billion new shares over that time, and rather than utilize its cash to acquire Alcanna, the company intends to issue another 387.3 million shares. In other words, Sundial could be weeks away from having 2.5 billion shares outstanding.</p>\n<p>With so many shares outstanding and cannabis operations that have gone nowhere in years, Sundial's chance of generating a meaningful per-share profit is pretty much zero. At this point, a reverse split might be the only thing that'll save this \"growth stock\" from delisting.</p>\n<h2>Inovio Pharmaceuticals: Consensus estimate of 3,258% sales growth in 2022</h2>\n<p>Another ultra-popular company that's expected to deliver jaw-dropping sales growth next year is clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). Wall Street anticipates Inovio will see sales skyrocket from a consensus of just $7.4 million this year to almost $126 million in 2022. That's an increase of well over 3,200%.</p>\n<p>Though Inovio has an extensive pipeline that covers infectious diseases, cancer, and human papillomavirus-targeted diseases, Wall Street's aggressive sales growth estimate appears to be tied to the company's development of a coronavirus disease 2019 (COVID-19) vaccine.</p>\n<p>At the moment, Inovio has two COVID-19 candidates in development. INO-4800 is the furthest along, with phase 3 global studies under way via the Innovate trial. The other is INO-4802, a preclinical \"next-generation\" COVID-19 vaccine targeted at major variants of the disease.</p>\n<p>While Inovio looked as if it would be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the first drugmakers to reach late-stage clinical trials in the U.S. last year, everything came crashing to a halt when the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on INO-4800 and the company's proprietary hand-held delivery device, Cellectra in September 2020. This partial hold on phase 3 trials was only lifted last month. Thus, for 14 months, Inovio couldn't advance its COVID-19 vaccine to late-stage trials in the U.S. and was forced to take its large-scale study overseas.</p>\n<p>Perhaps the bigger concern for investors is that Inovio Pharmaceuticals has never brought a drug to pharmacy shelves. As noted, Inovio is never hurting for promising preclinical and clinical candidates. But more than four decades after its inception, Inovio still doesn't have a way to generate recurring revenue. Though it's possible INO-4800 joins a crowded field of COVID-19 vaccine candidates, history suggests disappointment is the more likely outcome.</p>\n<h2>Nikola: Consensus estimate of 5,569% sales growth in 2022</h2>\n<p>However, the biggest growth opportunity, at least on this list, comes from electric vehicle (EV) and fuel-cell EV manufacturer <b>Nikola</b> (NASDAQ:NKLA). The expectation is for Nikola to grow revenue from an estimated $2.6 million in 2021 to about $148.5 million next year. That's an increase of more than 5,500%.</p>\n<p>Developed countries are going to take whatever steps they can over the coming years and decades to combat climate change. One of the easiest and most visible ways to reduce our carbon footprint is to go green with EVs. Replacing consumer and commercial vehicles is a multidecade process that could very well allow a dozen or more new automakers to shine. Nikola, which primarily targets enterprise fleets, is aiming to be one of those transformative businesses.</p>\n<p>The boost in sales for Nikola is almost certainly the result of landing two agreements in October. The company secured a letter of intent from PGT Trucking for 100 Nikola Tre heavy-duty fuel-cell EVs, and formed a collaboration with <b>TC Energy</b>&nbsp;to develop hydrogen hubs for the refueling of hydrogen-powered heavy-duty trucks.</p>\n<p>But for all the positive news and momentum in the sails of the EV industry, Nikola has been shrouded by a dark cloud. It began last year, when noted short-side firm Hindenburg Research alleged Nikola was a fraud. Although many of Hindenburg's claims would be proved untrue by an independent review, certain allegations, including Nikola's pre-sell figures, were deemed to be inaccurate. This led the Securities and Exchange Commission to probe the company.</p>\n<p>Additionally, founder Trevor Milton, who stepped down last year, was indicted by the U.S. Department of Justice this past July for making false and misleading statements to retail investors.</p>\n<p>What excitement did surround Nikola has long since disappeared as investor trust in the company has been decimated. It's also not clear if Nikola has anywhere near enough capital to ramp up production.</p>\n<p>Long story short, the lesson from this stock trio is that rapid sales growth often doesn't tell investors the full story.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks Expected to Increase Sales 981% to 5,569% in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks Expected to Increase Sales 981% to 5,569% in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 19:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/15/3-popular-stock-increase-sales-981-to-5569-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a little over two weeks, the curtain will close on what should go down as another winning year for the stock market. Through this past weekend, the broad-based S&P 500 had gained 25%, which is more...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/15/3-popular-stock-increase-sales-981-to-5569-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","BK4149":"建筑机械与重型卡车","INO":"伊诺维奥制药","NKLA":"Nikola Corporation","BK4551":"寇图资本持仓","BK4557":"大麻股","BK4562":"SPAC上市公司","BK4547":"WSB热门概念","BK4568":"美国抗疫概念","BK4555":"新能源车","SNDL":"SNDL Inc."},"source_url":"https://www.fool.com/investing/2021/12/15/3-popular-stock-increase-sales-981-to-5569-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191674549","content_text":"In a little over two weeks, the curtain will close on what should go down as another winning year for the stock market. Through this past weekend, the broad-based S&P 500 had gained 25%, which is more than double its average annual total return, including dividends, of 11% over the past four decades.\nBut for some ultra-popular stocks, their growth period is just beginning. According to Wall Street's consensus estimate, three widely followed companies are expected to deliver sales growth in 2022 ranging from a low of 981% to as much as 5,569%\nSundial Growers: Consensus estimate of 981% sales growth in 2022\nThe first ultra-popular stock expected to deliver a more than tenfold increase in revenue for the upcoming year is Canadian marijuana stock Sundial Growers (NASDAQ:SNDL). Wall Street has Sundial pegged to bring in almost $540 million in sales in 2022, up from an estimated $50.5 million this year.\nCannabis is a rapidly growing industry, and Canada was the first developed country to give adult-use weed the green light. Since the Oct. 17, 2018, legalization of recreational pot, legal weed sales have been on a fairly steady incline.\nUnfortunately, Canadian licensed producers (LPs) have fared poorly. National and provincial regulators have been slow to authorize growing and retail licenses, and the LPs themselves did a poor job of managing their assets, budgeting their cash, and assessing the actual demand for pot products.\nThe reason Sundial is expected to deliver such a sizable jump in revenue next year has everything to do with acquisitions and virtually nothing to do with organic growth. In July, Sundial closed a cash-and-stock deal to acquire retailer Inner Spirit Holdings. It's also in the midst of purchasing liquor store chain Alcanna (OTC:LQSIF) in an all-stock deal that was initially valued at $346 million.  The Alcanna buyout, should it close, will represent the bulk of Sundial's sales boost in 2022.\nWhile I understand that some investors are fascinated by penny stocks and believe they offer more upside potential than established companies with higher share prices, this rarely turns out to be the case. Sundial, whose shares could be purchased for less than $0.59 as of this past weekend, has been burying its investors under the weight of new share issuances for 14 months and counting. The company has issued approximately 1.6 billion new shares over that time, and rather than utilize its cash to acquire Alcanna, the company intends to issue another 387.3 million shares. In other words, Sundial could be weeks away from having 2.5 billion shares outstanding.\nWith so many shares outstanding and cannabis operations that have gone nowhere in years, Sundial's chance of generating a meaningful per-share profit is pretty much zero. At this point, a reverse split might be the only thing that'll save this \"growth stock\" from delisting.\nInovio Pharmaceuticals: Consensus estimate of 3,258% sales growth in 2022\nAnother ultra-popular company that's expected to deliver jaw-dropping sales growth next year is clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). Wall Street anticipates Inovio will see sales skyrocket from a consensus of just $7.4 million this year to almost $126 million in 2022. That's an increase of well over 3,200%.\nThough Inovio has an extensive pipeline that covers infectious diseases, cancer, and human papillomavirus-targeted diseases, Wall Street's aggressive sales growth estimate appears to be tied to the company's development of a coronavirus disease 2019 (COVID-19) vaccine.\nAt the moment, Inovio has two COVID-19 candidates in development. INO-4800 is the furthest along, with phase 3 global studies under way via the Innovate trial. The other is INO-4802, a preclinical \"next-generation\" COVID-19 vaccine targeted at major variants of the disease.\nWhile Inovio looked as if it would be one of the first drugmakers to reach late-stage clinical trials in the U.S. last year, everything came crashing to a halt when the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on INO-4800 and the company's proprietary hand-held delivery device, Cellectra in September 2020. This partial hold on phase 3 trials was only lifted last month. Thus, for 14 months, Inovio couldn't advance its COVID-19 vaccine to late-stage trials in the U.S. and was forced to take its large-scale study overseas.\nPerhaps the bigger concern for investors is that Inovio Pharmaceuticals has never brought a drug to pharmacy shelves. As noted, Inovio is never hurting for promising preclinical and clinical candidates. But more than four decades after its inception, Inovio still doesn't have a way to generate recurring revenue. Though it's possible INO-4800 joins a crowded field of COVID-19 vaccine candidates, history suggests disappointment is the more likely outcome.\nNikola: Consensus estimate of 5,569% sales growth in 2022\nHowever, the biggest growth opportunity, at least on this list, comes from electric vehicle (EV) and fuel-cell EV manufacturer Nikola (NASDAQ:NKLA). The expectation is for Nikola to grow revenue from an estimated $2.6 million in 2021 to about $148.5 million next year. That's an increase of more than 5,500%.\nDeveloped countries are going to take whatever steps they can over the coming years and decades to combat climate change. One of the easiest and most visible ways to reduce our carbon footprint is to go green with EVs. Replacing consumer and commercial vehicles is a multidecade process that could very well allow a dozen or more new automakers to shine. Nikola, which primarily targets enterprise fleets, is aiming to be one of those transformative businesses.\nThe boost in sales for Nikola is almost certainly the result of landing two agreements in October. The company secured a letter of intent from PGT Trucking for 100 Nikola Tre heavy-duty fuel-cell EVs, and formed a collaboration with TC Energy to develop hydrogen hubs for the refueling of hydrogen-powered heavy-duty trucks.\nBut for all the positive news and momentum in the sails of the EV industry, Nikola has been shrouded by a dark cloud. It began last year, when noted short-side firm Hindenburg Research alleged Nikola was a fraud. Although many of Hindenburg's claims would be proved untrue by an independent review, certain allegations, including Nikola's pre-sell figures, were deemed to be inaccurate. This led the Securities and Exchange Commission to probe the company.\nAdditionally, founder Trevor Milton, who stepped down last year, was indicted by the U.S. Department of Justice this past July for making false and misleading statements to retail investors.\nWhat excitement did surround Nikola has long since disappeared as investor trust in the company has been decimated. It's also not clear if Nikola has anywhere near enough capital to ramp up production.\nLong story short, the lesson from this stock trio is that rapid sales growth often doesn't tell investors the full story.","news_type":1},"isVote":1,"tweetType":1,"viewCount":514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690589177,"gmtCreate":1639691736246,"gmtModify":1639691849682,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"hurray","listText":"hurray","text":"hurray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690589177","repostId":"1117904160","repostType":2,"repost":{"id":"1117904160","pubTimestamp":1639620135,"share":"https://www.laohu8.com/m/news/1117904160?lang=&edition=full","pubTime":"2021-12-16 10:02","market":"us","language":"en","title":"Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18","url":"https://stock-news.laohu8.com/highlight/detail?id=1117904160","media":"InvestorPlace","summary":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s ","content":"<p><b>Nio</b>(NYSE:<b><u>NIO</u></b>) Day is quickly approaching and there’s a lot for investors to be excited about.</p>\n<p>Let’s dive into all the latest news that traders of NIO stock need to know about today.</p>\n<ul>\n <li>First off, it looks like Nio Day will see the company&nbsp;revealing several new electric vehicles (EVs).</li>\n <li>That includes a possible two new vehicle models, as well as a new vehicle brand.</li>\n <li>Current rumors claim one of the new vehicles in the ET5.</li>\n <li>This is a mid-size sedan that will likely compete with other EVs on the market&nbsp;at a lower price than the ET7.</li>\n <li>Talk about the ET5 continues to heat up today after the EV company shared an image on its website.</li>\n <li>This shows the outline of a still-unnamed vehicle from the company and many believe it to be the ET5.</li>\n <li>There’s also talk of a potential ET(, which would be a sports coupe.</li>\n</ul>\n<ul>\n <li>Other rumors claim we might see the company reveal a multipurpose EV as well during the event.</li>\n <li>Of course, investors will have to wait until Nio Day before they can truly know what the next EVs from the company are.</li>\n <li>Luckily, that’s not too far away.</li>\n <li>Nio will hold its special event on December 18, which is this Saturday.</li>\n <li>The reveal event will take place at the Olympic Sports Center in Suzhou, China.</li>\n <li>Now we just have to wait for Nio Day to get here and confirm or bust all these rumors!</li>\n</ul>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 10:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s dive into all the latest news that traders of NIO stock need to know about today.\n\nFirst off, it ...</p>\n\n<a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117904160","content_text":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s dive into all the latest news that traders of NIO stock need to know about today.\n\nFirst off, it looks like Nio Day will see the company revealing several new electric vehicles (EVs).\nThat includes a possible two new vehicle models, as well as a new vehicle brand.\nCurrent rumors claim one of the new vehicles in the ET5.\nThis is a mid-size sedan that will likely compete with other EVs on the market at a lower price than the ET7.\nTalk about the ET5 continues to heat up today after the EV company shared an image on its website.\nThis shows the outline of a still-unnamed vehicle from the company and many believe it to be the ET5.\nThere’s also talk of a potential ET(, which would be a sports coupe.\n\n\nOther rumors claim we might see the company reveal a multipurpose EV as well during the event.\nOf course, investors will have to wait until Nio Day before they can truly know what the next EVs from the company are.\nLuckily, that’s not too far away.\nNio will hold its special event on December 18, which is this Saturday.\nThe reveal event will take place at the Olympic Sports Center in Suzhou, China.\nNow we just have to wait for Nio Day to get here and confirm or bust all these rumors!","news_type":1},"isVote":1,"tweetType":1,"viewCount":726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690334260,"gmtCreate":1639632309401,"gmtModify":1639632440388,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690334260","repostId":"2191099021","repostType":2,"isVote":1,"tweetType":1,"viewCount":960,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690334652,"gmtCreate":1639632284485,"gmtModify":1639632416387,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"good thought","listText":"good thought","text":"good thought","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690334652","repostId":"1191022113","repostType":2,"repost":{"id":"1191022113","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639626011,"share":"https://www.laohu8.com/m/news/1191022113?lang=&edition=full","pubTime":"2021-12-16 11:40","market":"us","language":"en","title":"Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival","url":"https://stock-news.laohu8.com/highlight/detail?id=1191022113","media":"Benzinga","summary":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — i","content":"<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p>\n<p>The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p>\n<p>Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p>\n<p>Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p>\n<p>The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p>\n<p>Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p>\n<p>Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p>\n<p>Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p>\n<p>Here are the other key trades on Wednesday:</p>\n<ul>\n <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>\n <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-16 11:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p>\n<p>The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p>\n<p>Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p>\n<p>Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p>\n<p>The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p>\n<p>Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p>\n<p>Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p>\n<p>Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p>\n<p>Here are the other key trades on Wednesday:</p>\n<ul>\n <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>\n <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","ARKQ":"ARK Autonomous Technology & Robotics ETF","HOOD":"Robinhood","ROKU":"Roku Inc","ARKW":"ARK Next Generation Internation ETF","ARKK":"ARK Innovation ETF","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191022113","content_text":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in Tesla Inc, booking profit in the stock as it rose after days of losses.\nThe stock pared earlier losses to close 1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.\nArk Invest sold the shares via the Ark Innovation ETF(BATS:ARKK), the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ) and the Ark Next Generation Internet ETF(BATS:ARKW) on Wednesday.\nTesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.\nThe three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.\nArk Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.\nTesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the $3,000 mark by the end of 2025.\nWood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker Xpeng Inc.\nHere are the other key trades on Wednesday:\n\nBought 104,489 shares — estimated to be worth $21.3 million — in Roku Inc on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.\nBought 705,660 shares — estimated to be worth $13.7 million — in Robinhood Markets Inc. The stock closed 1.93% higher at $19.50 a share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690335703,"gmtCreate":1639632201836,"gmtModify":1639632202079,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"hurray","listText":"hurray","text":"hurray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690335703","repostId":"1117904160","repostType":2,"repost":{"id":"1117904160","pubTimestamp":1639620135,"share":"https://www.laohu8.com/m/news/1117904160?lang=&edition=full","pubTime":"2021-12-16 10:02","market":"us","language":"en","title":"Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18","url":"https://stock-news.laohu8.com/highlight/detail?id=1117904160","media":"InvestorPlace","summary":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s ","content":"<p><b>Nio</b>(NYSE:<b><u>NIO</u></b>) Day is quickly approaching and there’s a lot for investors to be excited about.</p>\n<p>Let’s dive into all the latest news that traders of NIO stock need to know about today.</p>\n<ul>\n <li>First off, it looks like Nio Day will see the company&nbsp;revealing several new electric vehicles (EVs).</li>\n <li>That includes a possible two new vehicle models, as well as a new vehicle brand.</li>\n <li>Current rumors claim one of the new vehicles in the ET5.</li>\n <li>This is a mid-size sedan that will likely compete with other EVs on the market&nbsp;at a lower price than the ET7.</li>\n <li>Talk about the ET5 continues to heat up today after the EV company shared an image on its website.</li>\n <li>This shows the outline of a still-unnamed vehicle from the company and many believe it to be the ET5.</li>\n <li>There’s also talk of a potential ET(, which would be a sports coupe.</li>\n</ul>\n<ul>\n <li>Other rumors claim we might see the company reveal a multipurpose EV as well during the event.</li>\n <li>Of course, investors will have to wait until Nio Day before they can truly know what the next EVs from the company are.</li>\n <li>Luckily, that’s not too far away.</li>\n <li>Nio will hold its special event on December 18, which is this Saturday.</li>\n <li>The reveal event will take place at the Olympic Sports Center in Suzhou, China.</li>\n <li>Now we just have to wait for Nio Day to get here and confirm or bust all these rumors!</li>\n</ul>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 10:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s dive into all the latest news that traders of NIO stock need to know about today.\n\nFirst off, it ...</p>\n\n<a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117904160","content_text":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s dive into all the latest news that traders of NIO stock need to know about today.\n\nFirst off, it looks like Nio Day will see the company revealing several new electric vehicles (EVs).\nThat includes a possible two new vehicle models, as well as a new vehicle brand.\nCurrent rumors claim one of the new vehicles in the ET5.\nThis is a mid-size sedan that will likely compete with other EVs on the market at a lower price than the ET7.\nTalk about the ET5 continues to heat up today after the EV company shared an image on its website.\nThis shows the outline of a still-unnamed vehicle from the company and many believe it to be the ET5.\nThere’s also talk of a potential ET(, which would be a sports coupe.\n\n\nOther rumors claim we might see the company reveal a multipurpose EV as well during the event.\nOf course, investors will have to wait until Nio Day before they can truly know what the next EVs from the company are.\nLuckily, that’s not too far away.\nNio will hold its special event on December 18, which is this Saturday.\nThe reveal event will take place at the Olympic Sports Center in Suzhou, China.\nNow we just have to wait for Nio Day to get here and confirm or bust all these rumors!","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690018127,"gmtCreate":1639613230300,"gmtModify":1639613230475,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"need booster","listText":"need booster","text":"need booster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690018127","repostId":"1194155872","repostType":4,"repost":{"id":"1194155872","pubTimestamp":1639613035,"share":"https://www.laohu8.com/m/news/1194155872?lang=&edition=full","pubTime":"2021-12-16 08:03","market":"us","language":"en","title":"Rebound Anticipated For Singapore Stock Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1194155872","media":"RTTNews","summary":"The Singapore stock market headed south again on Wednesday, one session after ending the two-day sli","content":"<p>The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.</p>\n<p>The global forecast for the Asian&nbsp;markets&nbsp;is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.</p>\n<p>The STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.</p>\n<p>For the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.</p>\n<p>Among the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.</p>\n<p>The lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.</p>\n<p>The Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&amp;P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.</p>\n<p>The late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.</p>\n<p>The Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.</p>\n<p>Meanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.</p>\n<p>Despite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.</p>\n<p>Crude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rebound Anticipated For Singapore Stock Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRebound Anticipated For Singapore Stock Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 08:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just ...</p>\n\n<a href=\"https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194155872","content_text":"The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.\nThe global forecast for the Asian markets is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.\nThe STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.\nFor the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.\nAmong the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.\nThe lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.\nThe Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.\nThe late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.\nThe Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.\nMeanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.\nDespite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.\nCrude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605090796,"gmtCreate":1639090444622,"gmtModify":1639090444779,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605090796","repostId":"1113203379","repostType":4,"repost":{"id":"1113203379","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639061813,"share":"https://www.laohu8.com/m/news/1113203379?lang=&edition=full","pubTime":"2021-12-09 22:56","market":"us","language":"en","title":"Crypto stocks dipped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1113203379","media":"Tiger Newspress","summary":"Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining","content":"<p>Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/bf3f2d610b479a57d75ff6df427bcd26\" tg-width=\"412\" tg-height=\"656\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks dipped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks dipped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-09 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/bf3f2d610b479a57d75ff6df427bcd26\" tg-width=\"412\" tg-height=\"656\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIOT":"Riot Platforms"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113203379","content_text":"Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605090515,"gmtCreate":1639090391250,"gmtModify":1639090391439,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605090515","repostId":"1165217477","repostType":4,"repost":{"id":"1165217477","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639067136,"share":"https://www.laohu8.com/m/news/1165217477?lang=&edition=full","pubTime":"2021-12-10 00:25","market":"us","language":"en","title":"Grab and Lucid stocks plunged more than 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165217477","media":"Tiger Newspress","summary":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","content":"<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab and Lucid stocks plunged more than 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab and Lucid stocks plunged more than 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 00:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings","LCID":"Lucid Group Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165217477","content_text":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603122557,"gmtCreate":1638376688184,"gmtModify":1638376715328,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"coming up soon","listText":"coming up soon","text":"coming up soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603122557","repostId":"1187123549","repostType":2,"repost":{"id":"1187123549","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638370614,"share":"https://www.laohu8.com/m/news/1187123549?lang=&edition=full","pubTime":"2021-12-01 22:56","market":"us","language":"en","title":"Xpeng Motors shares changed from up to down by 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187123549","media":"Tiger Newspress","summary":"Xpeng Motors shares changed from up to down by 4% in morning trading.\n\nXPeng Inc. today announced it","content":"<p>Xpeng Motors shares changed from up to down by 4%&nbsp;in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b410bb36e06e8b1a13514fa0a4ee9cf0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>XPeng Inc.&nbsp;today announced its vehicle delivery results for November 2021.</p>\n<p>XPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.</p>\n<p>Deliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).</p>\n<p>As of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.</p>\n<p>The Company’s cumulative deliveries reached 121,953 as of the end of November 2021.</p>\n<p>In November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.</p>\n<p>XPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xpeng Motors shares changed from up to down by 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXpeng Motors shares changed from up to down by 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xpeng Motors shares changed from up to down by 4%&nbsp;in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b410bb36e06e8b1a13514fa0a4ee9cf0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>XPeng Inc.&nbsp;today announced its vehicle delivery results for November 2021.</p>\n<p>XPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.</p>\n<p>Deliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).</p>\n<p>As of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.</p>\n<p>The Company’s cumulative deliveries reached 121,953 as of the end of November 2021.</p>\n<p>In November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.</p>\n<p>XPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187123549","content_text":"Xpeng Motors shares changed from up to down by 4% in morning trading.\n\nXPeng Inc. today announced its vehicle delivery results for November 2021.\nXPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.\nDeliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).\nAs of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.\nThe Company’s cumulative deliveries reached 121,953 as of the end of November 2021.\nIn November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.\nXPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.","news_type":1},"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609690307,"gmtCreate":1638274281322,"gmtModify":1638274281408,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609690307","repostId":"1192203085","repostType":4,"repost":{"id":"1192203085","pubTimestamp":1638273550,"share":"https://www.laohu8.com/m/news/1192203085?lang=&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p>\n<p>Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p>\n<p>Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p>\n<p>The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p>\n<p>Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p>\n<p>Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p>\n<p>They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p>\n<p>The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p>\n<p>Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p>\n<p>If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p>\n<p>One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p>\n<p>The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p>\n<p>“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p>\n<p>Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p>\n<p>More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p>\n<p>Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p>\n<p>She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p>\n<p>“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p>\n<p>A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p>\n<p>Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p>\n<p>Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p>\n<p>Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p>\n<p>Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p>\n<p>Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p>\n<p>“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p>\n<p>It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p>\n<p>“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p>\n<p>Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p>\n<p>Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p>\n<p>“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p>\n<p>Pfizer and Merck said they expect their drugs to be effective against Omicron.</p>\n<p>Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests ...</p>\n\n<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609604793,"gmtCreate":1638274097547,"gmtModify":1638274097637,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"think again","listText":"think again","text":"think again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609604793","repostId":"2187947581","repostType":4,"repost":{"id":"2187947581","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638270669,"share":"https://www.laohu8.com/m/news/2187947581?lang=&edition=full","pubTime":"2021-11-30 19:11","market":"us","language":"en","title":"Bitcoin miner Griid Infrastructure to go public via $3.3 bln SPAC deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2187947581","media":"Reuters","summary":"Nov 30 (Reuters) - Bitcoin miner Griid Infrastructure will go public by merging with blank-check fir","content":"<p>Nov 30 (Reuters) - Bitcoin miner Griid Infrastructure will go public by merging with blank-check firm <a href=\"https://laohu8.com/S/ADEX\">Adit EdTech Acquisition</a> Corp in a deal valuing the combined company at about $3.3 billion.</p>\n<p>Griid Infrastructure will list on the New York Stock Exchange under the new ticker symbol \"GRDI\" after its deal with the special purpose acquisition company (SPAC), Adit EdTech said in a statement on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin miner Griid Infrastructure to go public via $3.3 bln SPAC deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin miner Griid Infrastructure to go public via $3.3 bln SPAC deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-30 19:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nov 30 (Reuters) - Bitcoin miner Griid Infrastructure will go public by merging with blank-check firm <a href=\"https://laohu8.com/S/ADEX\">Adit EdTech Acquisition</a> Corp in a deal valuing the combined company at about $3.3 billion.</p>\n<p>Griid Infrastructure will list on the New York Stock Exchange under the new ticker symbol \"GRDI\" after its deal with the special purpose acquisition company (SPAC), Adit EdTech said in a statement on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2187947581","content_text":"Nov 30 (Reuters) - Bitcoin miner Griid Infrastructure will go public by merging with blank-check firm Adit EdTech Acquisition Corp in a deal valuing the combined company at about $3.3 billion.\nGriid Infrastructure will list on the New York Stock Exchange under the new ticker symbol \"GRDI\" after its deal with the special purpose acquisition company (SPAC), Adit EdTech said in a statement on Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609605147,"gmtCreate":1638273926952,"gmtModify":1638273927084,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"enjoy wen it go up","listText":"enjoy wen it go up","text":"enjoy wen it go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609605147","repostId":"1164097100","repostType":2,"repost":{"id":"1164097100","pubTimestamp":1638237374,"share":"https://www.laohu8.com/m/news/1164097100?lang=&edition=full","pubTime":"2021-11-30 09:56","market":"us","language":"en","title":"AMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets","url":"https://stock-news.laohu8.com/highlight/detail?id=1164097100","media":"InvestorPlace","summary":"AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is","content":"<p><b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible tokenswith Marvel&nbsp;<i>Spider-Man: No Way Home</i>tickets. The combo of meme stock and NFTs certainly has investors watching!</p>\n<p>So what do you need to know?</p>\n<p>AMC is truly breaking new ground with its first-ever NFT promotion. A joint effort between&nbsp;<b>Sony Pictures</b>&nbsp;and AMC, the collaboration will yield roughly 90,000 NFTs. The NFTs will go to a limited number of ticket buyers for the Dec. 16 premier.</p>\n<p>Now, there are some other conditions investors should note. To qualify for the NFTs, buyers must be members of AMC Stubs A-list, Stubs Premiere or AMC Investor Connect on the AMC website. Buyers must have their Stubs account number associated with the purchase, and their ticket must be scanned upon entrance to the movie. In addition, the NFTs must be redeemed by March 1.</p>\n<p>Despite the enticing offer, AMC stock was fairly unresponsive to the news, down 2% on the day.</p>\n<p>Can AMC Stock Overcome Its Meme-ified Past?</p>\n<p>AMC remains hopeful that it can entice the NFT bulls, and Spider-Man may be just the person it needs. Adam Aron, CEO of AMC,commented onthe giveaway and said this:</p>\n<blockquote>\n “… the incredibly talented artists at Cub Studios are creating more than 100 unique NFTs giving appropriate respect to this most recent incarnation of the timeless and ever so popular Spider-Man franchise. For those members of our AMC Stubs A-List, AMC Stubs Premiere and AMC Investor Connect program who are among the first to purchase or reserve their ticket to opening day at AMC, this unprecedented Spider-Man NFT is truly a ticket-purchase gift like nothing we’ve ever offered before. … So, my advice is to get your Spider-Man tickets as quickly as you can.”\n</blockquote>\n<p>AMC believes it can turn around its tumultuous past by calling in a crypto lifeline. If the moves catch the gaze of the Reddit bulls, it certainly remains a possibility.</p>\n<p>With AMC currently at $36.84, it remains to be seen how much movement the NFT offer will grant it. One thing for sure is that all eyes are on AMC stock prices heading into the December premier.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 09:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible ...</p>\n\n<a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164097100","content_text":"AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible tokenswith Marvel Spider-Man: No Way Hometickets. The combo of meme stock and NFTs certainly has investors watching!\nSo what do you need to know?\nAMC is truly breaking new ground with its first-ever NFT promotion. A joint effort between Sony Pictures and AMC, the collaboration will yield roughly 90,000 NFTs. The NFTs will go to a limited number of ticket buyers for the Dec. 16 premier.\nNow, there are some other conditions investors should note. To qualify for the NFTs, buyers must be members of AMC Stubs A-list, Stubs Premiere or AMC Investor Connect on the AMC website. Buyers must have their Stubs account number associated with the purchase, and their ticket must be scanned upon entrance to the movie. In addition, the NFTs must be redeemed by March 1.\nDespite the enticing offer, AMC stock was fairly unresponsive to the news, down 2% on the day.\nCan AMC Stock Overcome Its Meme-ified Past?\nAMC remains hopeful that it can entice the NFT bulls, and Spider-Man may be just the person it needs. Adam Aron, CEO of AMC,commented onthe giveaway and said this:\n\n “… the incredibly talented artists at Cub Studios are creating more than 100 unique NFTs giving appropriate respect to this most recent incarnation of the timeless and ever so popular Spider-Man franchise. For those members of our AMC Stubs A-List, AMC Stubs Premiere and AMC Investor Connect program who are among the first to purchase or reserve their ticket to opening day at AMC, this unprecedented Spider-Man NFT is truly a ticket-purchase gift like nothing we’ve ever offered before. … So, my advice is to get your Spider-Man tickets as quickly as you can.”\n\nAMC believes it can turn around its tumultuous past by calling in a crypto lifeline. If the moves catch the gaze of the Reddit bulls, it certainly remains a possibility.\nWith AMC currently at $36.84, it remains to be seen how much movement the NFT offer will grant it. One thing for sure is that all eyes are on AMC stock prices heading into the December premier.","news_type":1},"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126513,"gmtCreate":1637746134207,"gmtModify":1637746138028,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"enjoy the holiday","listText":"enjoy the holiday","text":"enjoy the holiday","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126513","repostId":"1151702113","repostType":4,"repost":{"id":"1151702113","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637559387,"share":"https://www.laohu8.com/m/news/1151702113?lang=&edition=full","pubTime":"2021-11-22 13:36","market":"us","language":"en","title":"Reminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1151702113","media":"Tiger Newspress","summary":"November 25th (this Thursday) is Thanksgiving Day.All financial markets in the United States, includ","content":"<p>November 25th&nbsp;(this&nbsp;Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.</p>\n<p>On November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at&nbsp;U.S.&nbsp;Eastern Time&nbsp;1 p.m.(Beijing time/SGT&nbsp;2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.</p>\n<p>Stocks&nbsp;in&nbsp;China,Britain, Australia&nbsp;and Singapore&nbsp;will&nbsp;trade as usual.</p>\n<p><b>Background</b></p>\n<p>Thanksgiving&nbsp;Day&nbsp;is a national&nbsp;holiday&nbsp;celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the&nbsp;harvest&nbsp;and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving&nbsp;Day&nbsp;is celebrated on the&nbsp;second Monday of October&nbsp;in Canada and on the&nbsp;fourth Thursday of November&nbsp;in the United States and around the same part of the year in other places.&nbsp;</p>\n<p>Black Friday&nbsp;is a colloquial term for the Friday following&nbsp;Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight&nbsp;or even on Thanksgiving Day.</p>\n<p><img src=\"https://static.tigerbbs.com/af950d731994581f416aa413e17585d3\" tg-width=\"450\" tg-height=\"281\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-22 13:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>November 25th&nbsp;(this&nbsp;Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.</p>\n<p>On November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at&nbsp;U.S.&nbsp;Eastern Time&nbsp;1 p.m.(Beijing time/SGT&nbsp;2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.</p>\n<p>Stocks&nbsp;in&nbsp;China,Britain, Australia&nbsp;and Singapore&nbsp;will&nbsp;trade as usual.</p>\n<p><b>Background</b></p>\n<p>Thanksgiving&nbsp;Day&nbsp;is a national&nbsp;holiday&nbsp;celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the&nbsp;harvest&nbsp;and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving&nbsp;Day&nbsp;is celebrated on the&nbsp;second Monday of October&nbsp;in Canada and on the&nbsp;fourth Thursday of November&nbsp;in the United States and around the same part of the year in other places.&nbsp;</p>\n<p>Black Friday&nbsp;is a colloquial term for the Friday following&nbsp;Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight&nbsp;or even on Thanksgiving Day.</p>\n<p><img src=\"https://static.tigerbbs.com/af950d731994581f416aa413e17585d3\" tg-width=\"450\" tg-height=\"281\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151702113","content_text":"November 25th (this Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.\nOn November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at U.S. Eastern Time 1 p.m.(Beijing time/SGT 2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.\nStocks in China,Britain, Australia and Singapore will trade as usual.\nBackground\nThanksgiving Day is a national holiday celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the harvest and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving Day is celebrated on the second Monday of October in Canada and on the fourth Thursday of November in the United States and around the same part of the year in other places. \nBlack Friday is a colloquial term for the Friday following Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight or even on Thanksgiving Day.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698851243,"gmtCreate":1640347676382,"gmtModify":1640347676614,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698851243","repostId":"2193127176","repostType":4,"repost":{"id":"2193127176","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640345481,"share":"https://www.laohu8.com/m/news/2193127176?lang=&edition=full","pubTime":"2021-12-24 19:31","market":"us","language":"en","title":"Japan health panel approves Merck's oral COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2193127176","media":"Reuters","summary":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COV","content":"<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan health panel approves Merck's oral COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan health panel approves Merck's oral COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","MRK":"默沙东","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4516":"特朗普概念","BK4007":"制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193127176","content_text":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck & Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.\nThe panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.\nJapan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.\nIn addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill developed by Pfizer Inc. And Japan's Shionogi & Co is expected to soon file for approval of its own treatment supplying another 1 million doses by early next year.\nU.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.\nCountries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.\nJapan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":869,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868026688,"gmtCreate":1632556527144,"gmtModify":1632657795625,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"hope to success","listText":"hope to success","text":"hope to success","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/868026688","repostId":"1117076176","repostType":4,"repost":{"id":"1117076176","pubTimestamp":1632530515,"share":"https://www.laohu8.com/m/news/1117076176?lang=&edition=full","pubTime":"2021-09-25 08:41","market":"us","language":"en","title":"Cathie Wood Knows Something About Zoom That You Don’t","url":"https://stock-news.laohu8.com/highlight/detail?id=1117076176","media":"investorplace","summary":"ZM stock is down about 20% YTD, but there are reasons to still favor this video-conferencing pick\nEd","content":"<p>ZM stock is down about 20% YTD, but there are reasons to still favor this video-conferencing pick</p>\n<p><i>Editor’s Note: This article is part ofJoanna’s Top Trades</i>—<i>a weekly feature dedicated toward making you money within a specific space. Joanna’s pick for this week is</i><b><i>Zoom</i></b><i>(NASDAQ:</i><i><b><u>ZM</u></b></i><i>) as the top stock to trade this week.</i></p>\n<p>We all know video-calling software maker<b>Zoom</b>&nbsp;(NASDAQ:<b><u>ZM</u></b>). The pandemic high-flier capitalized on a stay-at-home workforce, growing itsusage from 10 million daily meeting participants one year ago to over 200 million.ZM stock enjoyed a meteoric 400% rise in 2020.</p>\n<p><img src=\"https://static.tigerbbs.com/320cf0858628ccaaed68980cabbaefec\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: Michael Vi / Shutterstock.com</p>\n<p>However, Zoom knows firsthand — like a lot of last year’s tech gainers — that 2021 has been much less forgiving. As the world returns to normalcy, the company’s growth has naturally slowed. Investors have cooled on the story. ZM stock is down about 20% year-to-date (YTD). Plus, adding salt to the wound, the company ishaving trouble closing its recentlyproposed acquisitionof<b>Five9</b>(NASDAQ:<b><u>FIVN</u></b>).</p>\n<p>I love a stock with some good controversy. Zoom fits that bill. The shares are volatile, reflecting investor uncertainty around whether it has enough gas in the tank for a second growth wave.But add a celebrity investor to the mix and things get<i>even more intriguing</i>. Enter Cathie Wood, who’s been scooping up Zoom shares on the dip.</p>\n<p>Is it over for ZM stock? Or is it just the beginning? Here’s a place to start.</p>\n<p><b>ZM Stock: What a Difference a Year Makes</b></p>\n<p>We all know how well Zoom did last year. But investors have very short memories. So, when it comes to analyzing ZM stock, let’s focus our conversation on the present (and future potential).</p>\n<p>Business is still good at Zoom, but it’s slowing relative to last year. Fiscal second-quarter earnings were a mixed bag. The good news is the company beat expectations. The bad news? Year-over-year (YOY) comparisons are down. For example, revenueincreased 54%YOY — an impressive number — butdown from 191%in Q1. Now for Q3, growth is expected to taper further to 31%. No doubt, these are still impressive growth numbers. But they’re not a raise inguidance for the second half of the fiscal year.</p>\n<p>Wall Street doesn’t like slowing growth. That’s why negative comparisons almost always translate into declines in stock prices.</p>\n<p>There’s another thing Wall Street doesn’t like: competition. Zoom enjoyed wild success last year. But going forward, the company isn’t the only video-conference software maker in town. There are plenty of other options:<b>Microsoft</b>(NASDAQ:<b><u>MSFT</u></b>) has Skype and Teams,<b>Cisco</b>(NASDAQ:<b><u>CSCO</u></b>) offers Webex,<b>Adobe</b>(NASDAQ:<b><u>ADBE</u></b>) has Connect and<b>LogMeIn</b>has GoToMeeting, among others. This list of giant competitors also includes<b>Facebook</b>(NASDAQ:<b><u>FB</u></b>), which recently introduced a feature called Messenger Rooms.</p>\n<p>For these much larger tech companies, online meetings are just one of many software offerings. This leaves ZM stock vulnerable if one of these companies finds a competitive advantage.</p>\n<p><b>Looking for Growth</b></p>\n<p>With growth slowing and the company facing an increasingly crowded enterprise communications market,Zoom is naturally looking for its next leg of growth. In July, the company announced its&nbsp;intent to acquirecloud contact-center software providerFive9for $14.7 billion in stock. The deal terms were that Zoom would pay $200.28 for each share of Five9.</p>\n<p>However, the market has since soured on the deal, for two reasons. First: valuation. Sure, the deal terms sounded good to shareholders when it was initially announced (ZM stock was trading for over $350 at the time). But on the heels of a mixed quarter, the stock started sliding — and quickly. Investors then had more reason to question the lofty proposed purchase price.</p>\n<p>Last week, things came to a head. With Zoom shares down almost 20% from the deal announcement, proxy-analysis firm Institutional Shareholder Services (ISS) sounded the alarm bells. The firmadvised Five9 shareholders toreject the deal. ISS said that Five9 investors would be exposed to a more-volatile stock with a less-than-rosy outlook as economies reopen following the pandemic.</p>\n<p>Secondly, though, there’s the Justice Department and the Federal Communications Commission (FCC). Both agencies are looking into whether Zoom’s ties to China could make the deal a national-security risk. Still, Zoomsaid it expects to receive regulatory approvals by the first half of 2022. That could leave it on track to close the deal as originally planned.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Knows Something About Zoom That You Don’t</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Knows Something About Zoom That You Don’t\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-25 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/cathie-wood-knows-something-about-zm-stock-that-you-dont/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZM stock is down about 20% YTD, but there are reasons to still favor this video-conferencing pick\nEditor’s Note: This article is part ofJoanna’s Top Trades—a weekly feature dedicated toward making you...</p>\n\n<a href=\"https://investorplace.com/2021/09/cathie-wood-knows-something-about-zm-stock-that-you-dont/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/09/cathie-wood-knows-something-about-zm-stock-that-you-dont/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117076176","content_text":"ZM stock is down about 20% YTD, but there are reasons to still favor this video-conferencing pick\nEditor’s Note: This article is part ofJoanna’s Top Trades—a weekly feature dedicated toward making you money within a specific space. Joanna’s pick for this week isZoom(NASDAQ:ZM) as the top stock to trade this week.\nWe all know video-calling software makerZoom (NASDAQ:ZM). The pandemic high-flier capitalized on a stay-at-home workforce, growing itsusage from 10 million daily meeting participants one year ago to over 200 million.ZM stock enjoyed a meteoric 400% rise in 2020.\nSource: Michael Vi / Shutterstock.com\nHowever, Zoom knows firsthand — like a lot of last year’s tech gainers — that 2021 has been much less forgiving. As the world returns to normalcy, the company’s growth has naturally slowed. Investors have cooled on the story. ZM stock is down about 20% year-to-date (YTD). Plus, adding salt to the wound, the company ishaving trouble closing its recentlyproposed acquisitionofFive9(NASDAQ:FIVN).\nI love a stock with some good controversy. Zoom fits that bill. The shares are volatile, reflecting investor uncertainty around whether it has enough gas in the tank for a second growth wave.But add a celebrity investor to the mix and things geteven more intriguing. Enter Cathie Wood, who’s been scooping up Zoom shares on the dip.\nIs it over for ZM stock? Or is it just the beginning? Here’s a place to start.\nZM Stock: What a Difference a Year Makes\nWe all know how well Zoom did last year. But investors have very short memories. So, when it comes to analyzing ZM stock, let’s focus our conversation on the present (and future potential).\nBusiness is still good at Zoom, but it’s slowing relative to last year. Fiscal second-quarter earnings were a mixed bag. The good news is the company beat expectations. The bad news? Year-over-year (YOY) comparisons are down. For example, revenueincreased 54%YOY — an impressive number — butdown from 191%in Q1. Now for Q3, growth is expected to taper further to 31%. No doubt, these are still impressive growth numbers. But they’re not a raise inguidance for the second half of the fiscal year.\nWall Street doesn’t like slowing growth. That’s why negative comparisons almost always translate into declines in stock prices.\nThere’s another thing Wall Street doesn’t like: competition. Zoom enjoyed wild success last year. But going forward, the company isn’t the only video-conference software maker in town. There are plenty of other options:Microsoft(NASDAQ:MSFT) has Skype and Teams,Cisco(NASDAQ:CSCO) offers Webex,Adobe(NASDAQ:ADBE) has Connect andLogMeInhas GoToMeeting, among others. This list of giant competitors also includesFacebook(NASDAQ:FB), which recently introduced a feature called Messenger Rooms.\nFor these much larger tech companies, online meetings are just one of many software offerings. This leaves ZM stock vulnerable if one of these companies finds a competitive advantage.\nLooking for Growth\nWith growth slowing and the company facing an increasingly crowded enterprise communications market,Zoom is naturally looking for its next leg of growth. In July, the company announced its intent to acquirecloud contact-center software providerFive9for $14.7 billion in stock. The deal terms were that Zoom would pay $200.28 for each share of Five9.\nHowever, the market has since soured on the deal, for two reasons. First: valuation. Sure, the deal terms sounded good to shareholders when it was initially announced (ZM stock was trading for over $350 at the time). But on the heels of a mixed quarter, the stock started sliding — and quickly. Investors then had more reason to question the lofty proposed purchase price.\nLast week, things came to a head. With Zoom shares down almost 20% from the deal announcement, proxy-analysis firm Institutional Shareholder Services (ISS) sounded the alarm bells. The firmadvised Five9 shareholders toreject the deal. ISS said that Five9 investors would be exposed to a more-volatile stock with a less-than-rosy outlook as economies reopen following the pandemic.\nSecondly, though, there’s the Justice Department and the Federal Communications Commission (FCC). Both agencies are looking into whether Zoom’s ties to China could make the deal a national-security risk. Still, Zoomsaid it expects to receive regulatory approvals by the first half of 2022. That could leave it on track to close the deal as originally planned.","news_type":1},"isVote":1,"tweetType":1,"viewCount":19,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693712913,"gmtCreate":1640078865625,"gmtModify":1640078865830,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693712913","repostId":"1149530831","repostType":4,"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846181020,"gmtCreate":1636067995588,"gmtModify":1636067996114,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846181020","repostId":"1128227989","repostType":4,"repost":{"id":"1128227989","pubTimestamp":1636067303,"share":"https://www.laohu8.com/m/news/1128227989?lang=&edition=full","pubTime":"2021-11-05 07:08","market":"us","language":"en","title":"S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1128227989","media":"Reuters","summary":" - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.Financials dropped 1","content":"<p>(Reuters) - The S&amp;P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p>\n<p>The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase &amp; Co and Goldman Sachs Group weighed on the blue-chip index.</p>\n<p>Financials dropped 1.3%, most among S&amp;P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p>\n<p>“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p>\n<p>The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&amp;P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p>\n<p>The S&amp;P 500 growth index rose 1.2% while the S&amp;P 500 value index fell 0.5%.</p>\n<p>Among S&amp;P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p>\n<p>Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p>\n<p>The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p>\n<p>Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p>\n<p>“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p>\n<p>“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p>\n<p>Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&amp;P 500 healthcare sector, which fell 0.8%.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p>\n<p>About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq extend record streaks, with boost from chip, growth shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SDS":"两倍做空标普500ETF",".IXIC":"NASDAQ Composite","UPRO":"三倍做多标普500ETF","IVV":"标普500指数ETF",".DJI":"道琼斯","SH":"标普500反向ETF",".SPX":"S&P 500 Index","SPXU":"三倍做空标普500ETF","OEX":"标普100","SSO":"两倍做多标普500ETF","OEF":"标普100指数ETF-iShares"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128227989","content_text":"(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.\nThe Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.\nFinancials dropped 1.3%, most among S&P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.\n“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\n“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”\nThe Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.\nThe S&P 500 growth index rose 1.2% while the S&P 500 value index fell 0.5%.\nAmong S&P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.\nQualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.\nThe Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.\n“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.\n“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”\nModerna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&P 500 healthcare sector, which fell 0.8%.\nData showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.\nThe S&P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.\nAbout 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":46,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822013471,"gmtCreate":1634078431219,"gmtModify":1634078431459,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/822013471","repostId":"1198930462","repostType":4,"repost":{"id":"1198930462","pubTimestamp":1634044920,"share":"https://www.laohu8.com/m/news/1198930462?lang=&edition=full","pubTime":"2021-10-12 21:22","market":"us","language":"en","title":"Why you won’t know it when a bear market starts ","url":"https://stock-news.laohu8.com/highlight/detail?id=1198930462","media":"MarketWatch","summary":"It’s crucial to devise a strategy that you can live with through a bear market\nAFP via Getty Images\n","content":"<p>It’s crucial to devise a strategy that you can live with through a bear market</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/82a6b41119b11a31337948b9b003acab\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>AFP via Getty Images</span></p>\n<p></p>\n<p>It was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high prior to the beginning of the Financial Crisis-induced bear market.</p>\n<p>I am willing to bet that the last thing on your mind that day was whether a new bear market was beginning. Instead, you undoubtedly were sharing in the exuberance that accompanied yet another new bull-market high. The S&amp;P 500&nbsp;was 120% higher than where it had stood at the beginning of that bull market, five years previously.</p>\n<p>And, yet, one of the worst bear markets in U.S. history was beginning on that very day. The S&amp;P 500 over the subsequent 16 months would <i>lose</i> 55%.</p>\n<p>This walk down memory lane is important because it serves as a reminder that bull market tops aren’t recognized in real time. It’s only after the fact that it becomes clear that the bull market has ended.</p>\n<p>Many clients strenuously disagree with me about this, insisting that they in fact did have a good sense the bull market was topping out in October 2007. But they almost certainly are rewriting history, which is understandable. It’s human nature to rewrite the past to make it seem obvious that events would unfold as they did.</p>\n<p>But the beginning of the 2007-2009 bear market was anything but obvious in the moment.</p>\n<p>If you have any doubt, consider the average recommended equity exposure among a subset of nearly 100 short-term stock market timers my firm monitors on a daily basis. (This average is what’s represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI.) On average, the HSNSI reaches its highest level on the very day the bull market tops out.</p>\n<p>This is illustrated in the accompanying chart. It averages the HSNSI over the six weeks prior and six weeks subsequent to every bull market top of the last 40 years (per the calendar maintained by Ned Davis Research). As you can see, the HSNSI rises 20 percentage points over the final six weeks of the average bull market, and then plunges 40 percentage points over the first six weeks of the subsequent bear market.</p>\n<p><img src=\"https://static.tigerbbs.com/8bc18ef162a6e98217aada4619d99651\" tg-width=\"700\" tg-height=\"488\" width=\"100%\" height=\"auto\"></p>\n<p></p>\n<p>In other words, professional market timers on average are most optimistic on the very day they should be most pessimistic. They are professionals who follow the market all day, every day. If they can’t do better, then what makes you think you can?</p>\n<p><b>Comments of market timers</b></p>\n<p>I think these statistics make a compelling case. But to add anecdotal icing to the cake, consider a representative sampling of comments made by newsletter editors on the exact day of the October 2007 market top, or in the days immediately prior:</p>\n<ul>\n <li>“If you listen carefully, you can hear the rumbling. That rumbling is the distant thunder of the third phase of this great bull market… I see the good times rolling, I really do.”</li>\n <li>“It’s been a while since I’ve felt so confident about the potential for making some great gains with our serious money. So, if you haven’t done so already, it is essential that you get your money into this [stock] market as quickly as possible. Time waits for no man, and your money is waiting on you. So go to it.”</li>\n <li>“The global bull market in stocks not only continues, but… it’s also entering a strong phase… Now that the Fed has waved the flag that interest rates are going lower, there’s really nothing holding the market back.”</li>\n <li>“Dow 16,000 here we come… [I]t appears to us that the stock market is off to the races for the next 3 to 6 months.” [The Dow on the day of the October 2007 bull market top was 14,165.]</li>\n <li>“The risk of a cyclical bear market decline in excess of 20% is not on the radar screen.”</li>\n <li>“The longer-term bull market is intact… You should be looking to buy on any weakness.”</li>\n</ul>\n<p>Their exuberance is palpable, isn’t it? And odds are overwhelming that that’s how you felt too on that day—regardless of what story you may be telling yourself today.</p>\n<p><b>Investment lesson</b></p>\n<p>The investment implication is clear: Do not count on being able to reduce your equity exposure in order to sidestep a bear market.</p>\n<p>This is why you should devise and then follow a strategy you can live with through a bear market. It won’t necessarily make as much money as the theoretical maximum you could make if you were to be 100% invested during bull markets up until the exact day of the S&amp;P 500’s top, and then moved to be 100% in cash for the duration of the bear market. But no one achieves that theoretical maximum in the real world.</p>\n<p>The perfect is the enemy of the good, in other words.</p>\n<p>For the record, I have no idea whether a bear market has started. It’s been over a month now since the S&amp;P 500 hit what so far has been its bull market high, and it is currently trading nearly 3% lower than that high.</p>\n<p>But if it has started, we won’t know for sure until many months from now and when the market is a whole lot lower.</p>\n<p></p>\n<p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why you won’t know it when a bear market starts </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy you won’t know it when a bear market starts \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/why-you-wont-know-it-when-a-bear-market-starts-11633654477?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It’s crucial to devise a strategy that you can live with through a bear market\nAFP via Getty Images\n\nIt was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high ...</p>\n\n<a href=\"https://www.marketwatch.com/story/why-you-wont-know-it-when-a-bear-market-starts-11633654477?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/why-you-wont-know-it-when-a-bear-market-starts-11633654477?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198930462","content_text":"It’s crucial to devise a strategy that you can live with through a bear market\nAFP via Getty Images\n\nIt was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high prior to the beginning of the Financial Crisis-induced bear market.\nI am willing to bet that the last thing on your mind that day was whether a new bear market was beginning. Instead, you undoubtedly were sharing in the exuberance that accompanied yet another new bull-market high. The S&P 500 was 120% higher than where it had stood at the beginning of that bull market, five years previously.\nAnd, yet, one of the worst bear markets in U.S. history was beginning on that very day. The S&P 500 over the subsequent 16 months would lose 55%.\nThis walk down memory lane is important because it serves as a reminder that bull market tops aren’t recognized in real time. It’s only after the fact that it becomes clear that the bull market has ended.\nMany clients strenuously disagree with me about this, insisting that they in fact did have a good sense the bull market was topping out in October 2007. But they almost certainly are rewriting history, which is understandable. It’s human nature to rewrite the past to make it seem obvious that events would unfold as they did.\nBut the beginning of the 2007-2009 bear market was anything but obvious in the moment.\nIf you have any doubt, consider the average recommended equity exposure among a subset of nearly 100 short-term stock market timers my firm monitors on a daily basis. (This average is what’s represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI.) On average, the HSNSI reaches its highest level on the very day the bull market tops out.\nThis is illustrated in the accompanying chart. It averages the HSNSI over the six weeks prior and six weeks subsequent to every bull market top of the last 40 years (per the calendar maintained by Ned Davis Research). As you can see, the HSNSI rises 20 percentage points over the final six weeks of the average bull market, and then plunges 40 percentage points over the first six weeks of the subsequent bear market.\n\n\nIn other words, professional market timers on average are most optimistic on the very day they should be most pessimistic. They are professionals who follow the market all day, every day. If they can’t do better, then what makes you think you can?\nComments of market timers\nI think these statistics make a compelling case. But to add anecdotal icing to the cake, consider a representative sampling of comments made by newsletter editors on the exact day of the October 2007 market top, or in the days immediately prior:\n\n“If you listen carefully, you can hear the rumbling. That rumbling is the distant thunder of the third phase of this great bull market… I see the good times rolling, I really do.”\n“It’s been a while since I’ve felt so confident about the potential for making some great gains with our serious money. So, if you haven’t done so already, it is essential that you get your money into this [stock] market as quickly as possible. Time waits for no man, and your money is waiting on you. So go to it.”\n“The global bull market in stocks not only continues, but… it’s also entering a strong phase… Now that the Fed has waved the flag that interest rates are going lower, there’s really nothing holding the market back.”\n“Dow 16,000 here we come… [I]t appears to us that the stock market is off to the races for the next 3 to 6 months.” [The Dow on the day of the October 2007 bull market top was 14,165.]\n“The risk of a cyclical bear market decline in excess of 20% is not on the radar screen.”\n“The longer-term bull market is intact… You should be looking to buy on any weakness.”\n\nTheir exuberance is palpable, isn’t it? And odds are overwhelming that that’s how you felt too on that day—regardless of what story you may be telling yourself today.\nInvestment lesson\nThe investment implication is clear: Do not count on being able to reduce your equity exposure in order to sidestep a bear market.\nThis is why you should devise and then follow a strategy you can live with through a bear market. It won’t necessarily make as much money as the theoretical maximum you could make if you were to be 100% invested during bull markets up until the exact day of the S&P 500’s top, and then moved to be 100% in cash for the duration of the bear market. But no one achieves that theoretical maximum in the real world.\nThe perfect is the enemy of the good, in other words.\nFor the record, I have no idea whether a bear market has started. It’s been over a month now since the S&P 500 hit what so far has been its bull market high, and it is currently trading nearly 3% lower than that high.\nBut if it has started, we won’t know for sure until many months from now and when the market is a whole lot lower.","news_type":1},"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699829799,"gmtCreate":1639783265714,"gmtModify":1639783265921,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699829799","repostId":"2192497854","repostType":4,"repost":{"id":"2192497854","pubTimestamp":1639746681,"share":"https://www.laohu8.com/m/news/2192497854?lang=&edition=full","pubTime":"2021-12-17 21:11","market":"us","language":"en","title":"3 Warren Buffett Stocks I Like Heading Into 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2192497854","media":"Motley Fool","summary":"Three of Buffett's largest holdings look strong heading into 2022.","content":"<p>Warren Buffett and his company&nbsp;<b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) are well known for their stock-picking abilities that have been proven over many decades. For this prowess, along with Berkshire's success in the other businesses the conglomerate operates in, the stock has consistently been a winner.</p>\n<p>Between 1965 and 2020, Berkshire's stock has generated compounded annual gains of 20%, compared to the <b>S&amp;P 500</b>'s compounded annual gain of 10.2%, including dividends, over the same timeframe. It's for this very reason that investors watch Buffett and Berkshire's stock picks so closely. Here are three Buffett stocks I like heading into 2022.</p>\n<h2>1. Bank of America</h2>\n<p>America's second-largest bank by assets,&nbsp;<b>Bank of America</b> (NYSE:BAC), also happens to be the second-largest position in Buffett and Berkshire's equities portfolio. Buffett first got in on Bank of America coming out of the Great Recession and currently owns more than 1 billion shares worth nearly $45.8 billion. Early in the pandemic in the middle of 2020, Buffett took advantage of the beaten-down bank sector to plow another $2 billion into Bank of America and now owns nearly 12% of the financial institution's outstanding shares.</p>\n<p>Shares of Bank of America have climbed more than 47% this year and are up more than double from pandemic lows. While the valuation has gotten high, I like Bank of America because it is well-positioned to deal with higher inflation, higher interest rates, and more difficult market conditions that could be seen next year. Higher interest rates benefit Bank of America tremendously because the yields on many of the loans at the bank will increase along with the rate hikes. The consumer is currently in great shape. Since banking is linked to the overall economy and gross domestic product in the U.S. is expected to grow about 4% next year, I think the bank is going to have a good year.</p>\n<h2>2. American Express</h2>\n<p>Berkshire owns more than 151 million shares of the credit card company <b>American Express</b> (NYSE:AXP) for a total value of roughly $24.7 billion, making it the third-largest holding in Berkshire's portfolio. American Express has also had a nice year with the stock price up more than 38%.</p>\n<p>There are two main reasons I like American Express heading into 2022. For one, because the consumer has been so healthy, Americans have been paying off their credit card bills and haven't had as much need to take on debt. As money and benefits from previous stimulus bills run down, that won't always be the case. At the beginning of December, <i>The Wall Street Journal</i> reported that credit card applications had recently hit a pandemic high.</p>\n<p>American Express is also big in the travel, airlines, and lodging businesses, so the more the world continues to recover from the pandemic and COVID-19, the more its business will benefit. Some of those travel-related sectors still aren't fully back yet, especially when you think about international travel.</p>\n<h2>3. U.S. Bancorp</h2>\n<p>Buffett and Berkshire own more than 144 million shares valued at nearly $8.3 billion of the large regional bank <b>U.S. Bancorp </b>(NYSE:USB). The bank is a high-performing commercial bank. It also runs a unique payments business that includes retail credit, debit, prepaid cards, global merchant acquiring, and corporate payment solutions in sectors such as aviation, fleet, transportation, and travel.</p>\n<p>Because the payments business operates in these sectors, the segment could still recover further in 2022 as the world rebounds from COVID-19. Additionally, management is very focused on further integrating the payments and commercial banking businesses because 72% of the bank's business banking customers still don't have a payments product, and half of U.S. Bancorp's payments customers don't have a banking product.</p>\n<p>There's a lot of opportunity for cross-selling. U.S. Bancorp also recently announced its intention to acquire the U.S. banking division of <b>Mitsubishi UFJ Financial Group</b>. This deal will give U.S. Bancorp an additional 190,000 business banking customers and more scale in California, both things that are in line with U.S. Bancorp's current strategy.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Warren Buffett Stocks I Like Heading Into 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Warren Buffett Stocks I Like Heading Into 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/3-warren-buffett-stocks-i-like-heading-into-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett and his company Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) are well known for their stock-picking abilities that have been proven over many decades. For this prowess, along with ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/3-warren-buffett-stocks-i-like-heading-into-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4207":"综合性银行","BK4553":"喜马拉雅资本持仓","USB":"美国合众银行","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4176":"多领域控股","BRK.A":"伯克希尔","BK4166":"消费信贷","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4504":"桥水持仓","AXP":"美国运通","BRK.B":"伯克希尔B","BAC":"美国银行"},"source_url":"https://www.fool.com/investing/2021/12/17/3-warren-buffett-stocks-i-like-heading-into-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192497854","content_text":"Warren Buffett and his company Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) are well known for their stock-picking abilities that have been proven over many decades. For this prowess, along with Berkshire's success in the other businesses the conglomerate operates in, the stock has consistently been a winner.\nBetween 1965 and 2020, Berkshire's stock has generated compounded annual gains of 20%, compared to the S&P 500's compounded annual gain of 10.2%, including dividends, over the same timeframe. It's for this very reason that investors watch Buffett and Berkshire's stock picks so closely. Here are three Buffett stocks I like heading into 2022.\n1. Bank of America\nAmerica's second-largest bank by assets, Bank of America (NYSE:BAC), also happens to be the second-largest position in Buffett and Berkshire's equities portfolio. Buffett first got in on Bank of America coming out of the Great Recession and currently owns more than 1 billion shares worth nearly $45.8 billion. Early in the pandemic in the middle of 2020, Buffett took advantage of the beaten-down bank sector to plow another $2 billion into Bank of America and now owns nearly 12% of the financial institution's outstanding shares.\nShares of Bank of America have climbed more than 47% this year and are up more than double from pandemic lows. While the valuation has gotten high, I like Bank of America because it is well-positioned to deal with higher inflation, higher interest rates, and more difficult market conditions that could be seen next year. Higher interest rates benefit Bank of America tremendously because the yields on many of the loans at the bank will increase along with the rate hikes. The consumer is currently in great shape. Since banking is linked to the overall economy and gross domestic product in the U.S. is expected to grow about 4% next year, I think the bank is going to have a good year.\n2. American Express\nBerkshire owns more than 151 million shares of the credit card company American Express (NYSE:AXP) for a total value of roughly $24.7 billion, making it the third-largest holding in Berkshire's portfolio. American Express has also had a nice year with the stock price up more than 38%.\nThere are two main reasons I like American Express heading into 2022. For one, because the consumer has been so healthy, Americans have been paying off their credit card bills and haven't had as much need to take on debt. As money and benefits from previous stimulus bills run down, that won't always be the case. At the beginning of December, The Wall Street Journal reported that credit card applications had recently hit a pandemic high.\nAmerican Express is also big in the travel, airlines, and lodging businesses, so the more the world continues to recover from the pandemic and COVID-19, the more its business will benefit. Some of those travel-related sectors still aren't fully back yet, especially when you think about international travel.\n3. U.S. Bancorp\nBuffett and Berkshire own more than 144 million shares valued at nearly $8.3 billion of the large regional bank U.S. Bancorp (NYSE:USB). The bank is a high-performing commercial bank. It also runs a unique payments business that includes retail credit, debit, prepaid cards, global merchant acquiring, and corporate payment solutions in sectors such as aviation, fleet, transportation, and travel.\nBecause the payments business operates in these sectors, the segment could still recover further in 2022 as the world rebounds from COVID-19. Additionally, management is very focused on further integrating the payments and commercial banking businesses because 72% of the bank's business banking customers still don't have a payments product, and half of U.S. Bancorp's payments customers don't have a banking product.\nThere's a lot of opportunity for cross-selling. U.S. Bancorp also recently announced its intention to acquire the U.S. banking division of Mitsubishi UFJ Financial Group. This deal will give U.S. Bancorp an additional 190,000 business banking customers and more scale in California, both things that are in line with U.S. Bancorp's current strategy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609690307,"gmtCreate":1638274281322,"gmtModify":1638274281408,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609690307","repostId":"1192203085","repostType":4,"repost":{"id":"1192203085","pubTimestamp":1638273550,"share":"https://www.laohu8.com/m/news/1192203085?lang=&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p>\n<p>Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p>\n<p>Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p>\n<p>The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p>\n<p>Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p>\n<p>Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p>\n<p>They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p>\n<p>The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p>\n<p>Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p>\n<p>If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p>\n<p>One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p>\n<p>The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p>\n<p>“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p>\n<p>Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p>\n<p>More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p>\n<p>Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p>\n<p>She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p>\n<p>“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p>\n<p>A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p>\n<p>Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p>\n<p>Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p>\n<p>Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p>\n<p>Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p>\n<p>Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p>\n<p>“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p>\n<p>It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p>\n<p>“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p>\n<p>Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p>\n<p>Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p>\n<p>“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p>\n<p>Pfizer and Merck said they expect their drugs to be effective against Omicron.</p>\n<p>Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests ...</p>\n\n<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866126804,"gmtCreate":1632749416008,"gmtModify":1632798135036,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/866126804","repostId":"1143393352","repostType":4,"repost":{"id":"1143393352","pubTimestamp":1632747727,"share":"https://www.laohu8.com/m/news/1143393352?lang=&edition=full","pubTime":"2021-09-27 21:02","market":"us","language":"en","title":"Tesla and General Motors picked by Goldman Sachs as auto winners in tough environment","url":"https://stock-news.laohu8.com/highlight/detail?id=1143393352","media":"Seeking Alpha","summary":"Goldman Sachs lowers its global auto production forecast to reflect the tight supply and demand envi","content":"<ul>\n <li>Goldman Sachs lowers its global auto production forecast to reflect the tight supply and demand environment that is anticipated to last several more quarters as the global chip shortage and other supply chain issues impact production. The firm now sees 75M autos produced in 2021 vs. 83M prior forecast and 85M in 2022 vs. 90M prior forecast.t</li>\n <li>The unexpected backdrop sets up some automakers to outperform, per Goldman. \"Several of our Buy rated stocks strike a good balance in our opinion of having strong financial models (e.g., attractive margins and/or [free cash flow]) that we think can provide resiliency in a difficult supply chain environment,\" notes analyst Mark Delaney. In particular, Tesla&nbsp;is called an industry leader that is well positioned for growth and General Motors&nbsp;is seen as an attractive stock that captures the benefit from an industry recovery in production as well as opportunities to benefit from EVs and advanced driver-assistance systems. Both stocks have a Buy rating at Goldman and price targets that imply double-digit upside. The setup is seen being not nearly as favorable for Lordstown Motors, which was cut to a Sell rating.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla and General Motors picked by Goldman Sachs as auto winners in tough environment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla and General Motors picked by Goldman Sachs as auto winners in tough environment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-27 21:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3744831-tesla-and-general-motors-picked-by-goldman-sachs-as-auto-winners-in-tough-environment><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Goldman Sachs lowers its global auto production forecast to reflect the tight supply and demand environment that is anticipated to last several more quarters as the global chip shortage and other ...</p>\n\n<a href=\"https://seekingalpha.com/news/3744831-tesla-and-general-motors-picked-by-goldman-sachs-as-auto-winners-in-tough-environment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","GM":"通用汽车"},"source_url":"https://seekingalpha.com/news/3744831-tesla-and-general-motors-picked-by-goldman-sachs-as-auto-winners-in-tough-environment","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143393352","content_text":"Goldman Sachs lowers its global auto production forecast to reflect the tight supply and demand environment that is anticipated to last several more quarters as the global chip shortage and other supply chain issues impact production. The firm now sees 75M autos produced in 2021 vs. 83M prior forecast and 85M in 2022 vs. 90M prior forecast.t\nThe unexpected backdrop sets up some automakers to outperform, per Goldman. \"Several of our Buy rated stocks strike a good balance in our opinion of having strong financial models (e.g., attractive margins and/or [free cash flow]) that we think can provide resiliency in a difficult supply chain environment,\" notes analyst Mark Delaney. In particular, Tesla is called an industry leader that is well positioned for growth and General Motors is seen as an attractive stock that captures the benefit from an industry recovery in production as well as opportunities to benefit from EVs and advanced driver-assistance systems. Both stocks have a Buy rating at Goldman and price targets that imply double-digit upside. The setup is seen being not nearly as favorable for Lordstown Motors, which was cut to a Sell rating.","news_type":1},"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698851498,"gmtCreate":1640347839561,"gmtModify":1640347839791,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698851498","repostId":"1156159690","repostType":4,"repost":{"id":"1156159690","pubTimestamp":1640335867,"share":"https://www.laohu8.com/m/news/1156159690?lang=&edition=full","pubTime":"2021-12-24 16:51","market":"us","language":"en","title":"What are MKM Partners 'Black Swan' Internet predictions for 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1156159690","media":"seekingalpha","summary":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Bla","content":"<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.</p>\n<p>So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.</p>\n<p>The \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.</p>\n<p>Kulkarni said Facebook's(NASDAQ:FB)<a href=\"https://laohu8.com/S/CASH\">Meta</a> could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.</p>\n<p>\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.</p>\n<ul>\n <li>Kulkarni's other Black Swan predictions are:</li>\n <li>SPAC IPOs will outperform traditional IPOs and direct stock listings.</li>\n <li><a href=\"https://laohu8.com/S/UBER\">Uber</a>(NYSE:UBER)launches its own robotaxi service in several U.S. cities.</li>\n <li><a href=\"https://laohu8.com/S/TWTR\">Twitter</a>(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.</li>\n <li>DoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.</li>\n <li><a href=\"https://laohu8.com/S/AAPL\">Apple</a>(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.</li>\n <li>Google's(NASDAQ:GOOG)YouTube get in position to go public.</li>\n <li>Snap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.</li>\n <li>As a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and&nbsp;falling demand for Peloton (PTON) products next year.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What are MKM Partners 'Black Swan' Internet predictions for 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat are MKM Partners 'Black Swan' Internet predictions for 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 16:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as...</p>\n\n<a href=\"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","TWTR":"Twitter","GOOG":"谷歌","DASH":"DoorDash, Inc.","PINS":"Pinterest, Inc.","AAPL":"苹果","PTON":"Peloton Interactive, Inc."},"source_url":"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1156159690","content_text":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.\nThe \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.\nKulkarni said Facebook's(NASDAQ:FB)Meta could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.\n\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.\n\nKulkarni's other Black Swan predictions are:\nSPAC IPOs will outperform traditional IPOs and direct stock listings.\nUber(NYSE:UBER)launches its own robotaxi service in several U.S. cities.\nTwitter(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.\nDoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.\nApple(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.\nGoogle's(NASDAQ:GOOG)YouTube get in position to go public.\nSnap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.\nAs a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and falling demand for Peloton (PTON) products next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":992,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871950051,"gmtCreate":1637021099591,"gmtModify":1637021099673,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871950051","repostId":"2183907418","repostType":4,"repost":{"id":"2183907418","pubTimestamp":1637020461,"share":"https://www.laohu8.com/m/news/2183907418?lang=&edition=full","pubTime":"2021-11-16 07:54","market":"us","language":"en","title":"Lucid Stock Gains as Q3 Shows No Major Surprises for 'Car of the Year' Recipient","url":"https://stock-news.laohu8.com/highlight/detail?id=2183907418","media":"StreetInsider","summary":"Lucid Group, Inc.  shares were trading around 1.3% higher after-hours following the company’s report","content":"<p><a href=\"https://laohu8.com/S/LCID\">Lucid Group, Inc. </a> shares were trading around 1.3% higher after-hours following the company’s reported Q3 results, with EPS coming in at ($0.43), compared to ($6.64) in Q3/20.</p>\n<p>Quarterly revenue was $232,000, compared to $334,000 in Q3/20. Customer reservations grew to 13,000 during the quarter, reflecting an order book of around $1.3 billion. In Q3 the company significantly strengthened its balance sheet via the closing of the de-SPAC reverse merger + PIPE, closing the quarter with approximately $4.8 billion in cash.</p>\n<p>Earlier today, the company's first car, the Luicd Air, received MotorTrend's Car of the Year. It's the first time any automaker has won the award with its first car.</p>\n<p><img src=\"https://static.tigerbbs.com/5bc7a7e4199e26df17008cd8c5169e52\" tg-width=\"874\" tg-height=\"649\" referrerpolicy=\"no-referrer\"><b>Third Quarter Financial Highlights</b></p>\n<ul>\n <li>In the third quarter of 2021, Lucid significantly strengthened its balance sheet through the closing of the de-SPAC reverse merger + PIPE, bringing approximately$4.4Bonto Lucid's balance sheet.</li>\n <li>Continued to invest in the business, readying production and deliveries, globalization of our retail network and adding headcount across R&amp;D and SG&amp;A to continue growing our core operations.</li>\n <li>Initiated investment in property, plant, and equipment associated with Phase 2 expansion of manufacturing, continued investment in vehicle program development, and ongoing expansion of retail, delivery, and service capacities.</li>\n</ul>\n<p><b>Third Quarter Business Highlights</b></p>\n<ul>\n <li><b>Received EPA Certification as Longest Range Production EV</b>: Lucid's technological prowess is a key differentiator for the company, with a \"clean-sheet\" approach to vehicle development that resulted in the ground-breaking Lucid Air, with six trim variants whose range exceeds 450 miles on a single charge. The Dream Edition R achieves 520 miles of range on a single charge.</li>\n <li><b>Refined Quality and Received Certifications</b>: In the third quarter of 2021, Lucid's engineering efforts were focused on optimizing product quality and delivering final certifications in the lead-up to factory commissioning and customer deliveries. Lucid's laser focus on engineering was validated through significant positive press and third-party validation by media, customers, and certification agencies like the EPA.</li>\n <li><b>Commissioned and Started Production at the First Greenfield, Dedicated EV Factory inNorth America</b>: AMP-1 inCasa Grande, AZ, is operational with production capacity to deliver up to 34,000 vehicles per year. Lucid is further differentiated with in-house powertrain manufacturing at Lucid Powertrain Manufacturing Plant (LPM-1) a few miles from AMP-1 inCasa Grande, AZ.</li>\n <li><b>Kicked off expansion of production capacity and capabilities</b>: Lucid kicked off the expansion of AMP-1's manufacturing capacity, expected to provide production capacity for up to 90,000 vehicles per year by the end of 2023, by expanding Lucid Air production capacity and adding production capacity for the \"Project Gravity\" SUV. The phase 2 expansion is expected to add2.85Msq. ft. of production footprint and will further vertically integrate production processes.</li>\n <li><b>Hosted Media, Customers and Lucid Stakeholders at AMP-1 Commissioning Event</b>: Lucid hosted a commissioning event for more than 150 customers, members of the media, institutional investors, and sell-side analysts, among other Lucid stakeholders.</li>\n <li><b>Continued Expanding Retail Network:</b>&nbsp;Lucid's direct-to-consumer sales are supported by brick-and-mortar retail studio and service center locations, delivering best-in-class customer experience in all elements of our customers' journey of vehicle ownership. Lucid expanded its footprint in Q3 to 13 locations in key geographies that align with Lucid's expected customer demand, and will continue expansion of its retail and service network, including expansion intoCanada(4Q'21), EMEA ('22), andChina('23), unlocking global demand for the sale of our product in the luxury vehicle marketplace.</li>\n <li><b>Increased Reservation Volume</b>: Surpassed 13,000 reservations in Q3 for estimated order book of greater than$1.3B.</li>\n <li><b>Announced Lucid Care</b>:&nbsp;Lucid announced Lucid Care, detailing our service capabilities and offerings.</li>\n</ul>\n<p><b>Looking Forward</b></p>\n<p>Looking ahead,Peter Rawlinsonnoted \"We see significant demand for the award-winning Lucid Air, with accelerating reservations as we ramp production at our factory inArizona. We remain confident in our ability to achieve 20,000 units in 2022. This target is not without risk given ongoing challenges facing the automotive industry, with global disruptions to supply chains and logistics. We are taking steps to mitigate these challenges, however, and look forward to the launch of the Grand Touring, Touring, and Pure versions of Lucid Air through 2022.\"</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid Stock Gains as Q3 Shows No Major Surprises for 'Car of the Year' Recipient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid Stock Gains as Q3 Shows No Major Surprises for 'Car of the Year' Recipient\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-16 07:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19220968><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lucid Group, Inc.  shares were trading around 1.3% higher after-hours following the company’s reported Q3 results, with EPS coming in at ($0.43), compared to ($6.64) in Q3/20.\nQuarterly revenue was $...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19220968\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19220968","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183907418","content_text":"Lucid Group, Inc.  shares were trading around 1.3% higher after-hours following the company’s reported Q3 results, with EPS coming in at ($0.43), compared to ($6.64) in Q3/20.\nQuarterly revenue was $232,000, compared to $334,000 in Q3/20. Customer reservations grew to 13,000 during the quarter, reflecting an order book of around $1.3 billion. In Q3 the company significantly strengthened its balance sheet via the closing of the de-SPAC reverse merger + PIPE, closing the quarter with approximately $4.8 billion in cash.\nEarlier today, the company's first car, the Luicd Air, received MotorTrend's Car of the Year. It's the first time any automaker has won the award with its first car.\nThird Quarter Financial Highlights\n\nIn the third quarter of 2021, Lucid significantly strengthened its balance sheet through the closing of the de-SPAC reverse merger + PIPE, bringing approximately$4.4Bonto Lucid's balance sheet.\nContinued to invest in the business, readying production and deliveries, globalization of our retail network and adding headcount across R&D and SG&A to continue growing our core operations.\nInitiated investment in property, plant, and equipment associated with Phase 2 expansion of manufacturing, continued investment in vehicle program development, and ongoing expansion of retail, delivery, and service capacities.\n\nThird Quarter Business Highlights\n\nReceived EPA Certification as Longest Range Production EV: Lucid's technological prowess is a key differentiator for the company, with a \"clean-sheet\" approach to vehicle development that resulted in the ground-breaking Lucid Air, with six trim variants whose range exceeds 450 miles on a single charge. The Dream Edition R achieves 520 miles of range on a single charge.\nRefined Quality and Received Certifications: In the third quarter of 2021, Lucid's engineering efforts were focused on optimizing product quality and delivering final certifications in the lead-up to factory commissioning and customer deliveries. Lucid's laser focus on engineering was validated through significant positive press and third-party validation by media, customers, and certification agencies like the EPA.\nCommissioned and Started Production at the First Greenfield, Dedicated EV Factory inNorth America: AMP-1 inCasa Grande, AZ, is operational with production capacity to deliver up to 34,000 vehicles per year. Lucid is further differentiated with in-house powertrain manufacturing at Lucid Powertrain Manufacturing Plant (LPM-1) a few miles from AMP-1 inCasa Grande, AZ.\nKicked off expansion of production capacity and capabilities: Lucid kicked off the expansion of AMP-1's manufacturing capacity, expected to provide production capacity for up to 90,000 vehicles per year by the end of 2023, by expanding Lucid Air production capacity and adding production capacity for the \"Project Gravity\" SUV. The phase 2 expansion is expected to add2.85Msq. ft. of production footprint and will further vertically integrate production processes.\nHosted Media, Customers and Lucid Stakeholders at AMP-1 Commissioning Event: Lucid hosted a commissioning event for more than 150 customers, members of the media, institutional investors, and sell-side analysts, among other Lucid stakeholders.\nContinued Expanding Retail Network: Lucid's direct-to-consumer sales are supported by brick-and-mortar retail studio and service center locations, delivering best-in-class customer experience in all elements of our customers' journey of vehicle ownership. Lucid expanded its footprint in Q3 to 13 locations in key geographies that align with Lucid's expected customer demand, and will continue expansion of its retail and service network, including expansion intoCanada(4Q'21), EMEA ('22), andChina('23), unlocking global demand for the sale of our product in the luxury vehicle marketplace.\nIncreased Reservation Volume: Surpassed 13,000 reservations in Q3 for estimated order book of greater than$1.3B.\nAnnounced Lucid Care: Lucid announced Lucid Care, detailing our service capabilities and offerings.\n\nLooking Forward\nLooking ahead,Peter Rawlinsonnoted \"We see significant demand for the award-winning Lucid Air, with accelerating reservations as we ramp production at our factory inArizona. We remain confident in our ability to achieve 20,000 units in 2022. This target is not without risk given ongoing challenges facing the automotive industry, with global disruptions to supply chains and logistics. We are taking steps to mitigate these challenges, however, and look forward to the launch of the Grand Touring, Touring, and Pure versions of Lucid Air through 2022.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":42,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868026181,"gmtCreate":1632556506043,"gmtModify":1632657801629,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868026181","repostId":"1188909032","repostType":4,"repost":{"id":"1188909032","pubTimestamp":1632531451,"share":"https://www.laohu8.com/m/news/1188909032?lang=&edition=full","pubTime":"2021-09-25 08:57","market":"us","language":"en","title":"5 Top Consumer Stocks To Watch Ahead Of October 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1188909032","media":"Nasdaq","summary":"Do You Have These Top Consumer Stocks On Your Radar Now?\nThe past trading week has been exciting, to","content":"<p>Do You Have These Top Consumer Stocks On Your Radar Now?</p>\n<p>The past trading week has been exciting, to say the least. Despite all of the ups and downs,consumer stockscontinue to make waves in thestock market today. If anything, the consumer-focused industry continues to hold strong now. This is evident as August’s retail sales figures smashed expectations, rising by 0.7% versus an estimated drop of 0.8%. Moreover, the current broad-based rebound in thestock marketcould indicate that investors’ sentiment on the economy is improving.</p>\n<p>Evidently, we could look at the likes of<b>Roku</b>(NASDAQ: ROKU) right now. Just yesterday, Guggenheim analyst Michael Morris provided a positive update on the stock. Namely, Morris hit ROKU stock with a Buy rating and a price target of $395. Morris cites Roku’s aggressive expansion of its original content and penetration of international markets as core reasons for the upgrade.</p>\n<p>At the same time, there is some interesting movement going on with<b>Nike’s</b>(NYSE: NKE) shares as well. Yesterday, the company posted its first-quarter earnings after the closing bell. In short, Nike reported an earnings per share of $1.16 on revenue of $12.25 billion for the quarter. This is against estimates of $1.11 and $12.46 billion. Investors appear to be focusing on Nike’s revenue miss which is mostly due to temporary supply chain pressures. Regardless, as one of the biggest names in the sports apparel industry globally, some could see opportunity in NKE stocks’ current weakness. With all this activity in the space now, could one of these consumer stocks be worth investing in?</p>\n<p>Best Consumer Stocks To Buy [Or Sell] Today</p>\n<ul>\n <li><b>Beyond Meat Inc.</b>(NASDAQ: BYND)</li>\n <li><b>Trip.com Group Ltd.</b>(NASDAQ: TCOM)</li>\n <li><b>Vail Resorts Inc.</b>(NYSE: MTN)</li>\n <li><b>Costco Wholesale Corporation</b>(NASDAQ: COST)</li>\n <li><b>Stitch Fix Inc.</b>(NASDAQ: SFIX)</li>\n</ul>\n<p>Beyond Meat Inc.</p>\n<p><b>Beyond Meat</b>is a plant-based meat substitutes retailer with headquarters in California. The company offers plant-based options in the beef, poultry, and pork categories. In fact, it is one of the fastest-growing food companies in the U.S. as more people are increasingly alternating to plant-based options. Its products are designed to have the same taste and texture as animal-based meat while being the better option for the environment. BYND stock has almost doubled in valuation since its pandemic era low.</p>\n<p>In August, the company reported its second-quarter financials. Diving in, net revenue for the quarter was $149.4 million, increasing by 31.8% year-over-year. Furthermore, gross profit for the quarter was $47.4 million. The company saw record net revenues and also continues to return to growth in the foodservice industry as its customers welcome consumers back to their venues. Not resting on its laurels, the company also continues to make substantial investments in its long-term growth in the U.S. and abroad. Given all of this, will you consider investing in BYND stock right now?</p>\n<p><img src=\"https://static.tigerbbs.com/875119289e70dc28e620fb5eeb2d291b\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p>\n<p><b>[Read More]</b>&nbsp;What Stocks To Buy Today? 5 Tech Stocks To Watch</p>\n<p>Trip.com Group Ltd</p>\n<p>Following that, we have multinational online travel company<b>Trip.com</b>, a leading one-stop travel platform globally. It integrates a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for travelers in China and around the world. Impressively, it is currently one of the largest online travel agencies in China and also one of the largest travel service providers in the world.</p>\n<p>After yesterday’s closing bell, Trip.com posted solid figures in its second fiscal quarter earnings report. In it, the company saw a total revenue of $912 million for the quarter. This marks a significant year-over-year jump of 86%. In terms of net income, the company saw a 43% increase over the same period. CEO Jane Sun cites Trip.com’s focus on the domestic market as a core contributor to this solid quarter for the company. Overall, given this piece of news, will you consider adding TCOM stock to your portfolio right now?</p>\n<p><img src=\"https://static.tigerbbs.com/781e08ea2e30a4f9c94020727b3e77bc\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOSVail Resorts Inc.</p>\n<p><b>Vail Resorts</b>is a leading global mountain resort operator. The company and its subsidiaries operate 37 destination mountain resorts and regional ski areas. In essence, it owns and/or manages a collection of casually elegant hotels under the RockResorts brand. It also has a development company that is in the real estate planning and development business. MTN stock is up by over 40% in the past year alone.</p>\n<p>Recently, KeyBanc Capital Markets upgraded Vail Resorts to an Overweight rating from Sector Weight and hit it with a price target of $355. Analyst Brett Andreas says that demand for skiing vacations was exceeding expectations with some bookings already at record levels. Not to mention, the company continues to gain momentum on the financial front. In its fourth fiscal quarterearnings call, Vail reported a net income of $127.9 million, marking a sizable 29.4% year-over-year increase. After considering that pandemic-related factors still weigh on its key operations, the company’s fundamentals are admirable. Moreover, the company also declared a cash dividend of $0.88 per share, to investors’ delight. All things considered, will you buy MTN stock?</p>\n<p><img src=\"https://static.tigerbbs.com/c596fd2c2dc3ef4d15e9c9dfa89b8147\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p>\n<p><b>[Read More]</b>&nbsp;4 Semiconductor Stocks To Watch Right Now</p>\n<p>Costco Wholesale Corporation</p>\n<p>Next up, we will be taking a look at<b>Costco</b>. For the most part, the multinational consumer staples giant would be another player to consider in thestock market today. The main factor differentiating Costco from its retail competitors would be its membership-only big-box operations. Simply put, the company only caters to members and sells daily necessities in bulk. Amidst the ongoing pandemic and climate crises, Costco’s offerings could see greater demand from consumers.</p>\n<p>By and large, with COST stock sitting on year-to-date gains of over 19%, could it be worth investing in? Well, for one thing, the company beat Wall Streets’ projections across the board in its latest quarterly earnings report. In detail, Costco posted an earnings per share of $3.76 on revenue of $62.7 billion for the quarter. For some perspective, consensus estimates suggest an earnings per share of $3.59 on revenue of $61.6 billion. All in all, would you consider adding COST stock to your portfolio?</p>\n<p><img src=\"https://static.tigerbbs.com/0412ae414ccd0df0d5f93302bd037b56\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p>\n<p><b>[Read More]</b>&nbsp;Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist</p>\n<p>Stitch Fix Inc.</p>\n<p>Another name to know in the consumer stock space now would be<b>Stitch Fix</b>. In brief, it is an online personal styling service. Through a combination of artificial intelligence and data science, Stitch Fix provides customers with personalized e-commerce experiences. Given the prevalence of online shopping throughout the pandemic, SFIX stock could be in focus among investors. In fact, the company’s shares are up by over 15% just this week on account of its solid earnings report.</p>\n<p>Notably, Stitch Fix raked in a total revenue of $571.16 million for the quarter, marking a 28% year-over-year increase. Additionally, the company also reported massive year-over-year spikes of over 145% in both its net income and earnings per share. Despite beating analyst estimates on these fronts, Stitch Fix does not seem to be slowing down anytime soon. This appears to be the case as the company is expanding its services with Stitch Fix Freestyle, a “differentiated shopping experience”. This would give customers a more instant and flexible means of shopping on its platform. As such, could SFIX stock be a top pick in the stock market now?</p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Top Consumer Stocks To Watch Ahead Of October 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Top Consumer Stocks To Watch Ahead Of October 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-25 08:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/5-top-consumer-stocks-to-watch-ahead-of-october-2021-2021-09-24><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do You Have These Top Consumer Stocks On Your Radar Now?\nThe past trading week has been exciting, to say the least. Despite all of the ups and downs,consumer stockscontinue to make waves in thestock ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/5-top-consumer-stocks-to-watch-ahead-of-october-2021-2021-09-24\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COST":"好市多","ROKU":"Roku Inc","NKE":"耐克","SFIX":"Stitch Fix Inc.","TCOM":"携程网","BYND":"Beyond Meat, Inc."},"source_url":"https://www.nasdaq.com/articles/5-top-consumer-stocks-to-watch-ahead-of-october-2021-2021-09-24","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188909032","content_text":"Do You Have These Top Consumer Stocks On Your Radar Now?\nThe past trading week has been exciting, to say the least. Despite all of the ups and downs,consumer stockscontinue to make waves in thestock market today. If anything, the consumer-focused industry continues to hold strong now. This is evident as August’s retail sales figures smashed expectations, rising by 0.7% versus an estimated drop of 0.8%. Moreover, the current broad-based rebound in thestock marketcould indicate that investors’ sentiment on the economy is improving.\nEvidently, we could look at the likes ofRoku(NASDAQ: ROKU) right now. Just yesterday, Guggenheim analyst Michael Morris provided a positive update on the stock. Namely, Morris hit ROKU stock with a Buy rating and a price target of $395. Morris cites Roku’s aggressive expansion of its original content and penetration of international markets as core reasons for the upgrade.\nAt the same time, there is some interesting movement going on withNike’s(NYSE: NKE) shares as well. Yesterday, the company posted its first-quarter earnings after the closing bell. In short, Nike reported an earnings per share of $1.16 on revenue of $12.25 billion for the quarter. This is against estimates of $1.11 and $12.46 billion. Investors appear to be focusing on Nike’s revenue miss which is mostly due to temporary supply chain pressures. Regardless, as one of the biggest names in the sports apparel industry globally, some could see opportunity in NKE stocks’ current weakness. With all this activity in the space now, could one of these consumer stocks be worth investing in?\nBest Consumer Stocks To Buy [Or Sell] Today\n\nBeyond Meat Inc.(NASDAQ: BYND)\nTrip.com Group Ltd.(NASDAQ: TCOM)\nVail Resorts Inc.(NYSE: MTN)\nCostco Wholesale Corporation(NASDAQ: COST)\nStitch Fix Inc.(NASDAQ: SFIX)\n\nBeyond Meat Inc.\nBeyond Meatis a plant-based meat substitutes retailer with headquarters in California. The company offers plant-based options in the beef, poultry, and pork categories. In fact, it is one of the fastest-growing food companies in the U.S. as more people are increasingly alternating to plant-based options. Its products are designed to have the same taste and texture as animal-based meat while being the better option for the environment. BYND stock has almost doubled in valuation since its pandemic era low.\nIn August, the company reported its second-quarter financials. Diving in, net revenue for the quarter was $149.4 million, increasing by 31.8% year-over-year. Furthermore, gross profit for the quarter was $47.4 million. The company saw record net revenues and also continues to return to growth in the foodservice industry as its customers welcome consumers back to their venues. Not resting on its laurels, the company also continues to make substantial investments in its long-term growth in the U.S. and abroad. Given all of this, will you consider investing in BYND stock right now?\nSource: TD Ameritrade TOS\n[Read More] What Stocks To Buy Today? 5 Tech Stocks To Watch\nTrip.com Group Ltd\nFollowing that, we have multinational online travel companyTrip.com, a leading one-stop travel platform globally. It integrates a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for travelers in China and around the world. Impressively, it is currently one of the largest online travel agencies in China and also one of the largest travel service providers in the world.\nAfter yesterday’s closing bell, Trip.com posted solid figures in its second fiscal quarter earnings report. In it, the company saw a total revenue of $912 million for the quarter. This marks a significant year-over-year jump of 86%. In terms of net income, the company saw a 43% increase over the same period. CEO Jane Sun cites Trip.com’s focus on the domestic market as a core contributor to this solid quarter for the company. Overall, given this piece of news, will you consider adding TCOM stock to your portfolio right now?\nSource: TD Ameritrade TOSVail Resorts Inc.\nVail Resortsis a leading global mountain resort operator. The company and its subsidiaries operate 37 destination mountain resorts and regional ski areas. In essence, it owns and/or manages a collection of casually elegant hotels under the RockResorts brand. It also has a development company that is in the real estate planning and development business. MTN stock is up by over 40% in the past year alone.\nRecently, KeyBanc Capital Markets upgraded Vail Resorts to an Overweight rating from Sector Weight and hit it with a price target of $355. Analyst Brett Andreas says that demand for skiing vacations was exceeding expectations with some bookings already at record levels. Not to mention, the company continues to gain momentum on the financial front. In its fourth fiscal quarterearnings call, Vail reported a net income of $127.9 million, marking a sizable 29.4% year-over-year increase. After considering that pandemic-related factors still weigh on its key operations, the company’s fundamentals are admirable. Moreover, the company also declared a cash dividend of $0.88 per share, to investors’ delight. All things considered, will you buy MTN stock?\nSource: TD Ameritrade TOS\n[Read More] 4 Semiconductor Stocks To Watch Right Now\nCostco Wholesale Corporation\nNext up, we will be taking a look atCostco. For the most part, the multinational consumer staples giant would be another player to consider in thestock market today. The main factor differentiating Costco from its retail competitors would be its membership-only big-box operations. Simply put, the company only caters to members and sells daily necessities in bulk. Amidst the ongoing pandemic and climate crises, Costco’s offerings could see greater demand from consumers.\nBy and large, with COST stock sitting on year-to-date gains of over 19%, could it be worth investing in? Well, for one thing, the company beat Wall Streets’ projections across the board in its latest quarterly earnings report. In detail, Costco posted an earnings per share of $3.76 on revenue of $62.7 billion for the quarter. For some perspective, consensus estimates suggest an earnings per share of $3.59 on revenue of $61.6 billion. All in all, would you consider adding COST stock to your portfolio?\nSource: TD Ameritrade TOS\n[Read More] Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist\nStitch Fix Inc.\nAnother name to know in the consumer stock space now would beStitch Fix. In brief, it is an online personal styling service. Through a combination of artificial intelligence and data science, Stitch Fix provides customers with personalized e-commerce experiences. Given the prevalence of online shopping throughout the pandemic, SFIX stock could be in focus among investors. In fact, the company’s shares are up by over 15% just this week on account of its solid earnings report.\nNotably, Stitch Fix raked in a total revenue of $571.16 million for the quarter, marking a 28% year-over-year increase. Additionally, the company also reported massive year-over-year spikes of over 145% in both its net income and earnings per share. Despite beating analyst estimates on these fronts, Stitch Fix does not seem to be slowing down anytime soon. This appears to be the case as the company is expanding its services with Stitch Fix Freestyle, a “differentiated shopping experience”. This would give customers a more instant and flexible means of shopping on its platform. As such, could SFIX stock be a top pick in the stock market now?","news_type":1},"isVote":1,"tweetType":1,"viewCount":67,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605090515,"gmtCreate":1639090391250,"gmtModify":1639090391439,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605090515","repostId":"1165217477","repostType":4,"repost":{"id":"1165217477","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639067136,"share":"https://www.laohu8.com/m/news/1165217477?lang=&edition=full","pubTime":"2021-12-10 00:25","market":"us","language":"en","title":"Grab and Lucid stocks plunged more than 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165217477","media":"Tiger Newspress","summary":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","content":"<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab and Lucid stocks plunged more than 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab and Lucid stocks plunged more than 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 00:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings","LCID":"Lucid Group Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165217477","content_text":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868022399,"gmtCreate":1632556564711,"gmtModify":1632657774616,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"best","listText":"best","text":"best","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/868022399","repostId":"2170619785","repostType":4,"repost":{"id":"2170619785","pubTimestamp":1632518354,"share":"https://www.laohu8.com/m/news/2170619785?lang=&edition=full","pubTime":"2021-09-25 05:19","market":"hk","language":"en","title":"Dow Jones, S&P 500 end with gains up after bumpy week, but Nike drags","url":"https://stock-news.laohu8.com/highlight/detail?id=2170619785","media":"The Straits Times","summary":"NEW YORK (REUTERS) - The Dow and S&P 500 edged higher on Friday (Sept 24) and ended a turbulent week","content":"<div>\n<p>NEW YORK (REUTERS) - The Dow and S&P 500 edged higher on Friday (Sept 24) and ended a turbulent week with slight increases, helped by gains in Tesla and Facebook that offset a tumble by Nike.\nAthletic...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/dow-jones-sp-500-end-with-gains-up-after-bumpy-week-but-nike-drags\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow Jones, S&P 500 end with gains up after bumpy week, but Nike drags</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow Jones, S&P 500 end with gains up after bumpy week, but Nike drags\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-25 05:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/business/companies-markets/dow-jones-sp-500-end-with-gains-up-after-bumpy-week-but-nike-drags><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (REUTERS) - The Dow and S&P 500 edged higher on Friday (Sept 24) and ended a turbulent week with slight increases, helped by gains in Tesla and Facebook that offset a tumble by Nike.\nAthletic...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/dow-jones-sp-500-end-with-gains-up-after-bumpy-week-but-nike-drags\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SPXU":"三倍做空标普500ETF","NKE":"耐克",".DJI":"道琼斯",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","SPY":"标普500ETF","UPRO":"三倍做多标普500ETF",".IXIC":"NASDAQ Composite","IVV":"标普500指数ETF","SH":"标普500反向ETF","OEX":"标普100","SSO":"两倍做多标普500ETF"},"source_url":"http://www.straitstimes.com/business/companies-markets/dow-jones-sp-500-end-with-gains-up-after-bumpy-week-but-nike-drags","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170619785","content_text":"NEW YORK (REUTERS) - The Dow and S&P 500 edged higher on Friday (Sept 24) and ended a turbulent week with slight increases, helped by gains in Tesla and Facebook that offset a tumble by Nike.\nAthletic wear company Nike's shares fell 6.3% and were the biggest drag on the Dow and the S&P 500 after it delivered a downbeat sales forecast and warned of delays during the holiday shopping season, blaming a supply chain crunch.\nShares of footwear retailer Foot Locker also fell sharply. On the flip side, Facebook climbed 2% and Tesla rose 2.7%.\nThe S&P communication services sector climbed 0.7% and was the second-biggest sector gainer of the day after energy, up 0.8%.\nStocks bounced back from a sharp selloff at the start of the week tied in part to concerns over a default by China's Evergrande and its potential risk to global financial markets.\nOn Friday, Evergrande's electric car unit warned it faced an uncertain future unless it got a swift injection of cash, the clearest sign yet that the property developer's liquidity crisis is worsening in other parts of its business.\n\"You've had a good recovery from the lows\" this week, said Rick Meckler, partner, Cherry Lane Investments, a family investment office in New Vernon, New Jersey.\n\"With rates this low - even if they are going to move up slowly - and with the fiscal stimulus you'll probably see coming, I think investors still prefer stocks to any other asset class. Stocks remain in a weird way what investors see as the safe place.\"\nOn Wednesday, the Federal Reserve said it would reduce its monthly bond purchases \"soon\" and half of the Fed's policymakers projected borrowing costs will need to rise in 2022.\nThe Dow Jones Industrial Average rose 33.18 points, or 0.1%, to 34,798, the S&P 500 gained 6.5 points, or 0.15%, to 4,455.48 and the Nasdaq Composite dropped 4.55 points, or 0.03%, to 15,047.70.\nFor the week, the Dow was up 0.6%, the S&P 500 gained 0.5% and the Nasdaq was near flat.\nShares of cryptocurrency-related firms Coinbase Global, MicroStrategy Inc, Riot Blockchain and Marathon Patent Group fell after China's central bank put a ban on crypto trading and mining. \"It's been a very volatile week to say the least, so I think going into the last week of September the volatility is likely to continue especially with the end-of-the-quarter window dressing,\" said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.\nInvestors are also looking for signs of progress on President Joe Biden's spending and budget bills.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.40-to-1 ratio favored decliners.\nThe S&P 500 posted 21 new 52-week highs and 6 new lows; the Nasdaq Composite recorded 82 new highs and 73 new lows.\nVolume on US exchanges was 9.00 billion shares, compared with the 10.11 billion average for the full session over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":83,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690018127,"gmtCreate":1639613230300,"gmtModify":1639613230475,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"need booster","listText":"need booster","text":"need booster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690018127","repostId":"1194155872","repostType":4,"repost":{"id":"1194155872","pubTimestamp":1639613035,"share":"https://www.laohu8.com/m/news/1194155872?lang=&edition=full","pubTime":"2021-12-16 08:03","market":"us","language":"en","title":"Rebound Anticipated For Singapore Stock Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1194155872","media":"RTTNews","summary":"The Singapore stock market headed south again on Wednesday, one session after ending the two-day sli","content":"<p>The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.</p>\n<p>The global forecast for the Asian&nbsp;markets&nbsp;is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.</p>\n<p>The STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.</p>\n<p>For the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.</p>\n<p>Among the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.</p>\n<p>The lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.</p>\n<p>The Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&amp;P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.</p>\n<p>The late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.</p>\n<p>The Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.</p>\n<p>Meanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.</p>\n<p>Despite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.</p>\n<p>Crude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rebound Anticipated For Singapore Stock Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRebound Anticipated For Singapore Stock Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 08:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just ...</p>\n\n<a href=\"https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194155872","content_text":"The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.\nThe global forecast for the Asian markets is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.\nThe STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.\nFor the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.\nAmong the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.\nThe lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.\nThe Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.\nThe late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.\nThe Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.\nMeanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.\nDespite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.\nCrude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844425013,"gmtCreate":1636453342063,"gmtModify":1636453367859,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844425013","repostId":"1138347885","repostType":2,"repost":{"id":"1138347885","pubTimestamp":1636451829,"share":"https://www.laohu8.com/m/news/1138347885?lang=&edition=full","pubTime":"2021-11-09 17:57","market":"us","language":"en","title":"Earnings Scheduled For November 9, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1138347885","media":"Benzinga","summary":"Companies Reporting Before The Bell\n• Imara (NASDAQ:IMRA) is projected to report earnings for its th","content":"<p>Companies Reporting Before The Bell</p>\n<p>• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.</p>\n<p>• KT (NYSE:KT) is projected to report earnings for its third quarter.</p>\n<p>• Selecta Biosciences (NASDAQ:SELB) is projected to report quarterly loss at $0.07 per share on revenue of $12.19 million.</p>\n<p>• Ocugen (NASDAQ:OCGN) is likely to report earnings for its third quarter.</p>\n<p>• Madison Square Garden (NYSE:MSGE) is estimated to report quarterly loss at $1.14 per share on revenue of $281.24 million.</p>\n<p>• Mersana Therapeutics (NASDAQ:MRSN) is expected to report quarterly loss at $0.58 per share on revenue of $100.00 thousand.</p>\n<p>• Intra-Cellular Therapies (NASDAQ:ITCI) is estimated to report quarterly loss at $0.92 per share on revenue of $22.12 million.</p>\n<p>• IVERIC bio (NASDAQ:ISEE) is estimated to report earnings for its third quarter.</p>\n<p>• Amicus Therapeutics (NASDAQ:FOLD) is projected to report quarterly loss at $0.18 per share on revenue of $80.11 million.</p>\n<p>• Epizyme (NASDAQ:EPZM) is likely to report quarterly loss at $0.48 per share on revenue of $13.18 million.</p>\n<p>• Dicerna Pharmaceuticals (NASDAQ:DRNA) is estimated to report quarterly loss at $0.46 per share on revenue of $43.78 million.</p>\n<p>• BioNTech (NASDAQ:BNTX) is projected to report quarterly earnings at $12.03 per share on revenue of $5.93 billion.</p>\n<p>• Biohaven Pharma Hldgs (NYSE:BHVN) is expected to report quarterly loss at $2.40 per share on revenue of $128.40 million.</p>\n<p>• Motorcar Parts of America (NASDAQ:MPAA) is projected to report quarterly earnings at $0.45 per share on revenue of $142.67 million.</p>\n<p>• Kandi Technologies Gr (NASDAQ:KNDI) is expected to report quarterly earnings at $0.19 per share on revenue of $38.80 million.</p>\n<p>• Applied Genetic (NASDAQ:AGTC) is likely to report quarterly loss at $0.35 per share on revenue of $80.00 thousand.</p>\n<p>• TransAlta (NYSE:TAC) is likely to report quarterly earnings at $0.10 per share on revenue of $427.75 million.</p>\n<p>• Southwest Gas Holdings (NYSE:SWX) is projected to report quarterly earnings at $0.13 per share on revenue of $836.43 million.</p>\n<p>• EchoStar (NASDAQ:SATS) is estimated to report quarterly earnings at $0.34 per share on revenue of $493.85 million.</p>\n<p>• Studio City Intl Hldgs (NYSE:MSC) is expected to report earnings for its third quarter.</p>\n<p>• Ebix (NASDAQ:EBIX) is likely to report quarterly earnings at $0.62 per share on revenue of $221.18 million.</p>\n<p>• Concert Pharmaceuticals (NASDAQ:CNCE) is expected to report quarterly loss at $0.81 per share on revenue of $50.00 thousand.</p>\n<p>• WestRock (NYSE:WRK) is projected to report quarterly earnings at $1.15 per share on revenue of $5.03 billion.</p>\n<p>• Sysco (NYSE:SYY) is estimated to report quarterly earnings at $0.86 per share on revenue of $15.87 billion.</p>\n<p>• BP Midstream Partners (NYSE:BPMP) is likely to report quarterly earnings at $0.38 per share on revenue of $32.05 million.</p>\n<p>• Purple Innovation (NASDAQ:PRPL) is expected to report quarterly earnings at $0.17 per share on revenue of $199.53 million.</p>\n<p>• Thermon Group Holdings (NYSE:THR) is estimated to report quarterly earnings at $0.11 per share on revenue of $71.40 million.</p>\n<p>• Tufin Software (NYSE:TUFN) is projected to report quarterly loss at $0.25 per share on revenue of $26.17 million.</p>\n<p>• Katapult Holdings (NASDAQ:KPLT) is projected to report quarterly loss at $0.08 per share on revenue of $39.41 million.</p>\n<p>• Alight (NYSE:ALIT) is projected to report quarterly earnings at $0.13 per share on revenue of $686.57 million.</p>\n<p>• Stevanato Group (NYSE:STVN) is likely to report quarterly earnings at $0.11 per share on revenue of $238.52 million.</p>\n<p>• N-able (NYSE:NABL) is projected to report quarterly earnings at $0.09 per share on revenue of $86.81 million.</p>\n<p>• Reservoir Media (NASDAQ:RSVR) is estimated to report quarterly earnings at $0.13 per share on revenue of $31.75 million.</p>\n<p>• Ecovyst (NYSE:ECVT) is likely to report quarterly earnings at $0.15 per share on revenue of $152.32 million.</p>\n<p>• Absci (NASDAQ:ABSI) is estimated to report quarterly loss at $0.18 per share on revenue of $2.01 million.</p>\n<p>• Sovos Brands (NASDAQ:SOVO) is projected to report quarterly earnings at $0.07 per share on revenue of $169.33 million.</p>\n<p>• Sarcos Technology (NASDAQ:STRC) is estimated to report quarterly loss at $0.06 per share on revenue of $1.50 million.</p>\n<p>• Nuvei (NASDAQ:NVEI) is projected to report quarterly earnings at $0.36 per share on revenue of $178.20 million.</p>\n<p>• Armstrong Flooring (NYSE:AFI) is expected to report earnings for its third quarter.</p>\n<p>• Melco Resorts and Enter (NASDAQ:MLCO) is projected to report earnings for its third quarter.</p>\n<p>• Blue Owl Capital (NYSE:OWL) is projected to report quarterly earnings at $0.08 per share on revenue of $227.95 million.</p>\n<p>• Carter Bankshares (NASDAQ:CARE) is expected to report quarterly loss at $0.09 per share on revenue of $18.06 million.</p>\n<p>• Bioventus (NASDAQ:BVS) is likely to report quarterly earnings at $0.14 per share on revenue of $102.23 million.</p>\n<p>• UWM Holdings (NYSE:UWMC) is projected to report quarterly earnings at $0.12 per share on revenue of $612.93 million.</p>\n<p>• Atotech (NYSE:ATC) is projected to report quarterly earnings at $0.19 per share on revenue of $370.03 million.</p>\n<p>• InspireMD (NASDAQ:NSPR) is projected to report quarterly loss at $0.82 per share on revenue of $1.20 million.</p>\n<p>• Orion Energy Sys (NASDAQ:OESX) is likely to report quarterly earnings at $0.09 per share on revenue of $38.60 million.</p>\n<p>• Novanta (NASDAQ:NOVT) is likely to report quarterly earnings at $0.60 per share on revenue of $172.06 million.</p>\n<p>• Marinus Pharmaceuticals (NASDAQ:MRNS) is expected to report quarterly loss at $0.73 per share on revenue of $2.17 million.</p>\n<p>• International Seaways (NYSE:INSW) is likely to report quarterly loss at $0.77 per share on revenue of $77.97 million.</p>\n<p>• II-VI (NASDAQ:IIVI) is projected to report quarterly earnings at $0.83 per share on revenue of $808.60 million.</p>\n<p>• Harmony Biosciences (NASDAQ:HRMY) is likely to report quarterly earnings at $0.28 per share on revenue of $79.85 million.</p>\n<p>• Hilton Grand Vacations (NYSE:HGV) is expected to report quarterly earnings at $0.38 per share on revenue of $357.73 million.</p>\n<p>• Hyatt Hotels (NYSE:H) is likely to report quarterly earnings at $0.45 per share on revenue of $2.13 billion.</p>\n<p>• Global Indemnity Group (NASDAQ:GBLI) is projected to report earnings for its third quarter.</p>\n<p>• Whole Earth Brands (NASDAQ:FREE) is projected to report quarterly earnings at $0.20 per share on revenue of $130.27 million.</p>\n<p>• XPEL (NASDAQ:XPEL) is likely to report quarterly earnings at $0.32 per share on revenue of $64.37 million.</p>\n<p>• Vertex Energy (NASDAQ:VTNR) is expected to report quarterly earnings at $0.01 per share on revenue of $53.83 million.</p>\n<p>• Vital Farms (NASDAQ:VITL) is expected to report quarterly loss at $0.06 per share on revenue of $63.67 million.</p>\n<p>• Verona Pharma (NASDAQ:VRNA) is likely to report quarterly loss at $0.37 per share on revenue of $4.17 million.</p>\n<p>• Village Farms Intl (NASDAQ:VFF) is estimated to report quarterly earnings at $0.01 per share on revenue of $68.72 million.</p>\n<p>• Vericel (NASDAQ:VCEL) is likely to report quarterly loss at $0.03 per share on revenue of $38.07 million.</p>\n<p>• TravelCenters Of America (NASDAQ:TA) is projected to report quarterly earnings at $0.13 per share on revenue of $526.53 million.</p>\n<p>• Palantir Technologies (NYSE:PLTR) is expected to report quarterly earnings at $0.04 per share on revenue of $385.02 million.</p>\n<p>• ReNew Energy Glb (NASDAQ:RNW) is expected to report quarterly earnings at $0.13 per share on revenue of $98.99 million.</p>\n<p>• Momentive Global (NASDAQ:MNTV) is projected to report quarterly earnings at $0.01 per share on revenue of $114.21 million.</p>\n<p>• Neuronetics (NASDAQ:STIM) is likely to report quarterly loss at $0.30 per share on revenue of $14.10 million.</p>\n<p>• Scienjoy Holding (NASDAQ:SJ) is likely to report quarterly earnings at $0.65 per share on revenue of $696.23 million.</p>\n<p>• Establishment Labs Hldgs (NASDAQ:ESTA) is projected to report quarterly loss at $0.35 per share on revenue of $28.27 million.</p>\n<p>• Digital Media Solutions (NYSE:DMS) is expected to report quarterly earnings at $0.04 per share on revenue of $109.00 million.</p>\n<p>• Delcath Systems (NASDAQ:DCTH) is expected to report quarterly loss at $1.08 per share on revenue of $490.00 thousand.</p>\n<p>• Bentley Systems (NASDAQ:BSY) is estimated to report quarterly earnings at $0.17 per share on revenue of $0.22.</p>\n<p>• Gilat Satellite Networks (NASDAQ:GILT) is expected to report quarterly loss at $0.01 per share on revenue of $61.82 million.</p>\n<p>• Eagle Pharmaceuticals (NASDAQ:EGRX) is estimated to report quarterly earnings at $0.83 per share on revenue of $46.40 million.</p>\n<p>• Endeavour Silver (NYSE:EXK) is projected to report quarterly earnings at $0.03 per share on revenue of $41.68 million.</p>\n<p>• Computer Task Group (NASDAQ:CTG) is projected to report quarterly earnings at $0.10 per share on revenue of $91.18 million.</p>\n<p>• ChannelAdvisor (NYSE:ECOM) is expected to report quarterly earnings at $0.17 per share on revenue of $41.55 million.</p>\n<p>• CEVA (NASDAQ:CEVA) is likely to report quarterly earnings at $0.17 per share on revenue of $31.24 million.</p>\n<p>• Agenus (NASDAQ:AGEN) is likely to report quarterly earnings at $0.46 per share on revenue of $183.11 million.</p>\n<p>• Wabash National (NYSE:WNC) is estimated to report quarterly earnings at $0.20 per share on revenue of $514.07 million.</p>\n<p>• Triumph Group (NYSE:TGI) is likely to report quarterly earnings at $0.09 per share on revenue of $373.33 million.</p>\n<p>• SeaWorld Entertainment (NYSE:SEAS) is projected to report quarterly earnings at $1.67 per share on revenue of $536.55 million.</p>\n<p>• Starwood Property Trust (NYSE:STWD) is estimated to report quarterly earnings at $0.52 per share on revenue of $300.00 million.</p>\n<p>• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.00 per share on revenue of $825.88 million.</p>\n<p>• HUYA (NYSE:HUYA) is expected to report quarterly earnings at $0.04 per share on revenue of $475.52 million.</p>\n<p>• Haemonetics (NYSE:HAE) is expected to report quarterly earnings at $0.61 per share on revenue of $241.40 million.</p>\n<p>• Intl Game Tech (NYSE:IGT) is expected to report quarterly earnings at $0.34 per share on revenue of $981.09 million.</p>\n<p>• Gol Intelligent Airlines (NYSE:GOL) is likely to report quarterly loss at $0.93 per share on revenue of $330.26 million.</p>\n<p>• Hain Celestial Group (NASDAQ:HAIN) is projected to report quarterly earnings at $0.24 per share on revenue of $442.59 million.</p>\n<p>• Federal Signal (NYSE:FSS) is projected to report quarterly earnings at $0.46 per share on revenue of $325.50 million.</p>\n<p>• Audacy (NYSE:AUD) is expected to report quarterly earnings at $0.06 per share on revenue of $329.68 million.</p>\n<p>• Cardiovascular Systems (NASDAQ:CSII) is likely to report quarterly loss at $0.11 per share on revenue of $64.27 million.</p>\n<p>• CorEnergy Infr Trust (NYSE:CORR) is projected to report quarterly earnings at $0.10 per share on revenue of $35.32 million.</p>\n<p>• Allot (NASDAQ:ALLT) is likely to report quarterly loss at $0.05 per share on revenue of $37.01 million.</p>\n<p>• Golar LNG (NASDAQ:GLNG) is likely to report quarterly loss at $0.04 per share on revenue of $100.36 million.</p>\n<p>• Quotient (NASDAQ:QTNT) is projected to report quarterly loss at $0.26 per share on revenue of $8.56 million.</p>\n<p>• WhiteHorse Finance (NASDAQ:WHF) is likely to report quarterly earnings at $0.37 per share on revenue of $18.30 million.</p>\n<p>• Party City Holdco (NYSE:PRTY) is likely to report earnings for its third quarter.</p>\n<p>• D.R. Horton (NYSE:DHI) is likely to report quarterly earnings at $3.40 per share on revenue of $7.94 billion.</p>\n<p>• Clear Channel Outdoor (NYSE:CCO) is expected to report quarterly loss at $0.09 per share on revenue of $589.02 million.</p>\n<p>• Blue Apron Hldgs (NYSE:APRN) is projected to report quarterly loss at $0.58 per share on revenue of $120.40 million.</p>\n<p>• ADT (NYSE:ADT) is estimated to report quarterly earnings at $0.09 per share on revenue of $1.29 billion.</p>\n<p>• Cardinal Health (NYSE:CAH) is expected to report quarterly earnings at $1.33 per share on revenue of $41.93 billion.</p>\n<p>• Overseas Shipholding Gr (NYSE:OSG) is estimated to report earnings for its third quarter.</p>\n<p>• Smith-Midland (NASDAQ:SMID) is expected to report earnings for its third quarter.</p>\n<p>• Cano Health (NYSE:CANO) is likely to report quarterly loss at $0.01 per share on revenue of $435.82 million.</p>\n<p>• Nuwellis (NASDAQ:NUWE) is estimated to report quarterly loss at $0.73 per share on revenue of $2.22 million.</p>\n<p>Companies Reporting After The Bell</p>\n<p>• 180 Degree Capital (NASDAQ:TURN) is expected to report earnings for its third quarter.</p>\n<p>• SandRidge Energy (NYSE:SD) is likely to report earnings for its third quarter.</p>\n<p>• Lufax Holding (NYSE:LU) is likely to report earnings for its third quarter.</p>\n<p>• Ormat Technologies (NYSE:ORA) is expected to report earnings for its third quarter.</p>\n<p>• Osisko Gold Royalties (NYSE:OR) is projected to report earnings for its third quarter.</p>\n<p>• VIQ Solutions (NASDAQ:VQS) is likely to report quarterly loss at $0.10 per share on revenue of $9.61 million.</p>\n<p>• Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $15.00 million.</p>\n<p>• Tricon Residential (NYSE:TCN) is likely to report earnings for its third quarter.</p>\n<p>• Marchex (NASDAQ:MCHX) is likely to report quarterly loss at $0.02 per share on revenue of $14.35 million.</p>\n<p>• HyreCar (NASDAQ:HYRE) is estimated to report quarterly loss at $0.28 per share on revenue of $9.93 million.</p>\n<p>• Lument Finance Trust (NYSE:LFT) is likely to report quarterly earnings at $0.08 per share on revenue of $5.56 million.</p>\n<p>• eGain (NASDAQ:EGAN) is likely to report quarterly earnings at $0.04 per share on revenue of $21.09 million.</p>\n<p>• Ecopetrol (NYSE:EC) is likely to report quarterly earnings at $0.61 per share on revenue of $6.01 billion.</p>\n<p>• Cormedix (NASDAQ:CRMD) is projected to report quarterly loss at $0.18 per share on revenue of $20.00 thousand.</p>\n<p>• Cherry Hill Mortgage (NYSE:CHMI) is projected to report quarterly earnings at $0.30 per share on revenue of $6.76 million.</p>\n<p>• Brickell Biotech (NASDAQ:BBI) is expected to report earnings for its third quarter.</p>\n<p>• Avino Silver &amp; Gold Mines (AMEX:ASM) is estimated to report earnings for its third quarter.</p>\n<p>• Alcon (NYSE:ALC) is estimated to report quarterly earnings at $0.49 per share on revenue of $2.04 billion.</p>\n<p>• Aethlon Medical (NASDAQ:AEMD) is estimated to report quarterly loss at $0.15 per share on revenue of $190.00 thousand.</p>\n<p>• Plug Power (NASDAQ:PLUG) is estimated to report quarterly loss at $0.09 per share on revenue of $143.93 million.</p>\n<p>• Cumberland (NASDAQ:CPIX) is expected to report earnings for its third quarter.</p>\n<p>• ChemoCentryx (NASDAQ:CCXI) is expected to report quarterly loss at $0.45 per share on revenue of $13.48 million.</p>\n<p>• Tidewater (NYSE:TDW) is likely to report quarterly loss at $0.55 per share on revenue of $92.90 million.</p>\n<p>• Genpact (NYSE:G) is projected to report quarterly earnings at $0.49 per share on revenue of $877.65 million.</p>\n<p>• Callaway Golf (NYSE:ELY) is likely to report quarterly earnings at $0.09 per share on revenue of $845.60 million.</p>\n<p>• Darling Ingredients (NYSE:DAR) is expected to report quarterly earnings at $0.80 per share on revenue of $1.21 billion.</p>\n<p>• Clipper Realty (NYSE:CLPR) is likely to report quarterly loss at $0.07 per share on revenue of $31.09 million.</p>\n<p>• Capricor Therapeutics (NASDAQ:CAPR) is projected to report quarterly loss at $0.22 per share on revenue of $210.00 thousand.</p>\n<p>• Calithera Biosciences (NASDAQ:CALA) is estimated to report earnings for its third quarter.</p>\n<p>• Acorda Therapeutics (NASDAQ:ACOR) is likely to report quarterly loss at $1.56 per share on revenue of $30.57 million.</p>\n<p>• Aurora Cannabis (NASDAQ:ACB) is projected to report quarterly loss at $0.21 per share on revenue of $49.24 million.</p>\n<p>• Arlington Asset Inv (NYSE:AAIC) is projected to report quarterly earnings at $0.06 per share on revenue of $4.52 million.</p>\n<p>• DoorDash (NYSE:DASH) is likely to report quarterly loss at $0.26 per share on revenue of $1.18 billion.</p>\n<p>• Wynn Resorts (NASDAQ:WYNN) is estimated to report quarterly loss at $1.31 per share on revenue of $942.64 million.</p>\n<p>• FuboTV (NYSE:FUBO) is expected to report quarterly loss at $0.63 per share on revenue of $143.55 million.</p>\n<p>• Ashland Global Holdings (NYSE:ASH) is estimated to report quarterly earnings at $1.29 per share on revenue of $640.67 million.</p>\n<p>• Braskem (NYSE:BAK) is expected to report quarterly earnings at $2.44 per share on revenue of $5.00 billion.</p>\n<p>• Global E Online (NASDAQ:GLBE) is likely to report quarterly earnings at $0.01 per share on revenue of $55.74 million.</p>\n<p>• Augmedix (NASDAQ:AUGX) is expected to report quarterly loss at $0.10 per share on revenue of $5.61 million.</p>\n<p>• Curis (NASDAQ:CRIS) is projected to report quarterly loss at $0.13 per share on revenue of $2.79 million.</p>\n<p>• Omeros (NASDAQ:OMER) is expected to report quarterly loss at $0.52 per share on revenue of $26.96 million.</p>\n<p>• Pangaea Logistics Solns (NASDAQ:PANL) is projected to report quarterly earnings at $0.50 per share on revenue of $160.44 million.</p>\n<p>• Alto Ingredients (NASDAQ:ALTO) is likely to report quarterly earnings at $0.12 per share on revenue of $267.01 million.</p>\n<p>• Performant Financial (NASDAQ:PFMT) is projected to report quarterly loss at $0.08 per share on revenue of $28.30 million.</p>\n<p>• Recro Pharma (NASDAQ:REPH) is expected to report quarterly loss at $0.07 per share on revenue of $18.07 million.</p>\n<p>• Radiant Logistics (AMEX:RLGT) is expected to report quarterly earnings at $0.10 per share on revenue of $225.11 million.</p>\n<p>• Revance Therapeutics (NASDAQ:RVNC) is likely to report quarterly loss at $1.15 per share on revenue of $20.29 million.</p>\n<p>• Surgalign Holdings (NASDAQ:SRGA) is likely to report quarterly loss at $0.09 per share on revenue of $22.28 million.</p>\n<p>• Turning Point (NASDAQ:TPTX) is estimated to report earnings for its third quarter.</p>\n<p>• AerSale (NASDAQ:ASLE) is expected to report quarterly earnings at $0.20 per share on revenue of $93.50 million.</p>\n<p>• Zeta Global Holdings (NYSE:ZETA) is expected to report quarterly earnings at $0.06 per share on revenue of $109.85 million.</p>\n<p>• Flywire (NASDAQ:FLYW) is estimated to report earnings for its third quarter.</p>\n<p>• Singular Genomics Systems (NASDAQ:OMIC) is expected to report earnings for its third quarter.</p>\n<p>• Codex DNA (NASDAQ:DNAY) is expected to report quarterly loss at $0.28 per share on revenue of $2.93 million.</p>\n<p>• Angel Oak Mortgage (NYSE:AOMR) is expected to report quarterly earnings at $0.35 per share on revenue of $15.85 million.</p>\n<p>• ATI Physical Therapy (NYSE:ATIP) is estimated to report quarterly loss at $0.04 per share on revenue of $159.63 million.</p>\n<p>• Greenbrook TMS (NASDAQ:GBNH) is expected to report quarterly loss at $0.45 per share on revenue of $13.00 million.</p>\n<p>• Taboola.com (NASDAQ:TBLA) is estimated to report quarterly loss at $0.02 per share on revenue of $122.72 million.</p>\n<p>• Paymentus Holdings (NYSE:PAY) is likely to report quarterly earnings at $0.01 per share on revenue of $94.22 million.</p>\n<p>• Paycor HCM (NASDAQ:PYCR) is expected to report quarterly earnings at $0.02 per share on revenue of $89.82 million.</p>\n<p>• Krispy Kreme (NASDAQ:DNUT) is projected to report quarterly earnings at $0.06 per share on revenue of $337.67 million.</p>\n<p>• CS Disco (NYSE:LAW) is likely to report quarterly loss at $0.22 per share on revenue of $25.79 million.</p>\n<p>• Sera Prognostics (NASDAQ:SERA) is projected to report quarterly loss at $0.24 per share on revenue of $70.00 thousand.</p>\n<p>• Jackson Financial (NYSE:JXN) is estimated to report quarterly earnings at $5.31 per share on revenue of $4.83 billion.</p>\n<p>• a.k.a. Brands Holding (NYSE:AKA) is projected to report quarterly loss at $0.10 per share on revenue of $136.92 million.</p>\n<p>• Toast (NYSE:TOST) is projected to report quarterly loss at $0.25 per share on revenue of $429.97 million.</p>\n<p>• Amplitude (NASDAQ:AMPL) is expected to report quarterly loss at $0.14 per share on revenue of $43.57 million.</p>\n<p>• Velo3D (NYSE:VLD) is projected to report quarterly loss at $0.05 per share on revenue of $7.56 million.</p>\n<p>• Zai Lab (NASDAQ:ZLAB) is estimated to report quarterly loss at $1.65 per share on revenue of $32.40 million.</p>\n<p>• Stem (NYSE:STEM) is likely to report quarterly loss at $0.35 per share on revenue of $35.89 million.</p>\n<p>• iPath Series B Carbon Exchange-Traded Notes (NYSE:GRN) is projected to report earnings for its third quarter.</p>\n<p>• Beauty Health (NASDAQ:SKIN) is projected to report quarterly loss at $0.02 per share on revenue of $56.71 million.</p>\n<p>• Agiliti (NYSE:AGTI) is likely to report quarterly earnings at $0.09 per share on revenue of $242.14 million.</p>\n<p>• DoubleVerify Hldgs (NYSE:DV) is expected to report quarterly earnings at $0.06 per share on revenue of $82.02 million.</p>\n<p>• Natural Alternatives Intl (NASDAQ:NAII) is estimated to report earnings for its first quarter.</p>\n<p>• Hostess Brands (NASDAQ:TWNK) is likely to report quarterly earnings at $0.20 per share on revenue of $279.36 million.</p>\n<p>• Custom Truck One Source (NYSE:CTOS) is expected to report quarterly earnings at $0.01 per share on revenue of $357.00 million.</p>\n<p>• Coinbase Global (NASDAQ:COIN) is likely to report quarterly earnings at $1.56 per share on revenue of $1.57 billion.</p>\n<p>• Olo (NYSE:OLO) is likely to report quarterly earnings at $0.02 per share on revenue of $36.26 million.</p>\n<p>• Absolute Software (NASDAQ:ABST) is estimated to report earnings for its first quarter.</p>\n<p>• VIZIO Holding (NYSE:VZIO) is projected to report quarterly loss at $0.10 per share on revenue of $595.33 million.</p>\n<p>• Poshmark (NASDAQ:POSH) is estimated to report quarterly loss at $0.07 per share on revenue of $82.69 million.</p>\n<p>• Urban-gro (NASDAQ:UGRO) is likely to report quarterly earnings at $0.09 per share on revenue of $18.40 million.</p>\n<p>• InnovAge Holding (NASDAQ:INNV) is expected to report quarterly earnings at $0.05 per share on revenue of $171.37 million.</p>\n<p>• ON24 (NYSE:ONTF) is likely to report quarterly loss at $0.08 per share on revenue of $48.03 million.</p>\n<p>• Shoals Technologies Gr (NASDAQ:SHLS) is estimated to report quarterly earnings at $0.07 per share on revenue of $61.64 million.</p>\n<p>• Signify Health (NYSE:SGFY) is estimated to report quarterly earnings at $0.02 per share on revenue of $184.42 million.</p>\n<p>• Viant Technology (NASDAQ:DSP) is expected to report quarterly loss at $0.21 per share on revenue of $50.00 million.</p>\n<p>• PAR Technology (NYSE:PAR) is estimated to report quarterly loss at $0.55 per share on revenue of $72.12 million.</p>\n<p>• Pan American Silver (NASDAQ:PAAS) is likely to report quarterly earnings at $0.44 per share on revenue of $585.65 million.</p>\n<p>• PaySign (NASDAQ:PAYS) is estimated to report earnings for its third quarter.</p>\n<p>• OptimizeRx (NASDAQ:OPRX) is likely to report quarterly earnings at $0.13 per share on revenue of $15.06 million.</p>\n<p>• Neovasc (NASDAQ:NVCN) is likely to report quarterly loss at $0.09 per share on revenue of $1.20 million.</p>\n<p>• NV5 Global (NASDAQ:NVEE) is estimated to report quarterly earnings at $1.15 per share on revenue of $185.01 million.</p>\n<p>• NanoString Technologies (NASDAQ:NSTG) is estimated to report quarterly loss at $0.54 per share on revenue of $37.79 million.</p>\n<p>• Model N (NYSE:MODN) is projected to report quarterly earnings at $0.10 per share on revenue of $50.88 million.</p>\n<p>• NewAge (NASDAQ:NBEV) is expected to report quarterly loss at $0.03 per share on revenue of $123.80 million.</p>\n<p>• Nabriva Therapeutics (NASDAQ:NBRV) is projected to report quarterly loss at $0.24 per share on revenue of $9.50 million.</p>\n<p>• NGL Energy Partners (NYSE:NGL) is projected to report quarterly loss at $0.15 per share on revenue of $1.52 billion.</p>\n<p>• Montrose Environmental Gr (NYSE:MEG) is expected to report quarterly earnings at $0.03 per share on revenue of $119.10 million.</p>\n<p>• Lyra Therapeutics (NASDAQ:LYRA) is expected to report quarterly loss at $0.73 per share on revenue of $-0.73.</p>\n<p>• Gladstone Land (NASDAQ:LAND) is likely to report quarterly loss at $0.06 per share on revenue of $17.89 million.</p>\n<p>• Kaleyra (NYSE:KLR) is likely to report quarterly loss at $0.10 per share on revenue of $80.89 million.</p>\n<p>• Inovio Pharmaceuticals (NASDAQ:INO) is expected to report quarterly loss at $0.33 per share on revenue of $970.00 thousand.</p>\n<p>• Open Lending (NASDAQ:LPRO) is projected to report quarterly earnings at $0.21 per share on revenue of $54.69 million.</p>\n<p>• Ligand Pharmaceuticals (NASDAQ:LGND) is likely to report quarterly earnings at $1.04 per share on revenue of $55.65 million.</p>\n<p>• Intercorp Financial Servs (NYSE:IFS) is expected to report quarterly earnings at $0.76 per share on revenue of $295.00 million.</p>\n<p>• The Hackett Group (NASDAQ:HCKT) is likely to report quarterly earnings at $0.28 per share on revenue of $67.03 million.</p>\n<p>• Harrow Health (NASDAQ:HROW) is likely to report quarterly loss at $0.02 per share on revenue of $17.45 million.</p>\n<p>• icad (NASDAQ:ICAD) is expected to report quarterly loss at $0.08 per share on revenue of $9.91 million.</p>\n<p>• Hyliion Holdings (NYSE:HYLN) is expected to report earnings for its third quarter.</p>\n<p>• Health Catalyst (NASDAQ:HCAT) is expected to report quarterly loss at $0.21 per share on revenue of $60.63 million.</p>\n<p>• Grocery Outlet Holding (NASDAQ:GO) is likely to report quarterly earnings at $0.22 per share on revenue of $782.13 million.</p>\n<p>• GoHealth (NASDAQ:GOCO) is likely to report quarterly loss at $0.10 per share on revenue of $198.85 million.</p>\n<p>• Gulf Island Fabrication (NASDAQ:GIFI) is estimated to report quarterly loss at $0.20 per share on revenue of $22.88 million.</p>\n<p>• Fuel Tech (NASDAQ:FTEK) is expected to report earnings for its third quarter.</p>\n<p>• Franklin Covey (NYSE:FC) is likely to report quarterly earnings at $0.14 per share on revenue of $63.45 million.</p>\n<p>• FibroGen (NASDAQ:FGEN) is estimated to report quarterly loss at $0.01 per share on revenue of $143.46 million.</p>\n<p>• Fulgent Genetics (NASDAQ:FLGT) is projected to report quarterly earnings at $3.25 per share on revenue of $264.00 million.</p>\n<p>• Everbridge (NASDAQ:EVBG) is estimated to report quarterly loss at $0.14 per share on revenue of $94.25 million.</p>\n<p>• Certara (NASDAQ:CERT) is likely to report quarterly earnings at $0.06 per share on revenue of $72.82 million.</p>\n<p>• PubMatic (NASDAQ:PUBM) is likely to report quarterly earnings at $0.09 per share on revenue of $52.55 million.</p>\n<p>• Seer (NASDAQ:SEER) is likely to report quarterly loss at $0.28 per share on revenue of $1.23 million.</p>\n<p>• PARTS iD (AMEX:ID) is likely to report earnings for its third quarter.</p>\n<p>• Advantage Solutions (NASDAQ:ADV) is expected to report quarterly earnings at $0.18 per share on revenue of $913.15 million.</p>\n<p>• Vroom (NASDAQ:VRM) is likely to report quarterly loss at $0.73 per share on revenue of $888.00 million.</p>\n<p>• Unity Software (NYSE:U) is likely to report quarterly loss at $0.07 per share on revenue of $264.62 million.</p>\n<p>• Veracyte (NASDAQ:VCYT) is projected to report quarterly loss at $0.16 per share on revenue of $54.38 million.</p>\n<p>• Veritone (NASDAQ:VERI) is expected to report quarterly loss at $0.11 per share on revenue of $22.03 million.</p>\n<p>• Vermilion Energy (NYSE:VET) is likely to report quarterly earnings at $0.28 per share on revenue of $366.06 million.</p>\n<p>• Transact Technologies (NASDAQ:TACT) is estimated to report quarterly loss at $0.28 per share on revenue of $9.44 million.</p>\n<p>• TransMedics Group (NASDAQ:TMDX) is projected to report quarterly loss at $0.36 per share on revenue of $6.35 million.</p>\n<p>• Barings BDC (NYSE:BBDC) is expected to report quarterly earnings at $0.23 per share on revenue of $33.36 million.</p>\n<p>• Inari Medical (NASDAQ:NARI) is projected to report quarterly loss at $0.11 per share on revenue of $63.03 million.</p>\n<p>• OncoCyte (NASDAQ:OCX) is likely to report quarterly loss at $0.12 per share on revenue of $1.76 million.</p>\n<p>• Maiden Holdings (NASDAQ:MHLD) is estimated to report earnings for its third quarter.</p>\n<p>• Eastman Kodak (NYSE:KODK) is likely to report earnings for its third quarter.</p>\n<p>• Reed's (NASDAQ:REED) is estimated to report quarterly loss at $0.03 per share on revenue of $12.39 million.</p>\n<p>• Pixelworks (NASDAQ:PXLW) is expected to report quarterly loss at $0.05 per share on revenue of $14.85 million.</p>\n<p>• ePlus (NASDAQ:PLUS) is estimated to report quarterly earnings at $2.13 per share on revenue of $439.03 million.</p>\n<p>• Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:PEY) is projected to report quarterly earnings at $0.16 per share on revenue of $173.29 million.</p>\n<p>• PDF Solutions (NASDAQ:PDFS) is projected to report earnings for its third quarter.</p>\n<p>• RingCentral (NYSE:RNG) is likely to report quarterly earnings at $0.33 per share on revenue of $393.42 million.</p>\n<p>• Ring Energy (AMEX:REI) is projected to report quarterly earnings at $0.09 per share on revenue of $43.73 million.</p>\n<p>• Silk Road Medical (NASDAQ:SILK) is estimated to report quarterly loss at $0.30 per share on revenue of $26.23 million.</p>\n<p>• StepStone Group (NASDAQ:STEP) is estimated to report quarterly earnings at $0.29 per share on revenue of $108.26 million.</p>\n<p>• Smart Sand (NASDAQ:SND) is estimated to report quarterly loss at $0.17 per share on revenue of $27.15 million.</p>\n<p>• ShotSpotter (NASDAQ:SSTI) is estimated to report quarterly earnings at $0.01 per share on revenue of $14.96 million.</p>\n<p>• SailPoint Technologies (NYSE:SAIL) is estimated to report quarterly loss at $0.06 per share on revenue of $103.43 million.</p>\n<p>• Stepan (NYSE:SCL) is estimated to report quarterly earnings at $0.04 per share on revenue of $299.00 million.</p>\n<p>• Senseonics Holdings (AMEX:SENS) is expected to report quarterly loss at $0.06 per share on revenue of $3.52 million.</p>\n<p>• Repay Holdings (NASDAQ:RPAY) is estimated to report quarterly earnings at $0.18 per share on revenue of $59.31 million.</p>\n<p>• Electromed (AMEX:ELMD) is expected to report quarterly earnings at $0.06 per share on revenue of $8.90 million.</p>\n<p>• Evolution Petroleum (AMEX:EPM) is estimated to report quarterly earnings at $0.15 per share on revenue of $17.70 million.</p>\n<p>• Global X Super Dividend ETF (NYSE:DIV) is projected to report quarterly earnings at $0.04 per share on revenue of $11.06 million.</p>\n<p>• DermTech (NASDAQ:DMTK) is estimated to report quarterly loss at $0.64 per share on revenue of $3.41 million.</p>\n<p>• CuriosityStream (NASDAQ:CURI) is likely to report quarterly loss at $0.19 per share on revenue of $19.84 million.</p>\n<p>• Crexendo (NASDAQ:CXDO) is expected to report earnings for its third quarter.</p>\n<p>• ClearPoint Neuro (NASDAQ:CLPT) is estimated to report quarterly loss at $0.16 per share on revenue of $4.00 million.</p>\n<p>• Aziyo Biologics (NASDAQ:AZYO) is likely to report quarterly loss at $0.62 per share on revenue of $11.48 million.</p>\n<p>• Catalyst Pharmaceuticals (NASDAQ:CPRX) is likely to report quarterly earnings at $0.10 per share on revenue of $34.59 million.</p>\n<p>• Alexco Resource (AMEX:AXU) is projected to report earnings for its third quarter.</p>\n<p>• MannKind (NASDAQ:MNKD) is projected to report quarterly loss at $0.07 per share on revenue of $19.88 million.</p>\n<p>• Aptinyx (NASDAQ:APTX) is projected to report earnings for its third quarter.</p>\n<p>• Accelerate Diagnostics (NASDAQ:AXDX) is likely to report quarterly loss at $0.33 per share on revenue of $3.91 million.</p>\n<p>• Achieve Life Sciences (NASDAQ:ACHV) is estimated to report earnings for its third quarter.</p>\n<p>• Nautilus (NYSE:NLS) is estimated to report quarterly earnings at $0.10 per share on revenue of $152.73 million.</p>\n<p>• Airgain (NASDAQ:AIRG) is likely to report quarterly loss at $0.05 per share on revenue of $16.08 million.</p>\n<p>• Cannae Holdings (NYSE:CNNE) is expected to report quarterly earnings at $0.17 per share on revenue of $194.20 million.</p>\n<p>• Bottomline Technologies (NASDAQ:EPAY) is likely to report quarterly earnings at $0.25 per share on revenue of $122.39 million.</p>\n<p>• Cornerstone Building (NYSE:CNR) is likely to report quarterly earnings at $0.56 per share on revenue of $1.42 billion.</p>\n<p>• Vectrus (NYSE:VEC) is expected to report quarterly earnings at $0.79 per share on revenue of $434.00 million.</p>\n<p>• 2U (NASDAQ:TWOU) is likely to report quarterly loss at $0.25 per share on revenue of $232.21 million.</p>\n<p>• TTEC Holdings (NASDAQ:TTEC) is projected to report quarterly earnings at $0.85 per share on revenue of $569.21 million.</p>\n<p>• Sierra Wireless (NASDAQ:SWIR) is likely to report quarterly loss at $0.70 per share on revenue of $78.37 million.</p>\n<p>• ScanSource (NASDAQ:SCSC) is estimated to report quarterly earnings at $0.72 per share on revenue of $812.40 million.</p>\n<p>• NuVasive (NASDAQ:NUVA) is projected to report quarterly earnings at $0.54 per share on revenue of $291.79 million.</p>\n<p>• CPSI (NASDAQ:CPSI) is expected to report quarterly earnings at $0.63 per share on revenue of $71.07 million.</p>\n<p>• Arlo Technologies (NYSE:ARLO) is likely to report quarterly loss at $0.14 per share on revenue of $106.24 million.</p>\n<p>• Advanced Emissions Solns (NASDAQ:ADES) is estimated to report earnings for its third quarter.</p>\n<p>• Coca-Cola Consolidated (NASDAQ:COKE) is projected to report earnings for its third quarter.</p>\n<p>• Jazz Pharmaceuticals (NASDAQ:JAZZ) is estimated to report quarterly earnings at $3.31 per share on revenue of $832.52 million.</p>\n<p>• Avid Technology (NASDAQ:AVID) is projected to report quarterly earnings at $0.25 per share on revenue of $96.69 million.</p>\n<p>• NIO (NYSE:NIO) is estimated to report earnings for its third quarter.</p>\n<p>• Red Violet (NASDAQ:RDVT) is likely to report earnings for its third quarter.</p>\n<p>• Pure Cycle (NASDAQ:PCYO) is estimated to report earnings for its fourth quarter.</p>\n<p>• James Hardie Industries (NYSE:JHX) is estimated to report earnings for its second quarter.</p>\n<p>• Momentus (NASDAQ:MNTS) is projected to report earnings for its third quarter.</p>\n<p>• Synalloy (NASDAQ:SYNL) is expected to report earnings for its third quarter.</p>\n<p>• Western Midstream (NYSE:WES) is expected to report quarterly earnings at $0.62 per share on revenue of $736.12 million.</p>\n<p>• Scientific Games (NASDAQ:SGMS) is expected to report quarterly earnings at $0.32 per share on revenue of $823.43 million.</p>\n<p>• SciPlay (NASDAQ:SCPL) is estimated to report quarterly earnings at $0.22 per share on revenue of $154.65 million.</p>\n<p>• Doximity (NYSE:DOCS) is likely to report quarterly earnings at $0.10 per share on revenue of $73.50 million.</p>\n<p>• Latch (NASDAQ:LTCH) is estimated to report quarterly loss at $0.25 per share on revenue of $10.56 million.</p>\n<p>• SEMrush Hldgs (NYSE:SEMR) is expected to report earnings for its third quarter.</p>\n<p>• CarGurus (NASDAQ:CARG) is projected to report quarterly earnings at $0.32 per share on revenue of $217.72 million.</p>\n<p>• Upstart Holdings (NASDAQ:UPST) is projected to report quarterly earnings at $0.35 per share on revenue of $214.90 million.</p>\n<p>• AssetMark Financial Hldgs (NYSE:AMK) is projected to report quarterly earnings at $0.38 per share on revenue of $100.28 million.</p>\n<p>• AbCellera Biologics (NASDAQ:ABCL) is likely to report quarterly loss at $0.03 per share on revenue of $16.20 million.</p>\n<p>• FutureFuel (NYSE:FF) is estimated to report earnings for its third quarter.</p>\n<p>• Central Puerto (NYSE:CEPU) is projected to report earnings for its third quarter.</p>\n<p>• Organogenesis Holdings (NASDAQ:ORGO) is projected to report quarterly earnings at $0.06 per share on revenue of $112.67 million.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Earnings Scheduled For November 9, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEarnings Scheduled For November 9, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 17:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/21/11/23974533/earnings-scheduled-for-november-9-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Companies Reporting Before The Bell\n• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.\n• KT (NYSE:KT) is projected to report earnings for its third quarter.\n• Selecta ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/11/23974533/earnings-scheduled-for-november-9-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","NIO":"蔚来"},"source_url":"https://www.benzinga.com/news/earnings/21/11/23974533/earnings-scheduled-for-november-9-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138347885","content_text":"Companies Reporting Before The Bell\n• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.\n• KT (NYSE:KT) is projected to report earnings for its third quarter.\n• Selecta Biosciences (NASDAQ:SELB) is projected to report quarterly loss at $0.07 per share on revenue of $12.19 million.\n• Ocugen (NASDAQ:OCGN) is likely to report earnings for its third quarter.\n• Madison Square Garden (NYSE:MSGE) is estimated to report quarterly loss at $1.14 per share on revenue of $281.24 million.\n• Mersana Therapeutics (NASDAQ:MRSN) is expected to report quarterly loss at $0.58 per share on revenue of $100.00 thousand.\n• Intra-Cellular Therapies (NASDAQ:ITCI) is estimated to report quarterly loss at $0.92 per share on revenue of $22.12 million.\n• IVERIC bio (NASDAQ:ISEE) is estimated to report earnings for its third quarter.\n• Amicus Therapeutics (NASDAQ:FOLD) is projected to report quarterly loss at $0.18 per share on revenue of $80.11 million.\n• Epizyme (NASDAQ:EPZM) is likely to report quarterly loss at $0.48 per share on revenue of $13.18 million.\n• Dicerna Pharmaceuticals (NASDAQ:DRNA) is estimated to report quarterly loss at $0.46 per share on revenue of $43.78 million.\n• BioNTech (NASDAQ:BNTX) is projected to report quarterly earnings at $12.03 per share on revenue of $5.93 billion.\n• Biohaven Pharma Hldgs (NYSE:BHVN) is expected to report quarterly loss at $2.40 per share on revenue of $128.40 million.\n• Motorcar Parts of America (NASDAQ:MPAA) is projected to report quarterly earnings at $0.45 per share on revenue of $142.67 million.\n• Kandi Technologies Gr (NASDAQ:KNDI) is expected to report quarterly earnings at $0.19 per share on revenue of $38.80 million.\n• Applied Genetic (NASDAQ:AGTC) is likely to report quarterly loss at $0.35 per share on revenue of $80.00 thousand.\n• TransAlta (NYSE:TAC) is likely to report quarterly earnings at $0.10 per share on revenue of $427.75 million.\n• Southwest Gas Holdings (NYSE:SWX) is projected to report quarterly earnings at $0.13 per share on revenue of $836.43 million.\n• EchoStar (NASDAQ:SATS) is estimated to report quarterly earnings at $0.34 per share on revenue of $493.85 million.\n• Studio City Intl Hldgs (NYSE:MSC) is expected to report earnings for its third quarter.\n• Ebix (NASDAQ:EBIX) is likely to report quarterly earnings at $0.62 per share on revenue of $221.18 million.\n• Concert Pharmaceuticals (NASDAQ:CNCE) is expected to report quarterly loss at $0.81 per share on revenue of $50.00 thousand.\n• WestRock (NYSE:WRK) is projected to report quarterly earnings at $1.15 per share on revenue of $5.03 billion.\n• Sysco (NYSE:SYY) is estimated to report quarterly earnings at $0.86 per share on revenue of $15.87 billion.\n• BP Midstream Partners (NYSE:BPMP) is likely to report quarterly earnings at $0.38 per share on revenue of $32.05 million.\n• Purple Innovation (NASDAQ:PRPL) is expected to report quarterly earnings at $0.17 per share on revenue of $199.53 million.\n• Thermon Group Holdings (NYSE:THR) is estimated to report quarterly earnings at $0.11 per share on revenue of $71.40 million.\n• Tufin Software (NYSE:TUFN) is projected to report quarterly loss at $0.25 per share on revenue of $26.17 million.\n• Katapult Holdings (NASDAQ:KPLT) is projected to report quarterly loss at $0.08 per share on revenue of $39.41 million.\n• Alight (NYSE:ALIT) is projected to report quarterly earnings at $0.13 per share on revenue of $686.57 million.\n• Stevanato Group (NYSE:STVN) is likely to report quarterly earnings at $0.11 per share on revenue of $238.52 million.\n• N-able (NYSE:NABL) is projected to report quarterly earnings at $0.09 per share on revenue of $86.81 million.\n• Reservoir Media (NASDAQ:RSVR) is estimated to report quarterly earnings at $0.13 per share on revenue of $31.75 million.\n• Ecovyst (NYSE:ECVT) is likely to report quarterly earnings at $0.15 per share on revenue of $152.32 million.\n• Absci (NASDAQ:ABSI) is estimated to report quarterly loss at $0.18 per share on revenue of $2.01 million.\n• Sovos Brands (NASDAQ:SOVO) is projected to report quarterly earnings at $0.07 per share on revenue of $169.33 million.\n• Sarcos Technology (NASDAQ:STRC) is estimated to report quarterly loss at $0.06 per share on revenue of $1.50 million.\n• Nuvei (NASDAQ:NVEI) is projected to report quarterly earnings at $0.36 per share on revenue of $178.20 million.\n• Armstrong Flooring (NYSE:AFI) is expected to report earnings for its third quarter.\n• Melco Resorts and Enter (NASDAQ:MLCO) is projected to report earnings for its third quarter.\n• Blue Owl Capital (NYSE:OWL) is projected to report quarterly earnings at $0.08 per share on revenue of $227.95 million.\n• Carter Bankshares (NASDAQ:CARE) is expected to report quarterly loss at $0.09 per share on revenue of $18.06 million.\n• Bioventus (NASDAQ:BVS) is likely to report quarterly earnings at $0.14 per share on revenue of $102.23 million.\n• UWM Holdings (NYSE:UWMC) is projected to report quarterly earnings at $0.12 per share on revenue of $612.93 million.\n• Atotech (NYSE:ATC) is projected to report quarterly earnings at $0.19 per share on revenue of $370.03 million.\n• InspireMD (NASDAQ:NSPR) is projected to report quarterly loss at $0.82 per share on revenue of $1.20 million.\n• Orion Energy Sys (NASDAQ:OESX) is likely to report quarterly earnings at $0.09 per share on revenue of $38.60 million.\n• Novanta (NASDAQ:NOVT) is likely to report quarterly earnings at $0.60 per share on revenue of $172.06 million.\n• Marinus Pharmaceuticals (NASDAQ:MRNS) is expected to report quarterly loss at $0.73 per share on revenue of $2.17 million.\n• International Seaways (NYSE:INSW) is likely to report quarterly loss at $0.77 per share on revenue of $77.97 million.\n• II-VI (NASDAQ:IIVI) is projected to report quarterly earnings at $0.83 per share on revenue of $808.60 million.\n• Harmony Biosciences (NASDAQ:HRMY) is likely to report quarterly earnings at $0.28 per share on revenue of $79.85 million.\n• Hilton Grand Vacations (NYSE:HGV) is expected to report quarterly earnings at $0.38 per share on revenue of $357.73 million.\n• Hyatt Hotels (NYSE:H) is likely to report quarterly earnings at $0.45 per share on revenue of $2.13 billion.\n• Global Indemnity Group (NASDAQ:GBLI) is projected to report earnings for its third quarter.\n• Whole Earth Brands (NASDAQ:FREE) is projected to report quarterly earnings at $0.20 per share on revenue of $130.27 million.\n• XPEL (NASDAQ:XPEL) is likely to report quarterly earnings at $0.32 per share on revenue of $64.37 million.\n• Vertex Energy (NASDAQ:VTNR) is expected to report quarterly earnings at $0.01 per share on revenue of $53.83 million.\n• Vital Farms (NASDAQ:VITL) is expected to report quarterly loss at $0.06 per share on revenue of $63.67 million.\n• Verona Pharma (NASDAQ:VRNA) is likely to report quarterly loss at $0.37 per share on revenue of $4.17 million.\n• Village Farms Intl (NASDAQ:VFF) is estimated to report quarterly earnings at $0.01 per share on revenue of $68.72 million.\n• Vericel (NASDAQ:VCEL) is likely to report quarterly loss at $0.03 per share on revenue of $38.07 million.\n• TravelCenters Of America (NASDAQ:TA) is projected to report quarterly earnings at $0.13 per share on revenue of $526.53 million.\n• Palantir Technologies (NYSE:PLTR) is expected to report quarterly earnings at $0.04 per share on revenue of $385.02 million.\n• ReNew Energy Glb (NASDAQ:RNW) is expected to report quarterly earnings at $0.13 per share on revenue of $98.99 million.\n• Momentive Global (NASDAQ:MNTV) is projected to report quarterly earnings at $0.01 per share on revenue of $114.21 million.\n• Neuronetics (NASDAQ:STIM) is likely to report quarterly loss at $0.30 per share on revenue of $14.10 million.\n• Scienjoy Holding (NASDAQ:SJ) is likely to report quarterly earnings at $0.65 per share on revenue of $696.23 million.\n• Establishment Labs Hldgs (NASDAQ:ESTA) is projected to report quarterly loss at $0.35 per share on revenue of $28.27 million.\n• Digital Media Solutions (NYSE:DMS) is expected to report quarterly earnings at $0.04 per share on revenue of $109.00 million.\n• Delcath Systems (NASDAQ:DCTH) is expected to report quarterly loss at $1.08 per share on revenue of $490.00 thousand.\n• Bentley Systems (NASDAQ:BSY) is estimated to report quarterly earnings at $0.17 per share on revenue of $0.22.\n• Gilat Satellite Networks (NASDAQ:GILT) is expected to report quarterly loss at $0.01 per share on revenue of $61.82 million.\n• Eagle Pharmaceuticals (NASDAQ:EGRX) is estimated to report quarterly earnings at $0.83 per share on revenue of $46.40 million.\n• Endeavour Silver (NYSE:EXK) is projected to report quarterly earnings at $0.03 per share on revenue of $41.68 million.\n• Computer Task Group (NASDAQ:CTG) is projected to report quarterly earnings at $0.10 per share on revenue of $91.18 million.\n• ChannelAdvisor (NYSE:ECOM) is expected to report quarterly earnings at $0.17 per share on revenue of $41.55 million.\n• CEVA (NASDAQ:CEVA) is likely to report quarterly earnings at $0.17 per share on revenue of $31.24 million.\n• Agenus (NASDAQ:AGEN) is likely to report quarterly earnings at $0.46 per share on revenue of $183.11 million.\n• Wabash National (NYSE:WNC) is estimated to report quarterly earnings at $0.20 per share on revenue of $514.07 million.\n• Triumph Group (NYSE:TGI) is likely to report quarterly earnings at $0.09 per share on revenue of $373.33 million.\n• SeaWorld Entertainment (NYSE:SEAS) is projected to report quarterly earnings at $1.67 per share on revenue of $536.55 million.\n• Starwood Property Trust (NYSE:STWD) is estimated to report quarterly earnings at $0.52 per share on revenue of $300.00 million.\n• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.00 per share on revenue of $825.88 million.\n• HUYA (NYSE:HUYA) is expected to report quarterly earnings at $0.04 per share on revenue of $475.52 million.\n• Haemonetics (NYSE:HAE) is expected to report quarterly earnings at $0.61 per share on revenue of $241.40 million.\n• Intl Game Tech (NYSE:IGT) is expected to report quarterly earnings at $0.34 per share on revenue of $981.09 million.\n• Gol Intelligent Airlines (NYSE:GOL) is likely to report quarterly loss at $0.93 per share on revenue of $330.26 million.\n• Hain Celestial Group (NASDAQ:HAIN) is projected to report quarterly earnings at $0.24 per share on revenue of $442.59 million.\n• Federal Signal (NYSE:FSS) is projected to report quarterly earnings at $0.46 per share on revenue of $325.50 million.\n• Audacy (NYSE:AUD) is expected to report quarterly earnings at $0.06 per share on revenue of $329.68 million.\n• Cardiovascular Systems (NASDAQ:CSII) is likely to report quarterly loss at $0.11 per share on revenue of $64.27 million.\n• CorEnergy Infr Trust (NYSE:CORR) is projected to report quarterly earnings at $0.10 per share on revenue of $35.32 million.\n• Allot (NASDAQ:ALLT) is likely to report quarterly loss at $0.05 per share on revenue of $37.01 million.\n• Golar LNG (NASDAQ:GLNG) is likely to report quarterly loss at $0.04 per share on revenue of $100.36 million.\n• Quotient (NASDAQ:QTNT) is projected to report quarterly loss at $0.26 per share on revenue of $8.56 million.\n• WhiteHorse Finance (NASDAQ:WHF) is likely to report quarterly earnings at $0.37 per share on revenue of $18.30 million.\n• Party City Holdco (NYSE:PRTY) is likely to report earnings for its third quarter.\n• D.R. Horton (NYSE:DHI) is likely to report quarterly earnings at $3.40 per share on revenue of $7.94 billion.\n• Clear Channel Outdoor (NYSE:CCO) is expected to report quarterly loss at $0.09 per share on revenue of $589.02 million.\n• Blue Apron Hldgs (NYSE:APRN) is projected to report quarterly loss at $0.58 per share on revenue of $120.40 million.\n• ADT (NYSE:ADT) is estimated to report quarterly earnings at $0.09 per share on revenue of $1.29 billion.\n• Cardinal Health (NYSE:CAH) is expected to report quarterly earnings at $1.33 per share on revenue of $41.93 billion.\n• Overseas Shipholding Gr (NYSE:OSG) is estimated to report earnings for its third quarter.\n• Smith-Midland (NASDAQ:SMID) is expected to report earnings for its third quarter.\n• Cano Health (NYSE:CANO) is likely to report quarterly loss at $0.01 per share on revenue of $435.82 million.\n• Nuwellis (NASDAQ:NUWE) is estimated to report quarterly loss at $0.73 per share on revenue of $2.22 million.\nCompanies Reporting After The Bell\n• 180 Degree Capital (NASDAQ:TURN) is expected to report earnings for its third quarter.\n• SandRidge Energy (NYSE:SD) is likely to report earnings for its third quarter.\n• Lufax Holding (NYSE:LU) is likely to report earnings for its third quarter.\n• Ormat Technologies (NYSE:ORA) is expected to report earnings for its third quarter.\n• Osisko Gold Royalties (NYSE:OR) is projected to report earnings for its third quarter.\n• VIQ Solutions (NASDAQ:VQS) is likely to report quarterly loss at $0.10 per share on revenue of $9.61 million.\n• Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $15.00 million.\n• Tricon Residential (NYSE:TCN) is likely to report earnings for its third quarter.\n• Marchex (NASDAQ:MCHX) is likely to report quarterly loss at $0.02 per share on revenue of $14.35 million.\n• HyreCar (NASDAQ:HYRE) is estimated to report quarterly loss at $0.28 per share on revenue of $9.93 million.\n• Lument Finance Trust (NYSE:LFT) is likely to report quarterly earnings at $0.08 per share on revenue of $5.56 million.\n• eGain (NASDAQ:EGAN) is likely to report quarterly earnings at $0.04 per share on revenue of $21.09 million.\n• Ecopetrol (NYSE:EC) is likely to report quarterly earnings at $0.61 per share on revenue of $6.01 billion.\n• Cormedix (NASDAQ:CRMD) is projected to report quarterly loss at $0.18 per share on revenue of $20.00 thousand.\n• Cherry Hill Mortgage (NYSE:CHMI) is projected to report quarterly earnings at $0.30 per share on revenue of $6.76 million.\n• Brickell Biotech (NASDAQ:BBI) is expected to report earnings for its third quarter.\n• Avino Silver & Gold Mines (AMEX:ASM) is estimated to report earnings for its third quarter.\n• Alcon (NYSE:ALC) is estimated to report quarterly earnings at $0.49 per share on revenue of $2.04 billion.\n• Aethlon Medical (NASDAQ:AEMD) is estimated to report quarterly loss at $0.15 per share on revenue of $190.00 thousand.\n• Plug Power (NASDAQ:PLUG) is estimated to report quarterly loss at $0.09 per share on revenue of $143.93 million.\n• Cumberland (NASDAQ:CPIX) is expected to report earnings for its third quarter.\n• ChemoCentryx (NASDAQ:CCXI) is expected to report quarterly loss at $0.45 per share on revenue of $13.48 million.\n• Tidewater (NYSE:TDW) is likely to report quarterly loss at $0.55 per share on revenue of $92.90 million.\n• Genpact (NYSE:G) is projected to report quarterly earnings at $0.49 per share on revenue of $877.65 million.\n• Callaway Golf (NYSE:ELY) is likely to report quarterly earnings at $0.09 per share on revenue of $845.60 million.\n• Darling Ingredients (NYSE:DAR) is expected to report quarterly earnings at $0.80 per share on revenue of $1.21 billion.\n• Clipper Realty (NYSE:CLPR) is likely to report quarterly loss at $0.07 per share on revenue of $31.09 million.\n• Capricor Therapeutics (NASDAQ:CAPR) is projected to report quarterly loss at $0.22 per share on revenue of $210.00 thousand.\n• Calithera Biosciences (NASDAQ:CALA) is estimated to report earnings for its third quarter.\n• Acorda Therapeutics (NASDAQ:ACOR) is likely to report quarterly loss at $1.56 per share on revenue of $30.57 million.\n• Aurora Cannabis (NASDAQ:ACB) is projected to report quarterly loss at $0.21 per share on revenue of $49.24 million.\n• Arlington Asset Inv (NYSE:AAIC) is projected to report quarterly earnings at $0.06 per share on revenue of $4.52 million.\n• DoorDash (NYSE:DASH) is likely to report quarterly loss at $0.26 per share on revenue of $1.18 billion.\n• Wynn Resorts (NASDAQ:WYNN) is estimated to report quarterly loss at $1.31 per share on revenue of $942.64 million.\n• FuboTV (NYSE:FUBO) is expected to report quarterly loss at $0.63 per share on revenue of $143.55 million.\n• Ashland Global Holdings (NYSE:ASH) is estimated to report quarterly earnings at $1.29 per share on revenue of $640.67 million.\n• Braskem (NYSE:BAK) is expected to report quarterly earnings at $2.44 per share on revenue of $5.00 billion.\n• Global E Online (NASDAQ:GLBE) is likely to report quarterly earnings at $0.01 per share on revenue of $55.74 million.\n• Augmedix (NASDAQ:AUGX) is expected to report quarterly loss at $0.10 per share on revenue of $5.61 million.\n• Curis (NASDAQ:CRIS) is projected to report quarterly loss at $0.13 per share on revenue of $2.79 million.\n• Omeros (NASDAQ:OMER) is expected to report quarterly loss at $0.52 per share on revenue of $26.96 million.\n• Pangaea Logistics Solns (NASDAQ:PANL) is projected to report quarterly earnings at $0.50 per share on revenue of $160.44 million.\n• Alto Ingredients (NASDAQ:ALTO) is likely to report quarterly earnings at $0.12 per share on revenue of $267.01 million.\n• Performant Financial (NASDAQ:PFMT) is projected to report quarterly loss at $0.08 per share on revenue of $28.30 million.\n• Recro Pharma (NASDAQ:REPH) is expected to report quarterly loss at $0.07 per share on revenue of $18.07 million.\n• Radiant Logistics (AMEX:RLGT) is expected to report quarterly earnings at $0.10 per share on revenue of $225.11 million.\n• Revance Therapeutics (NASDAQ:RVNC) is likely to report quarterly loss at $1.15 per share on revenue of $20.29 million.\n• Surgalign Holdings (NASDAQ:SRGA) is likely to report quarterly loss at $0.09 per share on revenue of $22.28 million.\n• Turning Point (NASDAQ:TPTX) is estimated to report earnings for its third quarter.\n• AerSale (NASDAQ:ASLE) is expected to report quarterly earnings at $0.20 per share on revenue of $93.50 million.\n• Zeta Global Holdings (NYSE:ZETA) is expected to report quarterly earnings at $0.06 per share on revenue of $109.85 million.\n• Flywire (NASDAQ:FLYW) is estimated to report earnings for its third quarter.\n• Singular Genomics Systems (NASDAQ:OMIC) is expected to report earnings for its third quarter.\n• Codex DNA (NASDAQ:DNAY) is expected to report quarterly loss at $0.28 per share on revenue of $2.93 million.\n• Angel Oak Mortgage (NYSE:AOMR) is expected to report quarterly earnings at $0.35 per share on revenue of $15.85 million.\n• ATI Physical Therapy (NYSE:ATIP) is estimated to report quarterly loss at $0.04 per share on revenue of $159.63 million.\n• Greenbrook TMS (NASDAQ:GBNH) is expected to report quarterly loss at $0.45 per share on revenue of $13.00 million.\n• Taboola.com (NASDAQ:TBLA) is estimated to report quarterly loss at $0.02 per share on revenue of $122.72 million.\n• Paymentus Holdings (NYSE:PAY) is likely to report quarterly earnings at $0.01 per share on revenue of $94.22 million.\n• Paycor HCM (NASDAQ:PYCR) is expected to report quarterly earnings at $0.02 per share on revenue of $89.82 million.\n• Krispy Kreme (NASDAQ:DNUT) is projected to report quarterly earnings at $0.06 per share on revenue of $337.67 million.\n• CS Disco (NYSE:LAW) is likely to report quarterly loss at $0.22 per share on revenue of $25.79 million.\n• Sera Prognostics (NASDAQ:SERA) is projected to report quarterly loss at $0.24 per share on revenue of $70.00 thousand.\n• Jackson Financial (NYSE:JXN) is estimated to report quarterly earnings at $5.31 per share on revenue of $4.83 billion.\n• a.k.a. Brands Holding (NYSE:AKA) is projected to report quarterly loss at $0.10 per share on revenue of $136.92 million.\n• Toast (NYSE:TOST) is projected to report quarterly loss at $0.25 per share on revenue of $429.97 million.\n• Amplitude (NASDAQ:AMPL) is expected to report quarterly loss at $0.14 per share on revenue of $43.57 million.\n• Velo3D (NYSE:VLD) is projected to report quarterly loss at $0.05 per share on revenue of $7.56 million.\n• Zai Lab (NASDAQ:ZLAB) is estimated to report quarterly loss at $1.65 per share on revenue of $32.40 million.\n• Stem (NYSE:STEM) is likely to report quarterly loss at $0.35 per share on revenue of $35.89 million.\n• iPath Series B Carbon Exchange-Traded Notes (NYSE:GRN) is projected to report earnings for its third quarter.\n• Beauty Health (NASDAQ:SKIN) is projected to report quarterly loss at $0.02 per share on revenue of $56.71 million.\n• Agiliti (NYSE:AGTI) is likely to report quarterly earnings at $0.09 per share on revenue of $242.14 million.\n• DoubleVerify Hldgs (NYSE:DV) is expected to report quarterly earnings at $0.06 per share on revenue of $82.02 million.\n• Natural Alternatives Intl (NASDAQ:NAII) is estimated to report earnings for its first quarter.\n• Hostess Brands (NASDAQ:TWNK) is likely to report quarterly earnings at $0.20 per share on revenue of $279.36 million.\n• Custom Truck One Source (NYSE:CTOS) is expected to report quarterly earnings at $0.01 per share on revenue of $357.00 million.\n• Coinbase Global (NASDAQ:COIN) is likely to report quarterly earnings at $1.56 per share on revenue of $1.57 billion.\n• Olo (NYSE:OLO) is likely to report quarterly earnings at $0.02 per share on revenue of $36.26 million.\n• Absolute Software (NASDAQ:ABST) is estimated to report earnings for its first quarter.\n• VIZIO Holding (NYSE:VZIO) is projected to report quarterly loss at $0.10 per share on revenue of $595.33 million.\n• Poshmark (NASDAQ:POSH) is estimated to report quarterly loss at $0.07 per share on revenue of $82.69 million.\n• Urban-gro (NASDAQ:UGRO) is likely to report quarterly earnings at $0.09 per share on revenue of $18.40 million.\n• InnovAge Holding (NASDAQ:INNV) is expected to report quarterly earnings at $0.05 per share on revenue of $171.37 million.\n• ON24 (NYSE:ONTF) is likely to report quarterly loss at $0.08 per share on revenue of $48.03 million.\n• Shoals Technologies Gr (NASDAQ:SHLS) is estimated to report quarterly earnings at $0.07 per share on revenue of $61.64 million.\n• Signify Health (NYSE:SGFY) is estimated to report quarterly earnings at $0.02 per share on revenue of $184.42 million.\n• Viant Technology (NASDAQ:DSP) is expected to report quarterly loss at $0.21 per share on revenue of $50.00 million.\n• PAR Technology (NYSE:PAR) is estimated to report quarterly loss at $0.55 per share on revenue of $72.12 million.\n• Pan American Silver (NASDAQ:PAAS) is likely to report quarterly earnings at $0.44 per share on revenue of $585.65 million.\n• PaySign (NASDAQ:PAYS) is estimated to report earnings for its third quarter.\n• OptimizeRx (NASDAQ:OPRX) is likely to report quarterly earnings at $0.13 per share on revenue of $15.06 million.\n• Neovasc (NASDAQ:NVCN) is likely to report quarterly loss at $0.09 per share on revenue of $1.20 million.\n• NV5 Global (NASDAQ:NVEE) is estimated to report quarterly earnings at $1.15 per share on revenue of $185.01 million.\n• NanoString Technologies (NASDAQ:NSTG) is estimated to report quarterly loss at $0.54 per share on revenue of $37.79 million.\n• Model N (NYSE:MODN) is projected to report quarterly earnings at $0.10 per share on revenue of $50.88 million.\n• NewAge (NASDAQ:NBEV) is expected to report quarterly loss at $0.03 per share on revenue of $123.80 million.\n• Nabriva Therapeutics (NASDAQ:NBRV) is projected to report quarterly loss at $0.24 per share on revenue of $9.50 million.\n• NGL Energy Partners (NYSE:NGL) is projected to report quarterly loss at $0.15 per share on revenue of $1.52 billion.\n• Montrose Environmental Gr (NYSE:MEG) is expected to report quarterly earnings at $0.03 per share on revenue of $119.10 million.\n• Lyra Therapeutics (NASDAQ:LYRA) is expected to report quarterly loss at $0.73 per share on revenue of $-0.73.\n• Gladstone Land (NASDAQ:LAND) is likely to report quarterly loss at $0.06 per share on revenue of $17.89 million.\n• Kaleyra (NYSE:KLR) is likely to report quarterly loss at $0.10 per share on revenue of $80.89 million.\n• Inovio Pharmaceuticals (NASDAQ:INO) is expected to report quarterly loss at $0.33 per share on revenue of $970.00 thousand.\n• Open Lending (NASDAQ:LPRO) is projected to report quarterly earnings at $0.21 per share on revenue of $54.69 million.\n• Ligand Pharmaceuticals (NASDAQ:LGND) is likely to report quarterly earnings at $1.04 per share on revenue of $55.65 million.\n• Intercorp Financial Servs (NYSE:IFS) is expected to report quarterly earnings at $0.76 per share on revenue of $295.00 million.\n• The Hackett Group (NASDAQ:HCKT) is likely to report quarterly earnings at $0.28 per share on revenue of $67.03 million.\n• Harrow Health (NASDAQ:HROW) is likely to report quarterly loss at $0.02 per share on revenue of $17.45 million.\n• icad (NASDAQ:ICAD) is expected to report quarterly loss at $0.08 per share on revenue of $9.91 million.\n• Hyliion Holdings (NYSE:HYLN) is expected to report earnings for its third quarter.\n• Health Catalyst (NASDAQ:HCAT) is expected to report quarterly loss at $0.21 per share on revenue of $60.63 million.\n• Grocery Outlet Holding (NASDAQ:GO) is likely to report quarterly earnings at $0.22 per share on revenue of $782.13 million.\n• GoHealth (NASDAQ:GOCO) is likely to report quarterly loss at $0.10 per share on revenue of $198.85 million.\n• Gulf Island Fabrication (NASDAQ:GIFI) is estimated to report quarterly loss at $0.20 per share on revenue of $22.88 million.\n• Fuel Tech (NASDAQ:FTEK) is expected to report earnings for its third quarter.\n• Franklin Covey (NYSE:FC) is likely to report quarterly earnings at $0.14 per share on revenue of $63.45 million.\n• FibroGen (NASDAQ:FGEN) is estimated to report quarterly loss at $0.01 per share on revenue of $143.46 million.\n• Fulgent Genetics (NASDAQ:FLGT) is projected to report quarterly earnings at $3.25 per share on revenue of $264.00 million.\n• Everbridge (NASDAQ:EVBG) is estimated to report quarterly loss at $0.14 per share on revenue of $94.25 million.\n• Certara (NASDAQ:CERT) is likely to report quarterly earnings at $0.06 per share on revenue of $72.82 million.\n• PubMatic (NASDAQ:PUBM) is likely to report quarterly earnings at $0.09 per share on revenue of $52.55 million.\n• Seer (NASDAQ:SEER) is likely to report quarterly loss at $0.28 per share on revenue of $1.23 million.\n• PARTS iD (AMEX:ID) is likely to report earnings for its third quarter.\n• Advantage Solutions (NASDAQ:ADV) is expected to report quarterly earnings at $0.18 per share on revenue of $913.15 million.\n• Vroom (NASDAQ:VRM) is likely to report quarterly loss at $0.73 per share on revenue of $888.00 million.\n• Unity Software (NYSE:U) is likely to report quarterly loss at $0.07 per share on revenue of $264.62 million.\n• Veracyte (NASDAQ:VCYT) is projected to report quarterly loss at $0.16 per share on revenue of $54.38 million.\n• Veritone (NASDAQ:VERI) is expected to report quarterly loss at $0.11 per share on revenue of $22.03 million.\n• Vermilion Energy (NYSE:VET) is likely to report quarterly earnings at $0.28 per share on revenue of $366.06 million.\n• Transact Technologies (NASDAQ:TACT) is estimated to report quarterly loss at $0.28 per share on revenue of $9.44 million.\n• TransMedics Group (NASDAQ:TMDX) is projected to report quarterly loss at $0.36 per share on revenue of $6.35 million.\n• Barings BDC (NYSE:BBDC) is expected to report quarterly earnings at $0.23 per share on revenue of $33.36 million.\n• Inari Medical (NASDAQ:NARI) is projected to report quarterly loss at $0.11 per share on revenue of $63.03 million.\n• OncoCyte (NASDAQ:OCX) is likely to report quarterly loss at $0.12 per share on revenue of $1.76 million.\n• Maiden Holdings (NASDAQ:MHLD) is estimated to report earnings for its third quarter.\n• Eastman Kodak (NYSE:KODK) is likely to report earnings for its third quarter.\n• Reed's (NASDAQ:REED) is estimated to report quarterly loss at $0.03 per share on revenue of $12.39 million.\n• Pixelworks (NASDAQ:PXLW) is expected to report quarterly loss at $0.05 per share on revenue of $14.85 million.\n• ePlus (NASDAQ:PLUS) is estimated to report quarterly earnings at $2.13 per share on revenue of $439.03 million.\n• Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:PEY) is projected to report quarterly earnings at $0.16 per share on revenue of $173.29 million.\n• PDF Solutions (NASDAQ:PDFS) is projected to report earnings for its third quarter.\n• RingCentral (NYSE:RNG) is likely to report quarterly earnings at $0.33 per share on revenue of $393.42 million.\n• Ring Energy (AMEX:REI) is projected to report quarterly earnings at $0.09 per share on revenue of $43.73 million.\n• Silk Road Medical (NASDAQ:SILK) is estimated to report quarterly loss at $0.30 per share on revenue of $26.23 million.\n• StepStone Group (NASDAQ:STEP) is estimated to report quarterly earnings at $0.29 per share on revenue of $108.26 million.\n• Smart Sand (NASDAQ:SND) is estimated to report quarterly loss at $0.17 per share on revenue of $27.15 million.\n• ShotSpotter (NASDAQ:SSTI) is estimated to report quarterly earnings at $0.01 per share on revenue of $14.96 million.\n• SailPoint Technologies (NYSE:SAIL) is estimated to report quarterly loss at $0.06 per share on revenue of $103.43 million.\n• Stepan (NYSE:SCL) is estimated to report quarterly earnings at $0.04 per share on revenue of $299.00 million.\n• Senseonics Holdings (AMEX:SENS) is expected to report quarterly loss at $0.06 per share on revenue of $3.52 million.\n• Repay Holdings (NASDAQ:RPAY) is estimated to report quarterly earnings at $0.18 per share on revenue of $59.31 million.\n• Electromed (AMEX:ELMD) is expected to report quarterly earnings at $0.06 per share on revenue of $8.90 million.\n• Evolution Petroleum (AMEX:EPM) is estimated to report quarterly earnings at $0.15 per share on revenue of $17.70 million.\n• Global X Super Dividend ETF (NYSE:DIV) is projected to report quarterly earnings at $0.04 per share on revenue of $11.06 million.\n• DermTech (NASDAQ:DMTK) is estimated to report quarterly loss at $0.64 per share on revenue of $3.41 million.\n• CuriosityStream (NASDAQ:CURI) is likely to report quarterly loss at $0.19 per share on revenue of $19.84 million.\n• Crexendo (NASDAQ:CXDO) is expected to report earnings for its third quarter.\n• ClearPoint Neuro (NASDAQ:CLPT) is estimated to report quarterly loss at $0.16 per share on revenue of $4.00 million.\n• Aziyo Biologics (NASDAQ:AZYO) is likely to report quarterly loss at $0.62 per share on revenue of $11.48 million.\n• Catalyst Pharmaceuticals (NASDAQ:CPRX) is likely to report quarterly earnings at $0.10 per share on revenue of $34.59 million.\n• Alexco Resource (AMEX:AXU) is projected to report earnings for its third quarter.\n• MannKind (NASDAQ:MNKD) is projected to report quarterly loss at $0.07 per share on revenue of $19.88 million.\n• Aptinyx (NASDAQ:APTX) is projected to report earnings for its third quarter.\n• Accelerate Diagnostics (NASDAQ:AXDX) is likely to report quarterly loss at $0.33 per share on revenue of $3.91 million.\n• Achieve Life Sciences (NASDAQ:ACHV) is estimated to report earnings for its third quarter.\n• Nautilus (NYSE:NLS) is estimated to report quarterly earnings at $0.10 per share on revenue of $152.73 million.\n• Airgain (NASDAQ:AIRG) is likely to report quarterly loss at $0.05 per share on revenue of $16.08 million.\n• Cannae Holdings (NYSE:CNNE) is expected to report quarterly earnings at $0.17 per share on revenue of $194.20 million.\n• Bottomline Technologies (NASDAQ:EPAY) is likely to report quarterly earnings at $0.25 per share on revenue of $122.39 million.\n• Cornerstone Building (NYSE:CNR) is likely to report quarterly earnings at $0.56 per share on revenue of $1.42 billion.\n• Vectrus (NYSE:VEC) is expected to report quarterly earnings at $0.79 per share on revenue of $434.00 million.\n• 2U (NASDAQ:TWOU) is likely to report quarterly loss at $0.25 per share on revenue of $232.21 million.\n• TTEC Holdings (NASDAQ:TTEC) is projected to report quarterly earnings at $0.85 per share on revenue of $569.21 million.\n• Sierra Wireless (NASDAQ:SWIR) is likely to report quarterly loss at $0.70 per share on revenue of $78.37 million.\n• ScanSource (NASDAQ:SCSC) is estimated to report quarterly earnings at $0.72 per share on revenue of $812.40 million.\n• NuVasive (NASDAQ:NUVA) is projected to report quarterly earnings at $0.54 per share on revenue of $291.79 million.\n• CPSI (NASDAQ:CPSI) is expected to report quarterly earnings at $0.63 per share on revenue of $71.07 million.\n• Arlo Technologies (NYSE:ARLO) is likely to report quarterly loss at $0.14 per share on revenue of $106.24 million.\n• Advanced Emissions Solns (NASDAQ:ADES) is estimated to report earnings for its third quarter.\n• Coca-Cola Consolidated (NASDAQ:COKE) is projected to report earnings for its third quarter.\n• Jazz Pharmaceuticals (NASDAQ:JAZZ) is estimated to report quarterly earnings at $3.31 per share on revenue of $832.52 million.\n• Avid Technology (NASDAQ:AVID) is projected to report quarterly earnings at $0.25 per share on revenue of $96.69 million.\n• NIO (NYSE:NIO) is estimated to report earnings for its third quarter.\n• Red Violet (NASDAQ:RDVT) is likely to report earnings for its third quarter.\n• Pure Cycle (NASDAQ:PCYO) is estimated to report earnings for its fourth quarter.\n• James Hardie Industries (NYSE:JHX) is estimated to report earnings for its second quarter.\n• Momentus (NASDAQ:MNTS) is projected to report earnings for its third quarter.\n• Synalloy (NASDAQ:SYNL) is expected to report earnings for its third quarter.\n• Western Midstream (NYSE:WES) is expected to report quarterly earnings at $0.62 per share on revenue of $736.12 million.\n• Scientific Games (NASDAQ:SGMS) is expected to report quarterly earnings at $0.32 per share on revenue of $823.43 million.\n• SciPlay (NASDAQ:SCPL) is estimated to report quarterly earnings at $0.22 per share on revenue of $154.65 million.\n• Doximity (NYSE:DOCS) is likely to report quarterly earnings at $0.10 per share on revenue of $73.50 million.\n• Latch (NASDAQ:LTCH) is estimated to report quarterly loss at $0.25 per share on revenue of $10.56 million.\n• SEMrush Hldgs (NYSE:SEMR) is expected to report earnings for its third quarter.\n• CarGurus (NASDAQ:CARG) is projected to report quarterly earnings at $0.32 per share on revenue of $217.72 million.\n• Upstart Holdings (NASDAQ:UPST) is projected to report quarterly earnings at $0.35 per share on revenue of $214.90 million.\n• AssetMark Financial Hldgs (NYSE:AMK) is projected to report quarterly earnings at $0.38 per share on revenue of $100.28 million.\n• AbCellera Biologics (NASDAQ:ABCL) is likely to report quarterly loss at $0.03 per share on revenue of $16.20 million.\n• FutureFuel (NYSE:FF) is estimated to report earnings for its third quarter.\n• Central Puerto (NYSE:CEPU) is projected to report earnings for its third quarter.\n• Organogenesis Holdings (NASDAQ:ORGO) is projected to report quarterly earnings at $0.06 per share on revenue of $112.67 million.","news_type":1},"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691250012,"gmtCreate":1640213796164,"gmtModify":1640213796381,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691250012","repostId":"1131862374","repostType":4,"repost":{"id":"1131862374","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213195,"share":"https://www.laohu8.com/m/news/1131862374?lang=&edition=full","pubTime":"2021-12-23 06:46","market":"us","language":"en","title":"U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862374","media":"Reuters","summary":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill fo","content":"<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862374","content_text":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.\nPfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.\nPfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.\n\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.\n\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.\nPfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.\nThe Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.\nThe pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.\nMonoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.\nThe Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.\nThe FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.\nThe drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.\nWhile the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).\nThe second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.\nPfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.\nPfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.\nA rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":725,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603122557,"gmtCreate":1638376688184,"gmtModify":1638376715328,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"coming up soon","listText":"coming up soon","text":"coming up soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603122557","repostId":"1187123549","repostType":2,"repost":{"id":"1187123549","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638370614,"share":"https://www.laohu8.com/m/news/1187123549?lang=&edition=full","pubTime":"2021-12-01 22:56","market":"us","language":"en","title":"Xpeng Motors shares changed from up to down by 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187123549","media":"Tiger Newspress","summary":"Xpeng Motors shares changed from up to down by 4% in morning trading.\n\nXPeng Inc. today announced it","content":"<p>Xpeng Motors shares changed from up to down by 4%&nbsp;in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b410bb36e06e8b1a13514fa0a4ee9cf0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>XPeng Inc.&nbsp;today announced its vehicle delivery results for November 2021.</p>\n<p>XPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.</p>\n<p>Deliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).</p>\n<p>As of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.</p>\n<p>The Company’s cumulative deliveries reached 121,953 as of the end of November 2021.</p>\n<p>In November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.</p>\n<p>XPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xpeng Motors shares changed from up to down by 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXpeng Motors shares changed from up to down by 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xpeng Motors shares changed from up to down by 4%&nbsp;in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b410bb36e06e8b1a13514fa0a4ee9cf0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>XPeng Inc.&nbsp;today announced its vehicle delivery results for November 2021.</p>\n<p>XPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.</p>\n<p>Deliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).</p>\n<p>As of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.</p>\n<p>The Company’s cumulative deliveries reached 121,953 as of the end of November 2021.</p>\n<p>In November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.</p>\n<p>XPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187123549","content_text":"Xpeng Motors shares changed from up to down by 4% in morning trading.\n\nXPeng Inc. today announced its vehicle delivery results for November 2021.\nXPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.\nDeliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).\nAs of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.\nThe Company’s cumulative deliveries reached 121,953 as of the end of November 2021.\nIn November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.\nXPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.","news_type":1},"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862797981,"gmtCreate":1632910999764,"gmtModify":1632910999833,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"seriously?? hmm","listText":"seriously?? hmm","text":"seriously?? hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862797981","repostId":"2171798605","repostType":4,"repost":{"id":"2171798605","pubTimestamp":1632909569,"share":"https://www.laohu8.com/m/news/2171798605?lang=&edition=full","pubTime":"2021-09-29 17:59","market":"us","language":"en","title":"5 Ultra-Popular Stocks With 120% to 190% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2171798605","media":"Motley Fool","summary":"Analysts' loftiest price targets portend significant upside for these widely owned (and followed) stocks.","content":"<p>Patience pays off when investing on Wall Street. Despite navigating its way through the quickest 30% decline in its storied history during the first quarter of 2020, the benchmark <b>S&amp;P 500</b> has since doubled in value.</p>\n<p>But even with this widely followed index regularly knocking on the door of all-time highs this year, bargains still abound -- at least according to Wall Street. Based on analyst's highest published price target for each of the following ultra-popular stocks, upside of 120% to as much as 190% may await.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/347a9bf71fa296ad221e738bdaf31270\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Nio: Implied upside of 160%</h2>\n<p>One high-growth stock getting a lot of attention from investors that could drive higher is electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO). With a high price target of almost $92, the implication is Nio could return approximately 160% over the next 12 months.</p>\n<p>The company certainly finds itself in the right place at the right time. In an effort to combat climate change and reduce the global reliance on fossil fuels, many developed and developing countries are turning to EVs. This should create a multi-decade opportunity for auto stocks to benefit from consumer and enterprise vehicle replacements.</p>\n<p>Nio is based in China, which happens to be the largest auto market in the world. According to the Society of Automotive Engineers of China, roughly half of all new vehicle sales by 2035 could be powered by alternative energy, which would probably result in annual sales of 10 million-plus EVs. With China's EV market still nascent, market share is ripe for the picking.</p>\n<p>Although semiconductor chip supply issues are constraining Nio's EV output for the time being, the company looks well on its way to eventually hitting an annual run-rate of 150,000 EVs once the chip shortages are resolved. While 160% upside in 12 months is probably asking a bit much, we're seeing production and vehicle margins rise, which is a good sign.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a442339ef77177eb97fecfa070c7ac0\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a>: Implied upside of 155%</h2>\n<p>Among small-cap stocks, genome-analysis company <b>Bionano Genomics</b> (NASDAQ:BNGO) is creating a lot of buzz. With a peak price target of $14, the implication is it could gallop higher by as much as 155% over the next year.</p>\n<p>What makes Bionano so exciting is the company's optical genome mapping (OGM) system known as Saphyr. In January, Saphyr demonstrated its potential use by identifying three risk genes for autism spectrum disorder (ASD). ASD is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of many difficult-to-treat ailments. The potential here is that drugmakers could utilize Saphyr to identity certain genetic biomarkers that'll help them develop treatments to fight otherwise hard-to-treat diseases.</p>\n<p>A month prior, in December 2020, Saphyr also outperformed <b>Pacific Biosciences</b>&nbsp;OGM technology. Saphyr had considerably better success in identifying large structural genome variations, compared to Pacific Biosciences' OGM system.</p>\n<p>However, and this is a pretty big \"however,\" Saphyr is a long way away from getting approval from the U.S. Food and Drug Administration (FDA). This means the company's ability to generate revenue from licensing will be dicey at best. It's the perfect example of a company that may have game-changing potential in the healthcare space, but is still many years away from demonstrating that potential to the FDA.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69c8d46ab082fe9b933b958f3354a003\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Skillz: Implied upside of 120%</h2>\n<p>Another company with significant upside, according to analysts, is mobile gaming platform provider <b>Skillz</b> (NYSE:SKLZ). The high-water estimate on Wall Street of $25 suggests Skillz could return up to 120% over the next year.</p>\n<p>The gaming industry is incredibly competitive, capital intensive, and there are no guarantees that a developed game will be a hit with users. That's why Skillz avoided the development side of the equation in its entirety and is focused on being a competitive medium. Skillz provides a platform where mobile gamers can compete for cash prizes, with the company and game developers keeping a portion of the cash prize for themselves. It's a lot easier and cost-effective to maintain a gaming platform than it is to develop the next hit game.</p>\n<p>What's been particularly impressive about Skillz is the company's pay-to-play conversion rate. Whereas the average conversion rate in the industry is around 2%, the company noted at the end of the first quarter that 17% of its monthly active users (MAU) were paying to play on its platform. With the company still in its early stages of its growth and marketing, this is a fantastic MAU monetization ratio.</p>\n<p>Although higher-than-anticipated near-term costs will likely keep Skillz from getting anywhere near Wall Street's loftiest target over the next 12 months, it shouldn't have any issue surpassing $25 over the long run.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c5a0257bdd17a5ff3cf22a10de43ce0\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Viatris: Implied upside of 162%</h2>\n<p>It's not just growth stocks that Wall Street believes will soar. Drug stock <b>Viatris</b> (NASDAQ:VTRS) has a Street-high target of $35, which equates to as much as 162% upside, based on where it closed this past week.</p>\n<p>Viatris is a fairly new entity, which was formed by combining generic-drug company Mylan with <b>Pfizer</b>'s established drug unit, Upjohn. The expectation is this combination will have more operating clout than each company would have had separately.</p>\n<p>Viatris' management team has laid out a number of goals over the company's first three years. The belief is that by 2023 Viatris will realize over $1 billion in annual cost synergies, and that a quarter of its debt ($6.5 billion of an initial $26 billion) will be paid off. With improved financial flexibility, the company may be able to repurchase its own stock, lift its dividend, or kick start its internal drug development program. With the ability to generate well over $2 billion in annual operating cash flow, Viatris has choices.</p>\n<p>The company should also benefit immensely from the growing usage of generics. Though generics get a bad rap for their substantially lower margin, relative to brand-name drugs, rapidly rising prices for novel therapeutics will undoubtedly coerce patients, physicians, and insurers to lean on generics moving forward.</p>\n<p>A $35 price target over 12 months is highly unlikely given the pace of Viatris' transformation. However, an eventual rise to $35 appears reasonable given how profitable the company is.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5811406aed4001edc942cb25310a21cf\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Canopy Growth: Implied upside of 190%</h2>\n<p>Last, but not least, Canadian marijuana stock <b>Canopy Growth</b> (NASDAQ:CGC) is projected to have budding upside, at least according to MKM Partners, which has a Street-high target of $51 Canadian ($40.28 U.S.). If this price target proves accurate, Canopy Growth could nearly triple over the coming year.</p>\n<p>Canopy Growth has long been a favorite of investors because of its premier cash position. Spirits giant <b>Constellation Brands</b>&nbsp;has made four direct and indirect equity investment in Canopy, which has supplied the company with billions of dollars in working capital. The expectation has long been that this cash would help the company acquire earnings-accretive businesses and allow it to dominate the Canadian pot market.</p>\n<p>The unfortunate reality is that Canada's cannabis market has been plagued by oversupply and supply chain issues. Even though nationwide legal weed sales are climbing, Canopy Growth's operating losses aren't shrinking fast enough, and it's burned through many of its billions in available cash. To boot, federal reform has stalled in the U.S., meaning Canopy Growth hasn't been able to enter the world's most lucrative weed market.</p>\n<p>Although it's the clear market share leader in Canada, a CA$51 price target makes no sense for a company that registered a CA$187.7 million operating loss in the June-ended quarter.&nbsp; Of the five stocks on this list of ultra-popular companies, Canopy Growth is the one worth avoiding.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks With 120% to 190% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks With 120% to 190% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 17:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/29/5-ultra-popular-stocks-with-120-to-190-upside/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Patience pays off when investing on Wall Street. Despite navigating its way through the quickest 30% decline in its storied history during the first quarter of 2020, the benchmark S&P 500 has since ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/29/5-ultra-popular-stocks-with-120-to-190-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SKLZ":"Skillz Inc","CGC":"Canopy Growth Corporation","VTRS":"Viatris Inc.","BNGO":"Bionano Genomics","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/09/29/5-ultra-popular-stocks-with-120-to-190-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2171798605","content_text":"Patience pays off when investing on Wall Street. Despite navigating its way through the quickest 30% decline in its storied history during the first quarter of 2020, the benchmark S&P 500 has since doubled in value.\nBut even with this widely followed index regularly knocking on the door of all-time highs this year, bargains still abound -- at least according to Wall Street. Based on analyst's highest published price target for each of the following ultra-popular stocks, upside of 120% to as much as 190% may await.\nImage source: Getty Images.\nNio: Implied upside of 160%\nOne high-growth stock getting a lot of attention from investors that could drive higher is electric vehicle (EV) manufacturer Nio (NYSE:NIO). With a high price target of almost $92, the implication is Nio could return approximately 160% over the next 12 months.\nThe company certainly finds itself in the right place at the right time. In an effort to combat climate change and reduce the global reliance on fossil fuels, many developed and developing countries are turning to EVs. This should create a multi-decade opportunity for auto stocks to benefit from consumer and enterprise vehicle replacements.\nNio is based in China, which happens to be the largest auto market in the world. According to the Society of Automotive Engineers of China, roughly half of all new vehicle sales by 2035 could be powered by alternative energy, which would probably result in annual sales of 10 million-plus EVs. With China's EV market still nascent, market share is ripe for the picking.\nAlthough semiconductor chip supply issues are constraining Nio's EV output for the time being, the company looks well on its way to eventually hitting an annual run-rate of 150,000 EVs once the chip shortages are resolved. While 160% upside in 12 months is probably asking a bit much, we're seeing production and vehicle margins rise, which is a good sign.\nImage source: Getty Images.\nBionano Genomics: Implied upside of 155%\nAmong small-cap stocks, genome-analysis company Bionano Genomics (NASDAQ:BNGO) is creating a lot of buzz. With a peak price target of $14, the implication is it could gallop higher by as much as 155% over the next year.\nWhat makes Bionano so exciting is the company's optical genome mapping (OGM) system known as Saphyr. In January, Saphyr demonstrated its potential use by identifying three risk genes for autism spectrum disorder (ASD). ASD is one of many difficult-to-treat ailments. The potential here is that drugmakers could utilize Saphyr to identity certain genetic biomarkers that'll help them develop treatments to fight otherwise hard-to-treat diseases.\nA month prior, in December 2020, Saphyr also outperformed Pacific Biosciences OGM technology. Saphyr had considerably better success in identifying large structural genome variations, compared to Pacific Biosciences' OGM system.\nHowever, and this is a pretty big \"however,\" Saphyr is a long way away from getting approval from the U.S. Food and Drug Administration (FDA). This means the company's ability to generate revenue from licensing will be dicey at best. It's the perfect example of a company that may have game-changing potential in the healthcare space, but is still many years away from demonstrating that potential to the FDA.\nImage source: Getty Images.\nSkillz: Implied upside of 120%\nAnother company with significant upside, according to analysts, is mobile gaming platform provider Skillz (NYSE:SKLZ). The high-water estimate on Wall Street of $25 suggests Skillz could return up to 120% over the next year.\nThe gaming industry is incredibly competitive, capital intensive, and there are no guarantees that a developed game will be a hit with users. That's why Skillz avoided the development side of the equation in its entirety and is focused on being a competitive medium. Skillz provides a platform where mobile gamers can compete for cash prizes, with the company and game developers keeping a portion of the cash prize for themselves. It's a lot easier and cost-effective to maintain a gaming platform than it is to develop the next hit game.\nWhat's been particularly impressive about Skillz is the company's pay-to-play conversion rate. Whereas the average conversion rate in the industry is around 2%, the company noted at the end of the first quarter that 17% of its monthly active users (MAU) were paying to play on its platform. With the company still in its early stages of its growth and marketing, this is a fantastic MAU monetization ratio.\nAlthough higher-than-anticipated near-term costs will likely keep Skillz from getting anywhere near Wall Street's loftiest target over the next 12 months, it shouldn't have any issue surpassing $25 over the long run.\nImage source: Getty Images.\nViatris: Implied upside of 162%\nIt's not just growth stocks that Wall Street believes will soar. Drug stock Viatris (NASDAQ:VTRS) has a Street-high target of $35, which equates to as much as 162% upside, based on where it closed this past week.\nViatris is a fairly new entity, which was formed by combining generic-drug company Mylan with Pfizer's established drug unit, Upjohn. The expectation is this combination will have more operating clout than each company would have had separately.\nViatris' management team has laid out a number of goals over the company's first three years. The belief is that by 2023 Viatris will realize over $1 billion in annual cost synergies, and that a quarter of its debt ($6.5 billion of an initial $26 billion) will be paid off. With improved financial flexibility, the company may be able to repurchase its own stock, lift its dividend, or kick start its internal drug development program. With the ability to generate well over $2 billion in annual operating cash flow, Viatris has choices.\nThe company should also benefit immensely from the growing usage of generics. Though generics get a bad rap for their substantially lower margin, relative to brand-name drugs, rapidly rising prices for novel therapeutics will undoubtedly coerce patients, physicians, and insurers to lean on generics moving forward.\nA $35 price target over 12 months is highly unlikely given the pace of Viatris' transformation. However, an eventual rise to $35 appears reasonable given how profitable the company is.\nImage source: Getty Images.\nCanopy Growth: Implied upside of 190%\nLast, but not least, Canadian marijuana stock Canopy Growth (NASDAQ:CGC) is projected to have budding upside, at least according to MKM Partners, which has a Street-high target of $51 Canadian ($40.28 U.S.). If this price target proves accurate, Canopy Growth could nearly triple over the coming year.\nCanopy Growth has long been a favorite of investors because of its premier cash position. Spirits giant Constellation Brands has made four direct and indirect equity investment in Canopy, which has supplied the company with billions of dollars in working capital. The expectation has long been that this cash would help the company acquire earnings-accretive businesses and allow it to dominate the Canadian pot market.\nThe unfortunate reality is that Canada's cannabis market has been plagued by oversupply and supply chain issues. Even though nationwide legal weed sales are climbing, Canopy Growth's operating losses aren't shrinking fast enough, and it's burned through many of its billions in available cash. To boot, federal reform has stalled in the U.S., meaning Canopy Growth hasn't been able to enter the world's most lucrative weed market.\nAlthough it's the clear market share leader in Canada, a CA$51 price target makes no sense for a company that registered a CA$187.7 million operating loss in the June-ended quarter.  Of the five stocks on this list of ultra-popular companies, Canopy Growth is the one worth avoiding.","news_type":1},"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866128590,"gmtCreate":1632749356610,"gmtModify":1632798135519,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"hmm","listText":"hmm","text":"hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866128590","repostId":"1125374890","repostType":4,"isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605090796,"gmtCreate":1639090444622,"gmtModify":1639090444779,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605090796","repostId":"1113203379","repostType":4,"repost":{"id":"1113203379","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639061813,"share":"https://www.laohu8.com/m/news/1113203379?lang=&edition=full","pubTime":"2021-12-09 22:56","market":"us","language":"en","title":"Crypto stocks dipped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1113203379","media":"Tiger Newspress","summary":"Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining","content":"<p>Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/bf3f2d610b479a57d75ff6df427bcd26\" tg-width=\"412\" tg-height=\"656\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks dipped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks dipped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-09 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/bf3f2d610b479a57d75ff6df427bcd26\" tg-width=\"412\" tg-height=\"656\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIOT":"Riot Platforms"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113203379","content_text":"Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}